{"title":"Medical Oncology","description":"","products":[{"product_id":"global-academy-of-womens-cancer-2024","title":"Global Academy of Womens Cancer 2024","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: breast and gynecological cancers physicians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eDate:\u003c\/h3\u003e\n\u003ch3\u003eLocation:\u003c\/h3\u003e\n\u003cp\u003eHilton Munich Park, Munich Germany\u003c\/p\u003e\n\u003cp\u003eThe interactive congress offers a comprehensive overview of all new developments in breast and gynaecological cancers.\u003c\/p\u003e\n\u003cp\u003eCALL FOR ABSTRACTS\u003c\/p\u003e\n\u003cp\u003eWe invite abstract submissions from individuals passionate about sharing their insights, research findings, and expertise in gynecological oncology and breast cancer. This is a fantastic opportunity to showcase your work, engage with like-minded professionals, and contribute to the collective knowledge of our community.\u003c\/p\u003e\n\u003ch3\u003eTopics of Interest:\u003c\/h3\u003e\n\u003cp\u003eBREAST CANCER\u003c\/p\u003e\n\u003cp\u003eBiomarkers and translational research\u003c\/p\u003e\n\u003cp\u003eand precision medicine\u003c\/p\u003e\n\u003cp\u003eEarly breast cancer: Adjuvant therapy\u003c\/p\u003e\n\u003cp\u003eEarly breast cancer: Neoadjuvant therapy\u003c\/p\u003e\n\u003cp\u003eEarly breast cancer: Surgery and radiotherapy\u003c\/p\u003e\n\u003cp\u003eEarly detection, hereditary breast cancer and\u003c\/p\u003e\n\u003cp\u003eprevention\u003c\/p\u003e\n\u003cp\u003eMetastatic breast cancer\u003c\/p\u003e\n\u003cp\u003eSupportive care and survivorship\u003c\/p\u003e\n\u003cp\u003eMiscellaneous\u003c\/p\u003e\n\u003cp\u003eGYNAE-ONCOLOGY\u003c\/p\u003e\n\u003cp\u003eCervical cancer\u003c\/p\u003e\n\u003cp\u003eEndometrial cancer\u003c\/p\u003e\n\u003cp\u003eOvarian cancer\u003c\/p\u003e\n\u003cp\u003eVulva cancer\u003c\/p\u003e\n\u003cp\u003ePalliative care\u003c\/p\u003e\n\u003cp\u003eTranslational research\/biomarkers\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1 WELCOME AND OPENING.mp4\u003c\/p\u003e\n\u003cp\u003e2 JOINT LECTURE I.mp4\u003c\/p\u003e\n\u003cp\u003e3 SATELLITE SYMPOSIUM I.mp4\u003c\/p\u003e\n\u003cp\u003e6 BREAST CANCER SESSION I HR Early Breast Cancer.mp4\u003c\/p\u003e\n\u003cp\u003e7 SATELLITE SYMPOSIUM II.mp4\u003c\/p\u003e\n\u003cp\u003e8 JOINT LECTURE II.mp4\u003c\/p\u003e\n\u003cp\u003e9 SATELLITE SYMPOSIUM III.mp4\u003c\/p\u003e\n\u003cp\u003e13 BREAST CANCER SESSION III Her2 Overexpressing.mp4\u003c\/p\u003e\n\u003cp\u003e14 SATELLITE SYMPOSIUM IV.mp4\u003c\/p\u003e\n\u003cp\u003e15 SATELLITE SYMPOSIUM V.mp4\u003c\/p\u003e\n\u003cp\u003e17 SATELLITE SYMPOSIUM VI.mp4\u003c\/p\u003e\n\u003cp\u003e19 BREAST CANCER SESSION IV Triple Negative Breast Cancer.mp4\u003c\/p\u003e\n\u003cp\u003e20 SATELLITE SYMPOSIUM VII.mp4\u003c\/p\u003e\n\u003cp\u003e21 JOINT LECTURE III Special tutorial.mp4\u003c\/p\u003e\n\u003cp\u003ePre-Programme_GAWC-Munich2025.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405717033156,"sku":null,"price":52.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Global-Academy-of-Womens-Cancer-2024.webp?v=1784215300"},{"product_id":"oakstone-the-brigham-and-dana-farber-board-review-and-comprehensive-update-in-oncology-2025","title":"Oakstone The Brigham and Dana-Farber Board Review and Comprehensive Update in Oncology 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: fellows\/trainees, practicing oncology specialists (MDs), and other professional affiliates (internists with an interest in oncology)\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eInfections in Cancer Patients\u003c\/p\u003e\n\u003cp\u003eMultiple Myeloma\u003c\/p\u003e\n\u003cp\u003eWaldenstrom Macroglobulemia and Amyloidosis\u003c\/p\u003e\n\u003cp\u003eHead and Neck Cancers\u003c\/p\u003e\n\u003cp\u003eManagement of Non Small Cell Lung Cancer\u003c\/p\u003e\n\u003cp\u003eCarcinoid and Neuroendocrine Tumors\u003c\/p\u003e\n\u003cp\u003eNovel Approaches to Esophageal and Gastric Cancer Management\u003c\/p\u003e\n\u003cp\u003eand many more…\u003c\/p\u003e\n\u003cp\u003eDate of Original Release: March 15, 2025\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eAt the conclusion of this activity, the participant will be able to:\u003c\/h3\u003e\n\u003cp\u003eApply current\/recommended oncology guidelines in clinical practice\u003c\/p\u003e\n\u003cp\u003ePerform differential diagnosis of complex clinical presentations related to oncologic disorders\u003c\/p\u003e\n\u003cp\u003eIdentify\/apply current therapeutic options for specific oncologic disorders\u003c\/p\u003e\n\u003cp\u003eDemonstrate knowledge of pathophysiology as it applies to management of oncology disorders\u003c\/p\u003e\n\u003cp\u003eApply knowledge gained to the ABIM certification\/recertification oncology examinations\u003c\/p\u003e\n\u003cp\u003eIntended Audience\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eQuestions.pdf\u003c\/p\u003e\n\u003cp\u003eSyllabus.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405723259076,"sku":null,"price":32.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Oakstone-The-Brigham-and-Dana-Farber-Board-Review-and-Comprehensive-Update-in-Oncology-2025.jpg?v=1784215372"},{"product_id":"oakstone-the-brigham-and-dana-farber-board-review-and-comprehensive-update-in-hematology-2025","title":"Oakstone The Brigham and Dana-Farber Board Review and Comprehensive Update in Hematology 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: fellows\/trainees, practicing hematology specialists (MDs), and other professional affiliates (internists with an interest in hematology)\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eMaster Hematology\u003c\/p\u003e\n\u003cp\u003eHematopoiesis and Cytokines\u003c\/p\u003e\n\u003cp\u003eImmune and Non-immune Hemolytic Anemia\u003c\/p\u003e\n\u003cp\u003eMolecular Genetics of Cancer\u003c\/p\u003e\n\u003cp\u003eThalassemia and Other Hemoglobinopathies\u003c\/p\u003e\n\u003cp\u003eAcquired Thrombocytopenias\u003c\/p\u003e\n\u003cp\u003eVon Willebrand Disease and Congenital Platelet Disorders\u003c\/p\u003e\n\u003cp\u003eTransfusion Medicine\u003c\/p\u003e\n\u003cp\u003eand many more…\u003c\/p\u003e\n\u003cp\u003eDate of Original Release: March 15, 2025\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eAt the conclusion of this activity, the participant will be able to:\u003c\/h3\u003e\n\u003cp\u003eApply current\/recommended hematology guidelines in clinical practice\u003c\/p\u003e\n\u003cp\u003ePerform differential diagnosis of complex clinical presentations related to hematologic disorders\u003c\/p\u003e\n\u003cp\u003eIdentify\/apply current therapeutic options for specific hematologic disorders\u003c\/p\u003e\n\u003cp\u003eDemonstrate knowledge of pathophysiology as it applies to the management of hematology disorders\u003c\/p\u003e\n\u003cp\u003eApply knowledge gained to the ABIM certification\/recertification hematology examinations\u003c\/p\u003e\n\u003cp\u003eIntended Audience\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eQuestions.pdf\u003c\/p\u003e\n\u003cp\u003eSyllabus.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405723357380,"sku":null,"price":32.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Oakstone-The-Brigham-and-Dana-Farber-Board-Review-and-Comprehensive-Update-in-Hematology-2025.jpg?v=1784215374"},{"product_id":"oakstone-the-brigham-and-dana-farber-board-review-and-comprehensive-update-in-hematology-and-oncology-2025","title":"Oakstone The Brigham and Dana-Farber Board Review and Comprehensive Update in Hematology and Oncology 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: for fellows\/trainees, practicing hematology and oncology specialists (MDs)\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eEssential Hematology and Oncology\u003c\/p\u003e\n\u003cp\u003eHematopoiesis and Cytokines\u003c\/p\u003e\n\u003cp\u003ePlatelet Disorders\u003c\/p\u003e\n\u003cp\u003eMolecular Genetics of Cancer\u003c\/p\u003e\n\u003cp\u003eNew Therapies (Pharmacology)\u003c\/p\u003e\n\u003cp\u003ePalliative Care (Management of Symptoms\/End of Life)\u003c\/p\u003e\n\u003cp\u003eGastrointestinal Cancers (Neuroendocrine\/Esophageal\/Pancreas\/Colorectal)\u003c\/p\u003e\n\u003cp\u003eThoracic Oncology (Head\/Neck\/Lung\/Thyroid)\u003c\/p\u003e\n\u003cp\u003eand many more…\u003c\/p\u003e\n\u003cp\u003eDate of Original Release: March 15, 2025\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eAt the conclusion of this activity, the participant will be able to:\u003c\/h3\u003e\n\u003cp\u003eApply current\/recommended hematology and oncology guidelines in clinical practice\u003c\/p\u003e\n\u003cp\u003ePerform differential diagnosis of complex clinical presentations related to hematologic and oncologic disorders\u003c\/p\u003e\n\u003cp\u003eIdentify\/apply current therapeutic options for specific hematologic and oncologic disorders\u003c\/p\u003e\n\u003cp\u003eDemonstrate knowledge of pathophysiology as it applies to management of hematology and oncology disorders\u003c\/p\u003e\n\u003cp\u003eApply knowledge gained to the ABIM certification\/recertification hematology and oncology examinations\u003c\/p\u003e\n\u003cp\u003eIntended Audience\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eQuestions.pdf\u003c\/p\u003e\n\u003cp\u003eSyllabus.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405723783364,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Oakstone-The-Brigham-and-Dana-Farber-Board-Review-and-Comprehensive-Update-in-Hematology-and-Oncology-2025.jpg?v=1784215378"},{"product_id":"columbia-university-irving-medical-center-liver-summit-2025","title":"Columbia University Irving Medical Center Liver Summit 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: Primary Care Physicians, Pediatric Gastroenterologists, Pediatric Surgeons, Transplant Surgeons, Dieticians, Physician Assistants, Oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eProgram Overview Day 1: The 6th Annual Pediatric Liver Disease and Transplantation\u003c\/p\u003e\n\u003cp\u003eThe overall goals of the activity is to learn about commonly encountered liver disease in children and  understand the causes, signs, symptoms, risk factors, screening, as well as, innovative approaches to treatment and long-term management. The format of this program will consist of lectures and interactive discussions based on the overall goal of pediatric liver disease and transplantation.\u003c\/p\u003e\n\u003ch3\u003eLearning Objectives:\u003c\/h3\u003e\n\u003cp\u003eIdentify up-to-date management of pediatric liver disease\u003c\/p\u003e\n\u003cp\u003eExplain Metabolic disorders and their implications for pediatric liver transplantation.\u003c\/p\u003e\n\u003cp\u003eUnderstand state of the art management of pediatric liver transplant Identify Metabolic\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThis program has been designed for primary care physicians, Pediatric Gastroenterologists, Pediatric Surgeons, Transplant Surgeons, Nurses, Social Workers, Dieticians, Physician Assistants and any other clinicians involved in the management and treatment of pediatric liver disease and transplantation\u003c\/p\u003e\n\u003cp\u003eProgram Overview Day 2: The Third Annual Advances in the Management of Hepatocellular Carcinoma: A Multidisciplinary Approach\u003c\/p\u003e\n\u003cp\u003eThe Third Annual Advances in the Management of Hepatocellular Carcinoma: A Multidisciplinary Approach will be broken down into (3) sessions focusing on; screening, surveillance \u0026amp; evolving epidemiology to current treatments as well as a look to the future, evolving interventional options and a comprehensive understanding of transplant for the HCC patient. The format will consist of expert didactic lectures, case presentations, panel discussion with interactive audience Q\u0026amp;A.\u003c\/p\u003e\n\u003ch3\u003eLearning Objectives:\u003c\/h3\u003e\n\u003cp\u003eUnderstand the recent changes in epidemiology of HCC and adjustments in screening and surveillance guidelines.\u003c\/p\u003e\n\u003cp\u003eIdentify systemic chemotherapy, non-transplant surgical options, and patient management.\u003c\/p\u003e\n\u003cp\u003eExplain the most up-to-date oncology management of HCC including recent advances in immunotherapy\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThis program has been designed oncology providers, including surgeons, physicians, fellows, residents, nurse practitioners, and physician assistants who manage patients with hepatocellular carcinoma (HCC) across various clinical specialties including; general \u0026amp; transplant surgery, oncology, immunology, pulmonology, cardiology, gastroenterology, infectious disease, neuroscience \u0026amp; radiology.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below\u003c\/p\u003e\n\u003cp\u003eJanuary 30, 2025 Sixth Annual Pediatric Liver and Disease Transplantation.mp4 (6 hours 40 minutes)\u003c\/p\u003e\n\u003cp\u003eJanuary 31, 2025 Third Annual Advances in the Management of Hepatocellular Carcinoma.mp4 (6 hours 24 minutes)\u003c\/p\u003e\n\u003cp\u003eAgenda.pdf\u003c\/p\u003e\n\u003ch3\u003e* Detail:\u003c\/h3\u003e\n\u003cp\u003eThursday, January 30\u003c\/p\u003e\n\u003cp\u003eDay 1: Sixth Annual Pediatric Liver and Disease Transplantation\u003c\/p\u003e\n\u003cp\u003eRegistration | Breakfast | Vendor Exhibits\u003c\/p\u003e\n\u003cp\u003eWelcome Remarks\u003c\/p\u003e\n\u003cp\u003eTomoaki Kato, MD NYP\/Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eKEYNOTE ADDRESS: Unlocking the Potential of Gene Therapy to Manage\u003c\/p\u003e\n\u003cp\u003eModerator: Jean Emond MD, Mercedes Martinez, MD Speaker: Lorenzo D’Antiga, MD University of Milano – Bicocca Hospital Papa Giovanni XXIII, Bergamo, Italy\u003c\/p\u003e\n\u003cp\u003ePanel Discussion | Q\u0026amp;A Session\u003c\/p\u003e\n\u003cp\u003eSession I: Overview of Metabolic Disorders in the Pediatric Patient\u003c\/p\u003e\n\u003cp\u003eSpeaker: Steven Lobritto, MD NewYork-Presbyterian Morgan Stanley Children’s Hospital\u003c\/p\u003e\n\u003cp\u003eSession II: Metabolic Disorders Without Liver Injury\u003c\/p\u003e\n\u003cp\u003eSpeaker: John Bucuvalas, MD, FAASLD, FAST Mount Sinai Kravis Children’s Hospital\u003c\/p\u003e\n\u003cp\u003eSession III: Metabolic Disorders with Liver Injury\u003c\/p\u003e\n\u003cp\u003eSpeaker: Mercedes Martinez, MD NewYork-Presbyterian Morgan Stanley Children’s Hospital\u003c\/p\u003e\n\u003cp\u003ePanel Discussion | Q\u0026amp;A Session\u003c\/p\u003e\n\u003cp\u003eLunch | Vendor Exhibits\u003c\/p\u003e\n\u003cp\u003eJEOPARDY: GI Jeopardy Game: The Liver Edition\u003c\/p\u003e\n\u003cp\u003eModerator: Norberto Rodriguez-Beaz, MD UT Southwestern Medical Center Contestant: Adriana Perez, MD and Amanda Cantor, MD NYP\/Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003e1:40 PM\u003c\/p\u003e\n\u003cp\u003eSESSION IV: Management of Metabolic Disorders\u003c\/p\u003e\n\u003cp\u003eModerator: Adrina Perez, MD \u0026amp; Peter Liou, MD\u003c\/p\u003e\n\u003cp\u003eHyperammonemia Management\u003c\/p\u003e\n\u003cp\u003eSpeaker: Alejandro D. Iglesias, MD NYP\/Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eNutritional Management of Metabolic Patients\u003c\/p\u003e\n\u003cp\u003eSpeaker: Thandiwe C. Khonje, MA RD CDN NYP\/Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eLiver Transplant Indications for Metabolic Disorders\u003c\/p\u003e\n\u003cp\u003eSpeaker: George V. Mazariegos, MD FACS UPMC Children’s Hospital of Pittsburgh\u003c\/p\u003e\n\u003cp\u003ePsychosocial Factors in Pediatric Liver Transplant Success: Enhancing Child and Family Adaptation\u003c\/p\u003e\n\u003cp\u003eSpeaker: Corrine N Ahrabi-Nejad, PHD NYP\/Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003ePanel Discussion | Q\u0026amp;A Session\u003c\/p\u003e\n\u003cp\u003eCase Presentation #1\u003c\/p\u003e\n\u003cp\u003eModerator: Pooja Reddy Spector MD \u0026amp; Nathaly Llore, MD Case Presentation #1 Speaker: Amanda Cantor, MD\u003c\/p\u003e\n\u003cp\u003eCase Presentation #2\u003c\/p\u003e\n\u003cp\u003eCase Presentation #2 Speaker: Mercedes Martinez, MD\u003c\/p\u003e\n\u003cp\u003ePatient Testimonials\u003c\/p\u003e\n\u003cp\u003eClosing Remarks\u003c\/p\u003e\n\u003cp\u003eTomoaki Kato, MD NYP\/Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eFriday, January 31\u003c\/p\u003e\n\u003cp\u003eDay 2: The Third Annual Advances in the Management of Hepatocellular Carcinoma: A Multidisciplinary Approach\u003c\/p\u003e\n\u003cp\u003eRegistration | Breakfast | Vendor Exhibits\u003c\/p\u003e\n\u003cp\u003eWelcome Remarks\u003c\/p\u003e\n\u003cp\u003eTomoaki Kato, MD \u0026amp; Elizabeth C. Verna, MD, MS Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003e9:35 AM\u003c\/p\u003e\n\u003cp\u003eSession 1: Update in HCC Epidemiology, Biomarkers and Screening\u003c\/p\u003e\n\u003cp\u003eModerators: Lorna Dove, MD and Peter Liou, MD\u003c\/p\u003e\n\u003cp\u003eUpdate on Screening \u0026amp; Novel Biomarkers for HCC\u003c\/p\u003e\n\u003cp\u003eSpeaker: Neehar Parikh, MD University of Michigan\u003c\/p\u003e\n\u003cp\u003eEvolving Epidemiology of HCC and Disparities in Outcomes\u003c\/p\u003e\n\u003cp\u003eSpeaker: Meaghan Phipps, MD Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eNovel Mechanisms of HCC Pathogenesis\u003c\/p\u003e\n\u003cp\u003eRobert Schwabe, MD Professor of Medicine Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eDiagnostic Approach to Solid Liver Lesions \u0026amp; LIRADS Criteria\u003c\/p\u003e\n\u003cp\u003eVictoria Chernyak, MD, MS, FSAR, ESGAR, FSABI, FACR Professor of Radiology NYP\/Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eCase Presentations and Panel Discussion\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A Session\u003c\/p\u003e\n\u003cp\u003eAM Break | Exhibit Hall\u003c\/p\u003e\n\u003cp\u003eKEYNOTE ADDRESS: Immunotherapy for HCC: Current Recommendations \u0026amp; Future Directions\u003c\/p\u003e\n\u003cp\u003eRuth He, MD\u003c\/p\u003e\n\u003cp\u003e12:30 PM\u003c\/p\u003e\n\u003cp\u003eSession 2: Multi-Disciplinary \u0026amp; Multi-Modality Treatment for HCC\u003c\/p\u003e\n\u003cp\u003eModerators: Meaghan Phipps, MD and Jason Hawksworth, MD\u003c\/p\u003e\n\u003cp\u003eKEYNOTE ADDRESS Immunotherapy for HCC: Current Recommendations \u0026amp; Future Directions\u003c\/p\u003e\n\u003cp\u003eSpeaker: Ruth He, MD Georgetown University\u003c\/p\u003e\n\u003cp\u003eInterventional Radiology Approaches to HCC Treatments: TACE, Y90, Ablation, Histosonic\u003c\/p\u003e\n\u003cp\u003eSpeaker: Jonathan Susman, MD Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eSurgical Approach to HCC: Resection and Transplant\u003c\/p\u003e\n\u003cp\u003eSpeaker: Jason Hawksworth, MD Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eModerated Case Presentation and Panel Discussion\u003c\/p\u003e\n\u003cp\u003eTopic: Treatment of HCC: Systemic Therapy, IR-Based Treatment, and Liver Transplantation Moderator: Alyson Fox, MD, MS Associate Professor of Medicine, Medical Director of Liver Transplantation Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003e2:45 PM\u003c\/p\u003e\n\u003cp\u003eSession 3: Update on the Diagnosis \u0026amp; Management of Cholangiocarcinoma (CCA) Moderators: Jean Emond, MD, and Ruth He, MD, PhD\u003c\/p\u003e\n\u003cp\u003eModerators: Jean Emond, MD, and Ruth He, MD, PhD\u003c\/p\u003e\n\u003cp\u003eEpidemiology and Pathogenesis of CCA\u003c\/p\u003e\n\u003cp\u003eSpeaker: Gulam Manji, MD, PhD Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eSurgical Approaches to CCA Treatment\u003c\/p\u003e\n\u003cp\u003eSpeaker: Jean Emond, MD Columbia University Irving Medical Center\u003c\/p\u003e\n\u003cp\u003eUpdate on Systemic Therapies in CCA Management\u003c\/p\u003e\n\u003cp\u003eSpeaker: Lipika Goyal, MD (Virtual) Standford Medicine\u003c\/p\u003e\n\u003cp\u003eCase Presentations and Panel Discussion\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A Session | Panel Discussion\u003c\/p\u003e\n\u003cp\u003eClosing Remarks\u003c\/p\u003e\n\u003cp\u003eTomoaki Kato, MD \u0026amp; Elizabeth C. Verna, MD, MS Columbia University Irving Medical Center\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405724340420,"sku":null,"price":52.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Columbia-University-Irving-Medical-Center-Liver-Summit-2025.jpg?v=1784215388"},{"product_id":"memorial-sloan-kettering-cancer-center-update-in-hematology-and-medical-oncology-2025","title":"Memorial Sloan Kettering Cancer Center Update in Hematology and Medical Oncology 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: physicians, fellows, and residents for the ABIM certification and recertification examinations in Hematology and Medical Oncology\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecialties – Hematology, Infectious Diseases, Medical Oncology, Oncology and Hematology, Radiation Oncology, Surgical Oncology\u003c\/p\u003e\n\u003cp\u003eOverview\u003c\/p\u003e\n\u003cp\u003eThis course is a live virtual event designed for medical oncology professionals, including physicians, nurses, pharmacists, fellows, and residents. It aims to help participants effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology.\u003c\/p\u003e\n\u003cp\u003eObjectives\u003c\/p\u003e\n\u003ch3\u003eAt the conclusion of this course, attendees will be able to:\u003c\/h3\u003e\n\u003cp\u003eDefine state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers and hematologic cancers.\u003c\/p\u003e\n\u003cp\u003eDiscuss recent treatment advances in solid tumor and hematologic oncology and apply knowledge gained in modern clinical practice\u003c\/p\u003e\n\u003cp\u003ePrepare for ABIM examinations in medical oncology and hematology.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAcute Lymphocytic Leukemia.mp4\u003c\/p\u003e\n\u003cp\u003eAcute Lymphocytic Leukemia.pdf\u003c\/p\u003e\n\u003cp\u003eAcute Myeloid Leukemia.mp4\u003c\/p\u003e\n\u003cp\u003eAcute Myeloid Leukemia.pdf\u003c\/p\u003e\n\u003cp\u003eAnal and Rectal Cancers.mp4\u003c\/p\u003e\n\u003cp\u003eAnal and Rectal Cancers.pdf\u003c\/p\u003e\n\u003cp\u003eAntithrombotic and Antiplatelet Therapy.mp4\u003c\/p\u003e\n\u003cp\u003eAntithrombotic and Antiplatelet Therapy.pdf\u003c\/p\u003e\n\u003cp\u003eApproach to the Bleeding Patient.mp4\u003c\/p\u003e\n\u003cp\u003eApproach to the Bleeding Patient.pdf\u003c\/p\u003e\n\u003cp\u003eAuto _Allo.mp4\u003c\/p\u003e\n\u003cp\u003eAuto _Allo.pdf\u003c\/p\u003e\n\u003cp\u003eBreast Cancer Radiation Therapy.mp4\u003c\/p\u003e\n\u003cp\u003eBreast Cancer Radiation Therapy.pdf\u003c\/p\u003e\n\u003cp\u003eBreast Cancer Surgery.mp4\u003c\/p\u003e\n\u003cp\u003eBreast Cancer Surgery.pdf\u003c\/p\u003e\n\u003cp\u003eCAR T Cells.mp4\u003c\/p\u003e\n\u003cp\u003eCAR T Cells.pdf\u003c\/p\u003e\n\u003cp\u003eCarcinoma of Unknown Primary.mp4\u003c\/p\u003e\n\u003cp\u003eCarcinoma of Unknown Primary.pdf\u003c\/p\u003e\n\u003cp\u003eCentral Nervous System Tumors.mp4\u003c\/p\u003e\n\u003cp\u003eCentral Nervous System Tumors.pdf\u003c\/p\u003e\n\u003cp\u003eChronic Lymphocytic Leukemia _Small Lymphocytic Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eChronic Lymphocytic Leukemia _Small Lymphocytic Lymphoma.pdf\u003c\/p\u003e\n\u003cp\u003eChronic Myelogenous Leukemia.mp4\u003c\/p\u003e\n\u003cp\u003eChronic Myelogenous Leukemia.pdf\u003c\/p\u003e\n\u003cp\u003eClinical Indications for Use of Blood Products and Associated Risks.mp4\u003c\/p\u003e\n\u003cp\u003eClinical Indications for Use of Blood Products and Associated Risks.pdf\u003c\/p\u003e\n\u003cp\u003eColon Cancer.mp4\u003c\/p\u003e\n\u003cp\u003eColon Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eDiffuse Large B-Cell Lymphoma _Mantle Cell Lymphoma _Burkitt Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eDiffuse Large B-Cell Lymphoma _Mantle Cell Lymphoma _Burkitt Lymphoma.pdf\u003c\/p\u003e\n\u003cp\u003eEsophageal and Gastric Cancers.mp4\u003c\/p\u003e\n\u003cp\u003eEsophageal and Gastric Cancers.pdf\u003c\/p\u003e\n\u003cp\u003eHead and Neck, Thyroid, and Non-Melanoma Skin Cancers.mp4\u003c\/p\u003e\n\u003cp\u003eHead and Neck, Thyroid, and Non-Melanoma Skin Cancers.pdf\u003c\/p\u003e\n\u003cp\u003eHemolytic Anemia.mp4\u003c\/p\u003e\n\u003cp\u003eHemolytic Anemia.pdf\u003c\/p\u003e\n\u003cp\u003eHemOnc2025_Brochure.pdf\u003c\/p\u003e\n\u003cp\u003eHepatocellular Cancer and Cholangiocarcinoma.mp4\u003c\/p\u003e\n\u003cp\u003eHepatocellular Cancer and Cholangiocarcinoma.pdf\u003c\/p\u003e\n\u003cp\u003eHER2-Positive Breast Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eHereditary Cancer Genetics.mp4\u003c\/p\u003e\n\u003cp\u003eHereditary Cancer Genetics.pdf\u003c\/p\u003e\n\u003cp\u003eHodgkin Lymphoma _ T Cell.mp4\u003c\/p\u003e\n\u003cp\u003eHodgkin Lymphoma _ T Cell.pdf\u003c\/p\u003e\n\u003cp\u003eHormone Receptor-Positive Breast Cancer.mp4\u003c\/p\u003e\n\u003cp\u003eHormone Receptor-Positive Breast Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eInfectious Disease.mp4\u003c\/p\u003e\n\u003cp\u003eInfectious Disease.pdf\u003c\/p\u003e\n\u003cp\u003eKidney Cancer.mp4\u003c\/p\u003e\n\u003cp\u003eKidney Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eLow-Grade Non-Hodgkin Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eLow-Grade Non-Hodgkin Lymphoma.pdf\u003c\/p\u003e\n\u003cp\u003eMelanoma.mp4\u003c\/p\u003e\n\u003cp\u003eMelanoma.pdf\u003c\/p\u003e\n\u003cp\u003eMesothelioma.mp4\u003c\/p\u003e\n\u003cp\u003eMesothelioma.pdf\u003c\/p\u003e\n\u003cp\u003eMyelodysplastic.mp4\u003c\/p\u003e\n\u003cp\u003eMyelodysplastic.pdf\u003c\/p\u003e\n\u003cp\u003eMyeloma _Amyloid.mp4\u003c\/p\u003e\n\u003cp\u003eMyeloma _Amyloid.pdf\u003c\/p\u003e\n\u003cp\u003eMyeloproliferative Neoplasms.mp4\u003c\/p\u003e\n\u003cp\u003eMyeloproliferative Neoplasms.pdf\u003c\/p\u003e\n\u003cp\u003eNon-Small Cell Lung Cancer.mp4\u003c\/p\u003e\n\u003cp\u003eNon-Small Cell Lung Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eOvarian Cancer.mp4\u003c\/p\u003e\n\u003cp\u003eOvarian Cancer.pdf\u003c\/p\u003e\n\u003cp\u003ePancreatic and Neuroendocrine Cancers.mp4\u003c\/p\u003e\n\u003cp\u003ePancreatic and Neuroendocrine Cancers.pdf\u003c\/p\u003e\n\u003cp\u003ePharmacology I_II.mp4\u003c\/p\u003e\n\u003cp\u003ePharmacology I_II.pdf\u003c\/p\u003e\n\u003cp\u003eProstate Cancer.mp4\u003c\/p\u003e\n\u003cp\u003eProstate Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eSarcoma.mp4\u003c\/p\u003e\n\u003cp\u003eSarcoma.pdf\u003c\/p\u003e\n\u003cp\u003eSickle Cell Disease, Thalassemia.mp4\u003c\/p\u003e\n\u003cp\u003eSickle Cell Disease, Thalassemia.pdf\u003c\/p\u003e\n\u003cp\u003eSmall Cell Lung Cancer.mp4\u003c\/p\u003e\n\u003cp\u003eSmall Cell Lung Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eTestis Cancer.mp4\u003c\/p\u003e\n\u003cp\u003eTestis Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eThrombocytopenia and ITP.mp4\u003c\/p\u003e\n\u003cp\u003eThrombocytopenia and ITP.pdf\u003c\/p\u003e\n\u003cp\u003eThrombotic Disorders.mp4\u003c\/p\u003e\n\u003cp\u003eThrombotic Disorders.pdf\u003c\/p\u003e\n\u003cp\u003eTransfusion Reactions.mp4\u003c\/p\u003e\n\u003cp\u003eTransfusion Reactions.pdf\u003c\/p\u003e\n\u003cp\u003eTriple-Negative Breast Cancer.mp4\u003c\/p\u003e\n\u003cp\u003eTriple-Negative Breast Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eUrothelial Cancer.mp4\u003c\/p\u003e\n\u003cp\u003eUrothelial Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eUterine, Cervix, and Other Gynecologic Cancers.mp4\u003c\/p\u003e\n\u003cp\u003eUterine, Cervix, and Other Gynecologic Cancers.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405724700868,"sku":null,"price":117.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-Update-in-Hematology-and-Medical-Oncology-2025.jpg?v=1784215394"},{"product_id":"american-society-of-clinical-oncology-genitourinary-cancers-symposium-2025","title":"American Society of Clinical Oncology Genitourinary Cancers Symposium 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: oncologists, urologists, radiation oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025 is a premier event focused on the latest advancements in prostate, bladder, kidney, and other genitourinary cancers. It brings together oncologists, researchers, and healthcare professionals to discuss cutting-edge treatments, clinical trials, and emerging therapies.\u003c\/p\u003e\n\u003ch3\u003eHere are some key details:\u003c\/h3\u003e\n\u003cp\u003eLocation: San Francisco, CA\u003c\/p\u003e\n\u003ch3\u003eProgram Highlights:\u003c\/h3\u003e\n\u003cp\u003eProstate Cancer: Advances in radioligand therapies and androgen receptor pathway inhibitors.\u003c\/p\u003e\n\u003cp\u003eBladder Cancer: Innovations in antibody drug conjugates and immunotherapy.\u003c\/p\u003e\n\u003cp\u003eKidney Cancer: Biomarkers and new treatment strategies.\u003c\/p\u003e\n\u003cp\u003eUpper Tract Urothelial Carcinoma: Kidney-sparing approaches and perioperative therapies.\u003c\/p\u003e\n\u003ch3\u003eThe American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025 is tailored for professionals involved in genitourinary oncology, including:\u003c\/h3\u003e\n\u003cp\u003eMedical oncologists specializing in prostate, bladder, kidney, and other genitourinary cancers.\u003c\/p\u003e\n\u003cp\u003eUrologists and radiation oncologists focused on multimodal treatment strategies.\u003c\/p\u003e\n\u003cp\u003eResearchers and scientists presenting groundbreaking studies on biomarkers and emerging therapies.\u003c\/p\u003e\n\u003cp\u003eHealthcare providers interested in the latest advancements in immunotherapy, targeted treatments, and surgical innovations.\u003c\/p\u003e\n\u003cp\u003ePharmaceutical and biotech professionals exploring novel drug developments.\u003c\/p\u003e\n\u003cp\u003ePatient advocates and policy experts working to improve cancer care accessibility.\u003c\/p\u003e\n\u003cp\u003eThe symposium offers multidisciplinary perspectives, interactive sessions, and networking opportunities to enhance patient outcomes.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThursday, February 13, 2025\u003c\/p\u003e\n\u003cp\u003e7:00 AM-\u003c\/p\u003e\n\u003cp\u003e8:00 AM\u003c\/p\u003e\n\u003cp\u003eComplimentary Continental Breakfast\u003c\/p\u003e\n\u003cp\u003e7:00 AM-\u003c\/p\u003e\n\u003cp\u003e6:45 AM\u003c\/p\u003e\n\u003cp\u003eExhibits Open\u003c\/p\u003e\n\u003cp\u003e8:00 AM-\u003c\/p\u003e\n\u003cp\u003e9:40 AM\u003c\/p\u003e\n\u003cp\u003eOral Abstract Session A: Prostate CancerKosj Yamoah, MD, PhD—Chair\u003c\/p\u003e\n\u003cp\u003eH. Lee Moffitt Cancer Center and Research InstituteChanning Judith Paller, MD—Chair\u003c\/p\u003e\n\u003cp\u003eThe Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPeter Hoskin, MD, FRCP, FRCR\u003c\/p\u003e\n\u003cp\u003eWelcome of the Day\u003c\/p\u003e\n\u003cp\u003eABSTRACT 308: Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.\u003c\/p\u003e\n\u003cp\u003eABSTRACT 309: Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).\u003c\/p\u003e\n\u003cp\u003eEdwin Posadas, MD, FACP\u003c\/p\u003e\n\u003cp\u003eCedars-Sinai Medical Center\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003eABSTRACT 20: Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).\u003c\/p\u003e\n\u003cp\u003eTanya B. Dorff, MD\u003c\/p\u003e\n\u003cp\u003eCity of Hope Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eUnderstanding Radioligand Therapies for Advanced Prostate CancerAngela Y Jia, MD, PhD—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity Hospitals Seidman Cancer Center and Case Western Reserve UniversityDevaki Shilpa Surasi, MBBS—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of Texas at MD Anderson Cancer Center\u003c\/p\u003e\n\u003cp\u003ePSMA-Based Therapy in Advanced Disease: Touching on Combination SequencingWilliam Kevin Kelly, DO\u003c\/p\u003e\n\u003cp\u003eThomas Jefferson University Hospital\u003c\/p\u003e\n\u003cp\u003eBeyond PSMA-Targeted Agents for Advanced Disease\u003c\/p\u003e\n\u003cp\u003eDanny Mena Cortes\u003c\/p\u003e\n\u003cp\u003eNuclear Medicine World\u003c\/p\u003e\n\u003cp\u003eSeeing Is Believing: Radiographic Criteria to Assess Response\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003ePoster Session A: Prostate Cancer\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session A: Prostate Cancer\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eTrainee and Early-Career Networking LuncheonView the networking faculty list here\u003c\/p\u003e\n\u003cp\u003eCase-Based Session: Management of Biochemical Recurrence After Radiation Therapy for Localized Prostate CancerMichael Cookson, MD, MMHC, FACS—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of Oklahoma College of MedicineBarbara Jereczek-Fossa, MD—Chair\u003c\/p\u003e\n\u003cp\u003eIEO European Institute of Oncology IRCCSMichael Cookson, MD, MMHC, FACS\u003c\/p\u003e\n\u003cp\u003eUniversity of Oklahoma College of Medicine\u003c\/p\u003e\n\u003cp\u003eRecurrence After Radiation Therapy: Evaluation, Management, and Outcomes\u003c\/p\u003e\n\u003cp\u003eHeather H. Cheng, MD, PhD\u003c\/p\u003e\n\u003cp\u003eUniversity of Washington\u003c\/p\u003e\n\u003cp\u003eMedical Oncology\u003c\/p\u003e\n\u003cp\u003eJuanita Crook, FRCPC\u003c\/p\u003e\n\u003cp\u003eThe University of British Columbia\u003c\/p\u003e\n\u003cp\u003eRadiation Oncology\u003c\/p\u003e\n\u003cp\u003eThomas Polascik, MD\u003c\/p\u003e\n\u003cp\u003eDuke University Division of Urologic Surgery\u003c\/p\u003e\n\u003cp\u003eUrology (Ablative Focal)\u003c\/p\u003e\n\u003cp\u003eAshley Ross, MD, PhD\u003c\/p\u003e\n\u003cp\u003eNorthwestern University Feinberg School of Medicine\u003c\/p\u003e\n\u003cp\u003eUrology (Salvage Surgery)\u003c\/p\u003e\n\u003cp\u003eAlicia K. Morgans, MD, MPH, FASCO\u003c\/p\u003e\n\u003cp\u003eDana-Farber Cancer Institute\u003c\/p\u003e\n\u003cp\u003eThe Impact of Salvage Therapies: Functional Outcomes and Quality of Life\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eKeynotePeter Hoskin, MD, FRCP, FRCR – Chair\u003c\/p\u003e\n\u003cp\u003eMount Vernon Cancer Centre, University College London, and University of Manchester\u003c\/p\u003e\n\u003cp\u003eIntroduction of Dr. DahutWilliam L. Dahut, MD\u003c\/p\u003e\n\u003cp\u003eAmerican Cancer Society\u003c\/p\u003e\n\u003cp\u003eCreative Innovation: Driving Science to Improve Patient-Centered CareQuestion and Answer\u003c\/p\u003e\n\u003cp\u003e3:05 PM-\u003c\/p\u003e\n\u003cp\u003e3:30 PM\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003e3:30 PM-\u003c\/p\u003e\n\u003cp\u003e4:45 PM\u003c\/p\u003e\n\u003cp\u003eCase-Based Session: Evolving Landscape of the Management of Oligometastatic DiseaseKaren E. Hoffman, MD, MHSc, MPH—Chair\u003c\/p\u003e\n\u003cp\u003eThe University of Texas MD Anderson Cancer CenterNicholas David James—Chair\u003c\/p\u003e\n\u003cp\u003eInstitute of Cancer Research, The Royal Marsden Hospital NHS Foundation TrustABSTRACT 15: World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.\u003c\/p\u003e\n\u003cp\u003eKenneth L. Gage, MD, PhD\u003c\/p\u003e\n\u003cp\u003eH. Lee Moffitt Cancer Center and Research Institute\u003c\/p\u003e\n\u003cp\u003eRadiology\u003c\/p\u003e\n\u003cp\u003eBrandon A. Mahal, MD\u003c\/p\u003e\n\u003cp\u003eUniversity of Miami\u003c\/p\u003e\n\u003cp\u003eRadiation Oncology\u003c\/p\u003e\n\u003cp\u003eKasmintan A. Schrader, PhD, MBBS\u003c\/p\u003e\n\u003cp\u003eBC Cancer\u003c\/p\u003e\n\u003cp\u003eGenetics\u003c\/p\u003e\n\u003cp\u003eSandy Srinivas, MD\u003c\/p\u003e\n\u003cp\u003eStanford School of Medicine\u003c\/p\u003e\n\u003cp\u003eMedical Oncology\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003e5:00 PM-\u003c\/p\u003e\n\u003cp\u003e5:45 PM\u003c\/p\u003e\n\u003cp\u003eRapid Oral Abstract Session A: Prostate CancerMarjory Jolicoeur, MD, PhD, FRCPC—Chair\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003ePoster Session A (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Wine and Cheese Reception\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session A (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Wine and Cheese Reception\u003c\/p\u003e\n\u003cp\u003ePoster Walks: Prostate CancerMarjory Jolicoeur, MD, PhD, FRCPC\u003c\/p\u003e\n\u003cp\u003eHôpital Charles-LeMoyne\u003c\/p\u003e\n\u003cp\u003ePoster Walk LeaderChanning Judith Paller, MD\u003c\/p\u003e\n\u003cp\u003eThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\u003c\/p\u003e\n\u003cp\u003ePoster Walk Leader\u003c\/p\u003e\n\u003cp\u003e6:00 PM-\u003c\/p\u003e\n\u003cp\u003e6:45 PM\u003c\/p\u003e\n\u003cp\u003eWomen’s Networking Reception\u003c\/p\u003e\n\u003cp\u003eFriday, February 14, 2025\u003c\/p\u003e\n\u003cp\u003eComplimentary Continental Breakfast\u003c\/p\u003e\n\u003cp\u003eExhibits Open\u003c\/p\u003e\n\u003cp\u003eOral Abstract Session B: Urothelial CarcinomaElizabeth A. Guancial, MD—Chair\u003c\/p\u003e\n\u003cp\u003eFlorida Cancer Specialists \u0026amp; Research InstituteNicholas I. Simon, MD, MSc—Chair\u003c\/p\u003e\n\u003cp\u003eNational Cancer InstituteAndrea B Apolo, MD\u003c\/p\u003e\n\u003cp\u003eWelcome of the Day\u003c\/p\u003e\n\u003cp\u003eElizabeth R. Plimack, MD, FASCO, MS\u003c\/p\u003e\n\u003cp\u003eFox Chase Cancer Center, Temple Health\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003eScot Anthony Niglio, MD, MS\u003c\/p\u003e\n\u003cp\u003eNational Institutes of Health Division of Occupational Health and Safety\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eCase-Based Session: Non-Muscle Invasive Bladder Cancer: Exploring Therapies Beyond Bacillus Calmette-GuérinBrian Christopher Baumann, MD—Chair\u003c\/p\u003e\n\u003cp\u003eSpringfield ClinicBogdana Schmidt, MD, MPH—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of Utah\u003c\/p\u003e\n\u003cp\u003eThe Changing World of Non-Muscle Invasive Bladder CancerCase Presentation\u003c\/p\u003e\n\u003cp\u003eGirish S. Kulkarni, MD, PhD\u003c\/p\u003e\n\u003cp\u003eDepartment of Surgical Oncology, Princess Margaret Cancer Center, University Health Network\u003c\/p\u003e\n\u003cp\u003eUrology\u003c\/p\u003e\n\u003cp\u003eMark Tyson, MPH\u003c\/p\u003e\n\u003cp\u003eMayo Clinic Arizona\u003c\/p\u003e\n\u003cp\u003eUrology\u003c\/p\u003e\n\u003cp\u003eTracy L Rose, MD\u003c\/p\u003e\n\u003cp\u003eUniversity of North Carolina at Chapel Hill\u003c\/p\u003e\n\u003cp\u003eMedical Oncology\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003ePoster Session B: Urothelial Carcinoma\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session B: Urothelial Carcinoma\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eBreakout Session: Emerging Trends and Advances in Germ Cell TumorsAditya Bagrodia, MD—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of California, San Diego HealthAnja Lorch, MD—Chair\u003c\/p\u003e\n\u003cp\u003eUniversitätsspital ZürichNabil Adra, MD\u003c\/p\u003e\n\u003cp\u003eIndiana University Health Melvin and Bren Simon Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eHigh-Dose Chemotherapy in Testicular Cancer: Current Evidence and Clinical Indications\u003c\/p\u003e\n\u003cp\u003eAxel Heidenreich, MD\u003c\/p\u003e\n\u003cp\u003eUniversity Hospital of Cologne\u003c\/p\u003e\n\u003cp\u003ePrimary Retroperitoneal Lymph Node Dissection in Stage II Seminoma: Management Strategies and Current Controversies\u003c\/p\u003e\n\u003cp\u003eDarren R. Feldman, MD\u003c\/p\u003e\n\u003cp\u003eMemorial Sloan Kettering Cancer Center\u003c\/p\u003e\n\u003cp\u003eLandscape of New Trials and Targets in Refractory Germ Cell Tumors\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eThe ABCs of ADCs: Unleashing the Power of Antibody-Drug Conjugates in Advanced Bladder CancerKent William Mouw, MD, PhD—Chair\u003c\/p\u003e\n\u003cp\u003eDana-Farber Cancer Institute, Brigham and Women’s HospitalBenjamin Garmezy, MD—Chair\u003c\/p\u003e\n\u003cp\u003eSarah Cannon Research InstituteDi Maria Jiang, MD, MSc, FRCPC\u003c\/p\u003e\n\u003cp\u003ePrincess Margaret Hospital, University Health Network\u003c\/p\u003e\n\u003cp\u003eTargeting Bladder Cancer With Antibody Drug Conjugates\u003c\/p\u003e\n\u003cp\u003eFunda Meric-Bernstam, MD, FASCO\u003c\/p\u003e\n\u003cp\u003eUniversity of Texas MD Anderson Cancer Center\u003c\/p\u003e\n\u003cp\u003eHER2 Antibody-Drug Conjugate Therapy: A New Frontier in Bladder Cancer\u003c\/p\u003e\n\u003cp\u003eDaniel Castellano, MD\u003c\/p\u003e\n\u003cp\u003eServicio de Oncología Médica, Hospital Universitario 12 de Octubre\u003c\/p\u003e\n\u003cp\u003eOvercoming Challenges of Antibody-Drug Conjugate Toxicity in Bladder Cancer\u003c\/p\u003e\n\u003cp\u003eTerence W. Friedlander, MD\u003c\/p\u003e\n\u003cp\u003eUniversity of California, San Francisco Medical Center\u003c\/p\u003e\n\u003cp\u003eBetter Together? Exploring Novel Drug Combinations With Antibody-Drug Conjugates\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003ePanning for Gold: The Role of ctDNA as a Biomarker for Bladder CancerBernadett Szabados, MBBS—Chair\u003c\/p\u003e\n\u003cp\u003eBarts Cancer CentreJoaquim Bellmunt, MD—Chair\u003c\/p\u003e\n\u003cp\u003eDana-Farber Cancer InstituteRoger Li, MD\u003c\/p\u003e\n\u003cp\u003eH. Lee Moffitt Cancer Center and Research Institute\u003c\/p\u003e\n\u003cp\u003eCapturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease?\u003c\/p\u003e\n\u003cp\u003eAlexander William Wyatt, PhD\u003c\/p\u003e\n\u003cp\u003eVancouver Prostate Centre, University of British Columbia\u003c\/p\u003e\n\u003cp\u003eEvolution of Ctdna Detection with Next Generation Technology\u003c\/p\u003e\n\u003cp\u003eNimira S. Alimohamed, FRCPC\u003c\/p\u003e\n\u003cp\u003eArthur Child Comprehensive Cancer Centre, University of Calgary\u003c\/p\u003e\n\u003cp\u003ePotential Impact of ctDNA on Perioperative Management of Muscle-Invasive Bladder Cancer\u003c\/p\u003e\n\u003cp\u003eGillian Vandekerkhove, PhD, MSc\u003c\/p\u003e\n\u003cp\u003eVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia\u003c\/p\u003e\n\u003cp\u003eBeneath the Surface: Unleashing the Potential of Ctdna across the Spectrum of Urothelial Carcinoma\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eRapid Oral Abstract Session B: Urothelial CarcinomaKatie S. Murray, DO, FACS, MS—Chair\u003c\/p\u003e\n\u003cp\u003eABSTRACT 666: Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study.\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003ePoster Session B (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Wine and Cheese Reception\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session B (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Wine and Cheese Reception\u003c\/p\u003e\n\u003cp\u003ePoster Walks: Urothelial CarcinomaElias Chandran, FRACP, MBBS\u003c\/p\u003e\n\u003cp\u003eNational Cancer Institute\u003c\/p\u003e\n\u003cp\u003ePoster Walk LeaderArmine Smith, MD\u003c\/p\u003e\n\u003cp\u003eJohns Hopkins University School of Medicine\u003c\/p\u003e\n\u003cp\u003ePoster Walk Leader\u003c\/p\u003e\n\u003cp\u003eSaturday, February 15, 2025\u003c\/p\u003e\n\u003cp\u003eComplimentary Continental Breakfast\u003c\/p\u003e\n\u003cp\u003ePoster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers\u003c\/p\u003e\n\u003cp\u003eOral Abstract Session C: Renal Cell CancerArpita Desai, MD—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of California, San FranciscoDaniel Shapiro—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of Wisconsin-MadisonTodd Matthew Morgan, MD\u003c\/p\u003e\n\u003cp\u003eWelcome of the Day\u003c\/p\u003e\n\u003cp\u003eTian Zhang, MD, MHS\u003c\/p\u003e\n\u003cp\u003eUT Southwestern University\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003eABSTRACT 618: Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.\u003c\/p\u003e\n\u003cp\u003eClint Cary, MD, MBA, MPH\u003c\/p\u003e\n\u003cp\u003eIndiana University Simon Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eBiomarkers and Adjuvant Therapy for Renal Cell Carcinoma: Current State and Future DirectionsShuchi Gulati, MD, MS, FACP—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of California, Davis Comprehensive Cancer CenterAxel Bex, MD, PhD—Chair\u003c\/p\u003e\n\u003cp\u003eSimpa Samuel Salami, MD, MPH\u003c\/p\u003e\n\u003cp\u003eUniversity of Michigan\u003c\/p\u003e\n\u003cp\u003eBiomarkers in Renal Cell Carcinoma: Dead End or Turning Point?\u003c\/p\u003e\n\u003cp\u003eSamra Turajlic, MD, PhD\u003c\/p\u003e\n\u003cp\u003eThe Francis Crick Institute\u003c\/p\u003e\n\u003cp\u003eThe Future of Biomarkers in Renal Cell Carcinoma\u003c\/p\u003e\n\u003cp\u003eLaurence Albiges, MD, PhD\u003c\/p\u003e\n\u003cp\u003eGustave Roussy, Université Paris Saclay\u003c\/p\u003e\n\u003cp\u003eAdjuvant Therapy in Renal Cell Cancer: A Practical Guide\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003ePoster Session C (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session C (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eWomen in Genitourinary Cancers Networking LuncheonView the networking faculty list here\u003c\/p\u003e\n\u003cp\u003ePoster Walks: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral CancersBrittney Cotta, MD\u003c\/p\u003e\n\u003cp\u003eUniversity of Texas MD Anderson Cancer Center\u003c\/p\u003e\n\u003cp\u003ePoster Walk LeaderShuchi Gulati, MD, FACP, MS\u003c\/p\u003e\n\u003cp\u003eUC Davis Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003ePoster Walk Leader\u003c\/p\u003e\n\u003cp\u003e12:45 PM-\u003c\/p\u003e\n\u003cp\u003e​​​​​​​1:30 PM\u003c\/p\u003e\n\u003cp\u003eRapid Oral Abstract Session C: Renal Cell CancerBrittney Cotta, MD—Chair\u003c\/p\u003e\n\u003cp\u003eABSTRACT 444: Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO).\u003c\/p\u003e\n\u003cp\u003eABSTRACT 1: EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eCase-Based Session: Failure of Immunotherapy in Renal Cell Cancer: What’s Next?Leslie K. Ballas, MD—Chair\u003c\/p\u003e\n\u003cp\u003eCedars-Sinai Medical CenterKathryn Hacker Gessner, MD, PhD—Chair\u003c\/p\u003e\n\u003cp\u003eUNC School of MedicineMaria T. Bourlon, MD, MSc, FASCO\u003c\/p\u003e\n\u003cp\u003eInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán\u003c\/p\u003e\n\u003cp\u003eMedical Oncology\u003c\/p\u003e\n\u003cp\u003eMatthew T Campbell, MD, MS\u003c\/p\u003e\n\u003cp\u003eThe University of Texas MD Anderson Cancer Center\u003c\/p\u003e\n\u003cp\u003eMedical Oncology\u003c\/p\u003e\n\u003cp\u003eRaquibul Hannan, MD, PhD\u003c\/p\u003e\n\u003cp\u003eUniversity of Texas Southwestern Medical Center\u003c\/p\u003e\n\u003cp\u003eRadiation Oncology\u003c\/p\u003e\n\u003cp\u003eViraj A. Master, MD, PhD\u003c\/p\u003e\n\u003cp\u003eEmory School of Medicine\u003c\/p\u003e\n\u003cp\u003eUrology\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405726437572,"sku":null,"price":208.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/American-Society-of-Clinical-Oncology-Genitourinary-Cancers-Symposium-2025.jpg?v=1784215410"},{"product_id":"american-society-of-clinical-oncology-gastrointestinal-cancers-symposium-2025","title":"American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: oncologists, gastroenterologists, surgeons, radiation oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e2025 ASCO Gastrointestinal (GI) Cancers Symposium, which offers the latest innovative science, solution-focused strategies, and multidisciplinary approaches in GI cancer treatment, research, and care\u003c\/p\u003e\n\u003cp\u003eThe American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2025 will take place from Thursday, January 23 to Saturday, January 25, 2025. It offers cutting-edge science, solution-focused strategies, and multidisciplinary approaches in gastrointestinal cancer treatment, research, and care. The symposium includes sessions on emerging therapies, patient-centric management, and rapid oral abstracts on cancers of the esophagus and stomach.\u003c\/p\u003e\n\u003cp\u003eThe American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2025 is tailored for a diverse audience involved in the field of gastrointestinal oncology. This includes oncologists, gastroenterologists, surgeons, radiation oncologists, researchers, and other healthcare professionals dedicated to the treatment and management of gastrointestinal cancers. The symposium provides a platform for sharing the latest advancements in research, innovative therapies, and multidisciplinary approaches to patient care\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSyllabus: click here\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405728141508,"sku":null,"price":156.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/American-Society-of-Clinical-Oncology-Gastrointestinal-Cancers-Symposium-2025.png?v=1784215430"},{"product_id":"american-society-for-radiation-oncology-annual-refresher-course-2025","title":"American Society for Radiation Oncology Annual Refresher Course 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: radiation oncologists, radiation oncology residents, medical and clinical physicists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThe meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this  activity, participants should be able to do the following:\u003c\/h3\u003e\n\u003cp\u003eDescribe and implement the latest radiation therapy treatment recommendations for clinical scenarios commonly encountered in clinical practice.\u003c\/p\u003e\n\u003cp\u003eSafely utilize the latest radiation technologies to improve patient care.\u003c\/p\u003e\n\u003cp\u003eDescribe the data and clinical use of protons and heavy ions in the management of patients.\u003c\/p\u003e\n\u003cp\u003eAppropriately and safely incorporate the treatment of oligometastases into clinical practice.\u003c\/p\u003e\n\u003cp\u003eDescribe the management of benign diseases with radiation.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eHead and Neck\u003c\/p\u003e\n\u003cp\u003eGynecologic: Endometrial and Cervical\u003c\/p\u003e\n\u003cp\u003ePhysics: Protons and Heavy Ions\u003c\/p\u003e\n\u003cp\u003eGastrointestinal: Upper and Lower\u003c\/p\u003e\n\u003cp\u003eeContouring for Upper GI\u003c\/p\u003e\n\u003cp\u003eCentral Nervous System\u003c\/p\u003e\n\u003cp\u003eLung\u003c\/p\u003e\n\u003cp\u003eRadiobiology of Benign Disease\u003c\/p\u003e\n\u003cp\u003eBreast\u003c\/p\u003e\n\u003cp\u003eeContouring for Breast\u003c\/p\u003e\n\u003cp\u003eGenitourinary\u003c\/p\u003e\n\u003cp\u003eOligometastatic Cancers and SBRT\u003c\/p\u003e\n\u003cp\u003eSarcomas\u003c\/p\u003e\n\u003cp\u003eLymphomas\u003c\/p\u003e\n\u003cp\u003eeContouring for Lymphomas\u003c\/p\u003e\n\u003cp\u003ePediatrics\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405730369732,"sku":null,"price":58.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/American-Society-for-Radiation-Oncology-Annual-Refresher-Course-2025.png?v=1784215438"},{"product_id":"american-urological-association-annual-meeting-2025","title":"American Urological Association Annual Meeting 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: urologists, oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSunday, April 27, 202\u003c\/p\u003e\n\u003ch3\u003eOther AUA2025 Program Highlights Include:\u003c\/h3\u003e\n\u003cp\u003eNEW, Interactive Poster Sessions focused on conversations between moderators, authors, and attendees.\u003c\/p\u003e\n\u003ch3\u003eAUA2025 Learning Lab including:\u003c\/h3\u003e\n\u003cp\u003eClinical Trials in Progress: important clinical trials expected to influence practice when published\u003c\/p\u003e\n\u003cp\u003eStay for the Key Takeaways: Thought-provoking discussions with the experts on the top science presented at this year’s meeting\u003c\/p\u003e\n\u003cp\u003eThe American Urological Association (AUA) Annual Meeting 2025 is designed for urologists, oncologists, researchers, advanced practice professionals (such as physician assistants and nurse practitioners), educators, technicians, nurses, medical assistants, and medical students. It is the largest gathering of urologists worldwide, offering cutting-edge research, new guidelines, and the latest advancements in urologic medicine.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405733351620,"sku":null,"price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/American-Urological-Association-Annual-Meeting-2025.png?v=1784215456"},{"product_id":"memorial-sloan-kettering-cancer-center-foundations-in-immunotherapy-in-the-oncology-population-2026","title":"Memorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eThe Memorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026 course provides a comprehensive exploration of the principles, clinical applications, and management of immuno-oncology therapies. The program covers checkpoint inhibitors, CAR T-cell therapy, and bispecific agents across various malignancies, while offering evidence-based strategies for recognizing and mitigating immune-related adverse events.\u003c\/p\u003e\n\u003cp\u003eImmunotherapeutics have transformed the treatment landscape for patients with both solid tumors and hematologic malignancies. Since the landmark approval of ipilimumab, rapid and ongoing advancements in immunotherapy have continued to revolutionize clinical practice.\u003c\/p\u003e\n\u003cp\u003eThe goal of this program is to improve patient outcomes by advancing understanding of cancer immunology and enhancing the effective, evidence-based application of immunotherapeutic strategies in clinical practice.\u003c\/p\u003e\n\u003cp\u003eSpecialties\u003c\/p\u003e\n\u003cp\u003eSpecialties – Dermatology, Genitourinary Oncology, Hematology, Hepatology, Hospitalist, Immunotherapy, Leukemia, Lymphoma, Medical Oncology, Myeloma, Neuro-Oncology, Nurse Practitioner, Physician Assistant, Pulmonary Medicine, Solid Tumor Oncology\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eIdentify and define foundational concepts of immunotherapy, including key immune system components, mechanisms of action, and types of immunotherapeutic agents.\u003c\/p\u003e\n\u003cp\u003eExplain the biological rationale and mechanisms by which immunotherapy targets solid and hematologic malignancies, distinguishing between innate and adaptive immune responses.\u003c\/p\u003e\n\u003cp\u003eApply evidence-based immunotherapeutic approaches to the management of solid tumors and hematologic cancers, including appropriate patient selection, risk stratification, and development of individualized treatment plans.\u003c\/p\u003e\n\u003cp\u003eCompare and contrast novel immunotherapy agents, including checkpoint inhibitors, bispecific antibodies, and immune agonists, in terms of efficacy, safety profiles, and mechanisms of action.\u003c\/p\u003e\n\u003cp\u003eEvaluate the role of CAR T-cell therapy in current oncology practice, including patient eligibility, response rates, and long-term outcomes, and design a toxicity management plan for immune-related adverse events (irAEs) in immuno-oncology patients.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for oncologists and specialized nursing professionals who want foundational updates on immunotherapy protocols and adverse event management.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003eAdvancing CAR T-Cell Strategies and Combination Therapies to Improve Outcomes in Gynecologic Malignancies\u003c\/p\u003e\n\u003cp\u003eAdvancing Leukemia Care Through Immuno-Oncology\u003c\/p\u003e\n\u003cp\u003eApproaches to Immunotherapy-related Pneumonitis Management\u003c\/p\u003e\n\u003cp\u003eBreast Oncology- Using cfDNA to Forecast Immunotherapy Treatment Outcomes\u003c\/p\u003e\n\u003cp\u003eCheckpoint Inhibition as a Therapeutic Approach in Advanced Hodgkin Lymphoma\u003c\/p\u003e\n\u003cp\u003eClinical Approaches to Dermatologic Toxicity in Checkpoint Inhibitor Therapy\u003c\/p\u003e\n\u003cp\u003eDiscussion of Novel Checkpoint Inhibitors and Combination Therapy\u003c\/p\u003e\n\u003cp\u003eDostarlimab in MSI-High Gastrointestinal Cancers- Latest Data, Expansion Cohorts, and Basket Trial Insights\u003c\/p\u003e\n\u003cp\u003eEvolving Treatment Paradigms- Immunotherapy in Advanced Bladder Cancer\u003c\/p\u003e\n\u003cp\u003eIL-2-Stimulating Agents from Early Drug Development\u003c\/p\u003e\n\u003cp\u003eInnovations in Small Cell Lung Cancer- DLL3 Agents and Adjuvant Durvalumab\u003c\/p\u003e\n\u003cp\u003eIntrathecal Immunotherapy- A Novel Path in Treating Leptomeningeal Disease no video\u003c\/p\u003e\n\u003cp\u003eMelanoma Subtypes are a Microcosm for Immune Checkpoint Blockade Efficacy Across Oncology-\u003c\/p\u003e\n\u003cp\u003eNeurotoxicity in CAR T-Cell Therapy- Recognition and Management\u003c\/p\u003e\n\u003cp\u003eOverview of Adverse Events in the Cell Therapy Patient- A Discussion of CRS, ICANS, and Prolonged Cytopenias\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Discussion – 01\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Discussion – 02\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Discussion – 03\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Discussion – 04\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Discussion\u003c\/p\u003e\n\u003cp\u003eTargeting Multiple Myeloma with Bispecific Immune-Modulating Agents\u003c\/p\u003e\n\u003cp\u003eThe Role of T-Cell Therapy in Standard Care for Synovial Sarcoma\u003c\/p\u003e\n\u003cp\u003eUnderstanding Chimeric Antigen Receptor (CAR) T-Cell Therapy\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405744230596,"sku":null,"price":45.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-Foundations-in-Immunotherapy-in-the-Oncology-Population-2026.jpg?v=1784215535"},{"product_id":"oakstone-gynecologic-pathology-2026","title":"Oakstone Gynecologic Pathology 2026","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: pathologists, gynecologic oncologists, and pathology trainees\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eGynecologic Pathology Advances\u003c\/p\u003e\n\u003cp\u003eIn this online program, you’ll encounter the latest discoveries and diagnostic challenges in gynecologic pathology, focusing on biopsies, resections, and gestational trophoblastic neoplasia. You’ll examine commonly encountered specimens such as endometrial and cervical biopsies, as well as the complex mesenchymal lesions that often pose diagnostic difficulties.\u003c\/p\u003e\n\u003ch3\u003eOrganized by anatomic location and neoplasia subtypes, the Gynecologic Pathology course — part of our Masters of Pathology Series — will help you build a structured and practical approach to interpreting a wide range of gynecologic specimens. It’s continuing medical education that:\u003c\/h3\u003e\n\u003cp\u003eEnsures you’re current with novel emerging diagnostic classification schemes and the newly developed endometrial staging system\u003c\/p\u003e\n\u003cp\u003eDemonstrates how to integrate a wide array of immunohistochemical stains and molecular assays alongside morphologic features in surgical pathology\u003c\/p\u003e\n\u003cp\u003eDATE OF ORIGINAL RELEASE: March 31, 2026\u003c\/p\u003e\n\u003cp\u003eESTIMATED TIME TO COMPLETE: 14.25 hours\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this activity, participants should be able to:\u003c\/h3\u003e\n\u003cp\u003eDescribe the classification of vulvar squamous neoplasia and current staging approaches for vulvar cancer\u003c\/p\u003e\n\u003cp\u003eDescribe the classification of cervical squamous and glandular neoplasia and current staging approaches for cervical cancer\u003c\/p\u003e\n\u003cp\u003eApply the TCGA molecular classification of endometrial carcinoma and explain its implications for FIGO staging\u003c\/p\u003e\n\u003cp\u003eRecognize preinvasive endometrial lesions and diagnostic considerations in patients receiving progestin therapy\u003c\/p\u003e\n\u003cp\u003eDetermine appropriate ancillary testing strategies for the diagnosis of uterine mesenchymal neoplasms\u003c\/p\u003e\n\u003cp\u003eDescribe morphologic and immunohistochemical features of serous tubal intraepithelial carcinoma and other p53-abnormal lesions of the fallopian tube lesions\u003c\/p\u003e\n\u003cp\u003eAssess low-grade serous neoplasia and associated peritoneal implants\u003c\/p\u003e\n\u003cp\u003eDescribe key morphologic features and ancillary testing approaches used in the diagnosis of ovarian carcinomas\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThis educational activity is intended for pathologists, gynecologic oncologists, and pathology trainees (residents, fellows).\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eClassification of Vulvar Squamous Lesions – Non-Invasive – Jaclyn Watkins, MD, MS\u003c\/p\u003e\n\u003cp\u003eClassification and Staging of Vulvar Squamous Cell Carcinoma – Jaclyn Watkins, MD, MS\u003c\/p\u003e\n\u003cp\u003eVulvovaginal Mesenchymal Lesions – Tumors – Marisa R. Nucci, MD\u003c\/p\u003e\n\u003cp\u003eSquamous Dysplasia of the Lower Anogenital Tract – Eric Yang, MD, PhD\u003c\/p\u003e\n\u003cp\u003eClassification of Cervical Glandular Lesions – Non-Invasive – Kay Park, MD\u003c\/p\u003e\n\u003cp\u003eSlide Session – Non-Invasive Glandular Lesions of the Cervix – Kay Park, MD\u003c\/p\u003e\n\u003cp\u003eClassification of Invasive Cervical Adenocarcinoma – Kay Park, MD\u003c\/p\u003e\n\u003cp\u003eStaging of Cervical Carcinomas – Kay Park, MD\u003c\/p\u003e\n\u003cp\u003eSlide Session – HPVA Adenocarcinomas – Kay Park, MD\u003c\/p\u003e\n\u003cp\u003eSlide Session – HPVI Adenocarcinomas – Kay Park, MD\u003c\/p\u003e\n\u003cp\u003eApproach to the Endometrial Biopsy – Jaclyn Watkins, MD, MS\u003c\/p\u003e\n\u003cp\u003eDiagnosis of Atypical Hyperplasia-EIN and Progestin Therapy – Brooke E. Howitt, MD\u003c\/p\u003e\n\u003cp\u003eEndometrial Carcinoma – Molecular Classification – Brooke E. Howitt, MD\u003c\/p\u003e\n\u003cp\u003eEndometrial Carcinoma – Integration of Histotype and Molecular Subtype – Brooke E. Howitt, MD\u003c\/p\u003e\n\u003cp\u003eFIGO 2023 Endometrial Cancer Staging – Joseph Rabban MD MPH\u003c\/p\u003e\n\u003cp\u003eHigh Risk Endometrial Cancers that Mimic Low Grade Endometrioid Carcinoma – Joseph Rabban, MD, MPH\u003c\/p\u003e\n\u003cp\u003eSmooth Muscle Tumors of the Uterus and Mimics – Brooke E. Howitt, MD\u003c\/p\u003e\n\u003cp\u003eEndometrial Stromal and Non-Smooth Muscle Mesenchymal Neoplasms – Brooke E. Howitt, MD\u003c\/p\u003e\n\u003cp\u003eAdenosarcoma and Mimics – Brooke E. Howitt, MD\u003c\/p\u003e\n\u003cp\u003ePre-Invasive Lesions of the Fallopian Tube – Brooke E. Howitt, MD\u003c\/p\u003e\n\u003cp\u003eSlide Session – Lesions of the Fallopian Tube – Brooke E. Howitt, MD\u003c\/p\u003e\n\u003cp\u003eSerous Borderline-Low-Grade Serous Carcinomas of the Ovary and Implants – Teri A. Longacre, MD\u003c\/p\u003e\n\u003cp\u003eApproach to Tumor Typing of High Risk Ovarian Cancers – Joseph Rabban, MD, MPH\u003c\/p\u003e\n\u003cp\u003eSex Cord Stromal Tumors of the Ovary – Part 1 – Jaclyn Watkins, MD, MS\u003c\/p\u003e\n\u003cp\u003eSex Cord Stromal Tumors of the Ovary – Part 2 – Jaclyn Watkins, MD, MS\u003c\/p\u003e\n\u003cp\u003eEndometriosis and Endometriosis-Associated Cancers – Jaclyn Watkins, MD, MS\u003c\/p\u003e\n\u003cp\u003eGestational Trophoblastic Disease – Ann Folkins, MD\u003c\/p\u003e\n\u003cp\u003eBiomarker Interpretation in Gynecologic Tumors – Brooke E. Howitt, MD\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405749342404,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}]},{"product_id":"arbeitsgemeinschaft-dermatologie-onkologie-dermato-onkologie-update-2026-german","title":"Arbeitsgemeinschaft Dermatologie Onkologie Dermato-Onkologie UPDATE 2026 German","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: dermatologists and oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWARNING: This course German, not English\u003c\/p\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eEvaluate evidence-based approaches to cancer screening and understand the impact of nutrition and structured exercise on tumor diseases.\u003c\/p\u003e\n\u003cp\u003eImplement updated adjuvant, neoadjuvant, and intratumoral therapies for advanced cutaneous melanoma, ocular melanoma, and non-melanoma skin cancers.\u003c\/p\u003e\n\u003cp\u003eIdentify key cutaneous tumor syndromes and effectively utilize radiological diagnostics for pre- and post-therapeutic dermatological assessments.\u003c\/p\u003e\n\u003cp\u003eFormulate comprehensive patient care plans addressing fertility preservation, structured rehabilitation, and side-effect management of targeted, immune, and chemotherapies.\u003c\/p\u003e\n\u003cp\u003eAssess the practical applications and limitations of AI tools, such as ChatGPT, in the field of dermato-oncology.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for dermatologists and oncologists who want updates on melanoma treatments, non-melanoma skin cancers, and dermato-oncology management.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003ch3\u003eTopics (17 Lectures):\u003c\/h3\u003e\n\u003cp\u003e01 Begrüßung und Eröffnung der Veranstaltung\u003c\/p\u003e\n\u003cp\u003e02 Krebsfrüherkennung – Was sagt die Evidenz\u003c\/p\u003e\n\u003cp\u003e03 Welchen Einfluss hat die Ernährung auf Tumorerkrankungen\u003c\/p\u003e\n\u003cp\u003e04 Die adjuvante und neoadjuvante Therapie des Melanoms- Eine Erfolgsgeschichte\u003c\/p\u003e\n\u003cp\u003e05 Das fortgeschrittene kutane und okuläre Melanom- Was tun\u003c\/p\u003e\n\u003cp\u003e06 Podiumsdiskussion- Kontroversen in der Behandlung des Melanoms\u003c\/p\u003e\n\u003cp\u003e07 Hauttumor-Syndrome- Welche sollten wir kennen\u003c\/p\u003e\n\u003cp\u003e08 Radiologische Diagnostik für Dermatologen (prä- und posttherapeutische Beurteilungen)\u003c\/p\u003e\n\u003cp\u003e09 Basiswissen für onkologische Therapien (ein Kursus für „noch nicht-Experten“)\u003c\/p\u003e\n\u003cp\u003e10 Kinderwunsch bei Tumorerkrankungen\u003c\/p\u003e\n\u003cp\u003e11 Strukturierte Bewegungstherapie bei Krebs- Was bringt es\u003c\/p\u003e\n\u003cp\u003e12 Rehabilitation bei Hauttumorerkrankungen- was ist möglich und was bringt es\u003c\/p\u003e\n\u003cp\u003e13 Podiumsdiskussion- Kontroversen beim Non Melanoma Skin Cancer\u003c\/p\u003e\n\u003cp\u003e14 Neue Publikationen und Studien zum CSCC BCC MCC\u003c\/p\u003e\n\u003cp\u003e15 Intratumorale Therapien beim (metastasierten) Melanom und Non Melanoma Skin Cancer\u003c\/p\u003e\n\u003cp\u003e16 Wie kann uns Chat-GPT in der Dermato-Onkologie weiterhelfen.\u003c\/p\u003e\n\u003cp\u003e17 Tipps und Tricks beim Nebenwirkungsmanagement von Targeted Therapies, Immun- und Chemotherapien\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405749539012,"sku":null,"price":52.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Arbeitsgemeinschaft-Dermatologie-Onkologie-Dermato-Onkologie-UPDATE-2026-German.jpg?v=1784215596"},{"product_id":"memorial-sloan-kettering-cancer-center-update-in-hematology-and-medical-oncology-2026","title":"Memorial Sloan Kettering Cancer Center Update in Hematology and Medical Oncology 2026","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: hematologists and medical oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eThis course is designed for medical oncology professionals — including physicians, nurses, pharmacists, advanced practice providers, fellows, and residents — seeking a comprehensive update in Medical Oncology and Hematology.\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eDefine state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers and hematologic cancers\u003c\/p\u003e\n\u003cp\u003eDiscuss recent treatment advances in solid tumor and hematologic oncology and apply knowledge gained in modern clinical practice\u003c\/p\u003e\n\u003cp\u003ePrepare for ABIM examinations in medical oncology and hematology\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for hematologists and medical oncologists who want comprehensive updates on the management of hematologic malignancies and solid tumors.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003eAcute Lymphocytic Leukemia\u003c\/p\u003e\n\u003cp\u003eAcute Myeloid Leukemia\u003c\/p\u003e\n\u003cp\u003eAnal and Rectal Cancers\u003c\/p\u003e\n\u003cp\u003eAnticoagulation- Update on an Evolving Field\u003c\/p\u003e\n\u003cp\u003eApporach to the Bleeding Patient\u003c\/p\u003e\n\u003cp\u003eAuto _Allo\u003c\/p\u003e\n\u003cp\u003eBreast Cancer- Radiation Therapy\u003c\/p\u003e\n\u003cp\u003eBreast Cancer- Surgery\u003c\/p\u003e\n\u003cp\u003eCAR T Cell\u003c\/p\u003e\n\u003cp\u003eCarcinoma of Unknown Primary\u003c\/p\u003e\n\u003cp\u003eCentral Nervous System Tumors\u003c\/p\u003e\n\u003cp\u003eChronic Lymphocytic Leukemia _Small Lymphocytic Lymphoma\u003c\/p\u003e\n\u003cp\u003eChronic Myelogenous Leukemia\u003c\/p\u003e\n\u003cp\u003eClinical Indications for Use of Blood Products and Associated Risks\u003c\/p\u003e\n\u003cp\u003eColon Cancer\u003c\/p\u003e\n\u003cp\u003eDiffuse Large B-Cell Lymphoma _Mantle Cell Lymphoma _Burkitt Lymphoma\u003c\/p\u003e\n\u003cp\u003eEsophageal and Gastric Cancers\u003c\/p\u003e\n\u003cp\u003eHead and Neck, Thyroid, and Non-Melanoma Skin Cancers\u003c\/p\u003e\n\u003cp\u003eHemolytic Anemia\u003c\/p\u003e\n\u003cp\u003eHepatocellular Cancer and Cholangiocarcinoma\u003c\/p\u003e\n\u003cp\u003eHER2-Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eHereditary Cancer Genetics\u003c\/p\u003e\n\u003cp\u003eHodgkin Lymphoma_T Cell\u003c\/p\u003e\n\u003cp\u003eHormone Receptor-Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eInfectious Disease\u003c\/p\u003e\n\u003cp\u003eKidney Cancer\u003c\/p\u003e\n\u003cp\u003eLow-Grade Non-Hodgkin Lymphoma\u003c\/p\u003e\n\u003cp\u003eMelanoma\u003c\/p\u003e\n\u003cp\u003eMesothelioma\u003c\/p\u003e\n\u003cp\u003eMyelodysplastic\u003c\/p\u003e\n\u003cp\u003eMyeloma_Amyloid\u003c\/p\u003e\n\u003cp\u003eMyeloproliferative Neoplasms\u003c\/p\u003e\n\u003cp\u003eNon-Small Cell Lung Cancer\u003c\/p\u003e\n\u003cp\u003eOvarian Cancer\u003c\/p\u003e\n\u003cp\u003ePancreatic and Neuroendocrine Cancers\u003c\/p\u003e\n\u003cp\u003ePharmacology I_II\u003c\/p\u003e\n\u003cp\u003eProstate Cancer\u003c\/p\u003e\n\u003cp\u003eSarcoma\u003c\/p\u003e\n\u003cp\u003eSickle Cell Disease, Thalassemia\u003c\/p\u003e\n\u003cp\u003eSmall Cell Lung Cancer\u003c\/p\u003e\n\u003cp\u003eTestis Cancer\u003c\/p\u003e\n\u003cp\u003eThrombocytopenia and ITP\u003c\/p\u003e\n\u003cp\u003eThrombotic Disorders\u003c\/p\u003e\n\u003cp\u003eTransfusion Reactions\u003c\/p\u003e\n\u003cp\u003eTriple-Negative Breast Cancer\u003c\/p\u003e\n\u003cp\u003eUrothelial Cancer\u003c\/p\u003e\n\u003cp\u003eUterine, Cervix, and Other Gynecologic Cancers\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405749997764,"sku":null,"price":260.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-Update-in-Hematology-and-Medical-Oncology-2026.jpg?v=1784215610"},{"product_id":"international-iv-nutritional-therapy-iv-nutrient-therapies-in-oncology-jan-2026","title":"International IV Nutritional Therapy IV Nutrient Therapies in Oncology JAN 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude: 2 videos, size: 5.72 GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: integrative oncologists, naturopathic doctors, and specialized nurses\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eUnderstand the physiological rationale and mechanisms of action for utilizing IV nutrient therapies in the context of oncology.\u003c\/p\u003e\n\u003cp\u003eFormulate safe and effective intravenous protocols to support nutritional status and mitigate the side effects of conventional cancer treatments.\u003c\/p\u003e\n\u003cp\u003eEvaluate the latest clinical evidence regarding high-dose IV Vitamin C and other targeted nutrient infusions in cancer care.\u003c\/p\u003e\n\u003cp\u003eImplement strict safety, osmolarity, and compounding standards when administering IV therapies to immunocompromised or frail oncology patients.\u003c\/p\u003e\n\u003cp\u003eIntegrate IV nutritional therapies cohesively with existing conventional oncological treatment plans to optimize overall patient well-being.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for integrative oncologists, naturopathic doctors, and specialized nurses who want updates on IV nutrient protocols for cancer support.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003e*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below\u003c\/p\u003e\n\u003cp\u003eJanuary 17.mp4\u003c\/p\u003e\n\u003cp\u003eJanuary 18.mp4\u003c\/p\u003e\n\u003cp\u003e* Detail: no information\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405750161604,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/International-IV-Nutritional-Therapy_78c50772-2368-44e9-bbac-5e44c30ece20.png?v=1784215617"},{"product_id":"meetings-by-mail-cleveland-clinic-2nd-annual-cleveland-clinic-cancer-conference-2026","title":"Meetings By Mail Cleveland Clinic 2nd Annual Cleveland Clinic Cancer Conference 2026","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: medical oncologists, hematologists, radiation oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRelease Date: 3\/2\/26\u003c\/p\u003e\n\u003cp\u003eThe 2nd Annual Cleveland Clinic Cancer Conference features the latest advances in the diagnosis and management of the most prevalent cancers at all stages of disease and treatment.  A world renowned faculty provide disease specific, evidence-based, practical presentations representing a variety of medical disciplines.  This includes current and future strategies for cancer care, while detailing the role of emerging technologies, support and non-pharmacologic therapeutics for the cancer patient.\u003c\/p\u003e\n\u003cp\u003eTopics include: Hematologic malignancies, myeloma, amyloidosis, tumor boards, genomics, precision oncology, lung cancer, palliative care, AI, novel therapies, gynecologic cancers, sarcoma, melanoma, GI cancers, breast cancer and much more.\u003c\/p\u003e\n\u003cp\u003eTheme: Innovations in Multidisciplinary Care.\u003c\/p\u003e\n\u003cp\u003eLocation: Margaritaville Hollywood Beach Resort, Hollywood, FL (and streaming via Meetings By Mail).\u003c\/p\u003e\n\u003cp\u003eTarget Audience: Medical oncologists, hematologists, radiation oncologists, and other oncology professionals.\u003c\/p\u003e\n\u003cp\u003eKey Topics: Hematological malignancies, genomics, precision oncology, AI in cancer care, gynecological cancers, sarcoma, and palliative care.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSession 1 – Updates and State of the Art Therapy in Hematologic Malignancies\u003c\/p\u003e\n\u003cp\u003eAdvances in the Management of Myeloproliferative Neoplasm\u003c\/p\u003e\n\u003cp\u003eYehuda Galili, MD\u003c\/p\u003e\n\u003cp\u003eRecent Advances in MDS and AML: What’s Practice Changing?\u003c\/p\u003e\n\u003cp\u003eAkriti Jain, MD\u003c\/p\u003e\n\u003cp\u003eAdvances in the Management of Myeloma\/AL Amyloidosis\u003c\/p\u003e\n\u003cp\u003eJack Khouri, MD\u003c\/p\u003e\n\u003cp\u003eTumor Boards Case Panels\u003c\/p\u003e\n\u003cp\u003eBetty Hamilton, MD; Alex Mejia Garcia, MD\u003c\/p\u003e\n\u003cp\u003eSession 2 – Genomics\/Precision Oncology\u003c\/p\u003e\n\u003cp\u003eGenetic Testing: What Oncologists Should Know\u003c\/p\u003e\n\u003cp\u003eSara Rhode, MS, CGC\u003c\/p\u003e\n\u003cp\u003eThe Future of AI in Cancer Care\u003c\/p\u003e\n\u003cp\u003eAli Zarrinpar, MD, PhD\u003c\/p\u003e\n\u003cp\u003eThe Power of Minimal Residual Disease Monitoring in Personalized Cancer Care\u003c\/p\u003e\n\u003cp\u003eShlomo Koyfman, MD\u003c\/p\u003e\n\u003cp\u003ePrecision Oncology Case Presentation and Panel Discussion\u003c\/p\u003e\n\u003cp\u003eJacob Miller, MD\u003c\/p\u003e\n\u003cp\u003eSession 3 – Updates and State of the Art Therapy in Lung Cancer\u003c\/p\u003e\n\u003cp\u003eSurgical Challenges After Neo-Adjuvant Therapy\u003c\/p\u003e\n\u003cp\u003eMonisha Sudarshan, MD, MPH\u003c\/p\u003e\n\u003cp\u003eTreatment of Early-Stage and Locally Advanced NSCLC\u003c\/p\u003e\n\u003cp\u003eSuresh S. Ramalingam, MD\u003c\/p\u003e\n\u003cp\u003eSpecial Issues in Managing Metastatic NSCLC\u003c\/p\u003e\n\u003cp\u003eKhaled Hassan, MD\u003c\/p\u003e\n\u003cp\u003eCurrent Management of Small Cell Lung Cancer\u003c\/p\u003e\n\u003cp\u003eLukas Delasos, DO\u003c\/p\u003e\n\u003cp\u003eTumor Boards Case Panels\u003c\/p\u003e\n\u003cp\u003eKhaled Hassan, MD; Diana Saravia, MD\u003c\/p\u003e\n\u003cp\u003eSession 4 – Key Issues in Palliative Care\u003c\/p\u003e\n\u003cp\u003eCancer Related Anorexia-Cachexia Syndrome and Cancer Related Fatigue: Evidence Based Management and Emerging Treatments\u003c\/p\u003e\n\u003cp\u003eNivia Ruiz, MD\u003c\/p\u003e\n\u003cp\u003eAcupuncture’s Role in Cancer-Related Symptom Management\u003c\/p\u003e\n\u003cp\u003eThuy Nguyen, DAOM, LAc\u003c\/p\u003e\n\u003cp\u003eBenzodiazepines: Friend or Foe?\u003c\/p\u003e\n\u003cp\u003eKaleena Chilcote, MD\u003c\/p\u003e\n\u003cp\u003eCancer Therapy-Induced Neuropathy Management\u003c\/p\u003e\n\u003cp\u003eRenato Samala, MD\u003c\/p\u003e\n\u003cp\u003eTumor Boards Case Panels\u003c\/p\u003e\n\u003cp\u003eLaura Shoemaker, DO\u003c\/p\u003e\n\u003cp\u003eSession 5 – Novel Therapies\u003c\/p\u003e\n\u003cp\u003eAntibody Drug Conjugate: Innocent Bystander?\u003c\/p\u003e\n\u003cp\u003eWen Wee Ma, MBBS\u003c\/p\u003e\n\u003cp\u003eCAR-T Cells and Cellular Therapy\u003c\/p\u003e\n\u003cp\u003ePaolo Caimi, MD\u003c\/p\u003e\n\u003cp\u003eInnovations in Anti-Cancer RNA Therapeutics\u003c\/p\u003e\n\u003cp\u003eNatalie Silver, MD\u003c\/p\u003e\n\u003cp\u003eWhen to Watch and Wait vs. Refer to Surgery: Best Practices for Defining cCR After TNT\u003c\/p\u003e\n\u003cp\u003eEmre Gorgun, MD\u003c\/p\u003e\n\u003cp\u003eTumor Boards Case Panels\u003c\/p\u003e\n\u003cp\u003eWen Wee Ma, MBBS; Natalie Silver, MD\u003c\/p\u003e\n\u003cp\u003eSession 6 – Updates and State of the Art Therapy in Selected Solid Tumors\u003c\/p\u003e\n\u003cp\u003eMultidisciplinary Management of Gynecologic Cancers\u003c\/p\u003e\n\u003cp\u003eRobert DeBernardo, MD\u003c\/p\u003e\n\u003cp\u003eDale Shepard, MD, PhD\u003c\/p\u003e\n\u003cp\u003eMelanoma\u003c\/p\u003e\n\u003cp\u003eJames Isaacs, MD\u003c\/p\u003e\n\u003cp\u003eState of the Art Therapy in Head\/Neck and Non-Melanoma Skin Cancers: Updates in Particle Therapy and Perioperative Immunotherapy\u003c\/p\u003e\n\u003cp\u003eJacob Miller, MD\u003c\/p\u003e\n\u003cp\u003eTumor Boards Case Panels\u003c\/p\u003e\n\u003cp\u003eRobert DeBernardo, MD; Sudha Amarnath, MD\u003c\/p\u003e\n\u003cp\u003eSession 7 – Updates and State of the Art Therapy in GI Cancers\u003c\/p\u003e\n\u003cp\u003eEarly-Onset Colorectal and Other GI Cancers: Implications for Diagnosis and Treatment\u003c\/p\u003e\n\u003cp\u003eAlok Khorana, MD\u003c\/p\u003e\n\u003cp\u003eNovel Surgical Strategies in Colorectal Liver Metastases\u003c\/p\u003e\n\u003cp\u003eFederico Aucejo, MD\u003c\/p\u003e\n\u003cp\u003eShifting Treatment Paradigms in Gastro-Esophageal Cancers\u003c\/p\u003e\n\u003cp\u003eTumor Boards Case Panels\u003c\/p\u003e\n\u003cp\u003eMatthew Walsh, MD; Alok Khorana, MD\u003c\/p\u003e\n\u003cp\u003eSession 8 – Breast Cancer\u003c\/p\u003e\n\u003cp\u003eBreast Surgery Update\u003c\/p\u003e\n\u003cp\u003eStephen Grobmyer, MD\u003c\/p\u003e\n\u003cp\u003eBreast Radiation Oncology Updates\u003c\/p\u003e\n\u003cp\u003ePraveen Pendyala, MD\u003c\/p\u003e\n\u003cp\u003eAdvances in Adjuvant Therapy for Breast Cancer\u003c\/p\u003e\n\u003cp\u003eErin Roesch, MD\u003c\/p\u003e\n\u003cp\u003eLatest Updates on the Management of Metastatic Breast Cancer: Antibody -Drug Conjugates for Advanced Stage Disease\u003c\/p\u003e\n\u003cp\u003eRita Nanda, MD\u003c\/p\u003e\n\u003cp\u003eTumor Boards Case Panels\u003c\/p\u003e\n\u003cp\u003eMegan Kruse, MD; Stephen Grobmyer, MD\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405750751428,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Meetings-By-Mail-Cleveland-Clinic-2nd-Annual-Cleveland-Clinic-Cancer-Conference-2026.jpg?v=1784215634"},{"product_id":"harvard-molecular-diagnostics-current-roles-in-cancer-diagnosis-2026","title":"Harvard Molecular Diagnostics Current Roles in Cancer Diagnosis 2026","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: pathologists, oncologists, and laboratory directors\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eThe Harvard Molecular Diagnostics: Current Roles in Cancer Diagnosis 2026 program provides a comprehensive exploration of the latest advancements and practical applications in molecular oncology. The course covers critical topics such as Next-Generation Sequencing (NGS) pipelines, bioinformatics, liquid biopsies, and tumor-specific molecular markers, empowering practitioners to enhance precision medicine and diagnostic accuracy in clinical settings.\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eExplain the fundamental principles and methodologies of molecular diagnostics relevant to cancer care.\u003c\/p\u003e\n\u003cp\u003eInterpret and apply molecular test results to guide diagnosis, prognosis, and therapeutic decision-making.\u003c\/p\u003e\n\u003cp\u003eCommunicate molecular test findings effectively within interdisciplinary care teams and with patients.\u003c\/p\u003e\n\u003cp\u003eEvaluate the practical considerations of molecular testing, including test selection, cost, and access.\u003c\/p\u003e\n\u003cp\u003eIntegrate recent advances in molecular oncology into clinical practice to improve patient-centered outcomes.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for pathologists, oncologists, and laboratory directors who want updates on NGS, liquid biopsy, and advanced molecular cancer diagnostics.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003e01 Integrated Molecular Oncology in 2026 Trends and Tools for Gene Fusion Detection\u003c\/p\u003e\n\u003cp\u003e03 Translation of Molecular to Immunohistochemistry\u003c\/p\u003e\n\u003cp\u003e04 Informatics Architecture\u003c\/p\u003e\n\u003cp\u003e05 NGS Pipelines Demystified Practical Bioinformatics\u003c\/p\u003e\n\u003cp\u003e06 Tumor Mutation Burden, MSI, and HRD\u003c\/p\u003e\n\u003cp\u003e07 Indel Detection\u003c\/p\u003e\n\u003cp\u003e08 Viral Sequence Detection and Other Signatures\u003c\/p\u003e\n\u003cp\u003e09 Gene Fusion Detection and Interpretation by RNA-based NGS a Practical, Cased-based Approach\u003c\/p\u003e\n\u003cp\u003e10 Additional Informatics Analyses Detection of Clinically Significant Isoforms and Sub-gene Events through RNA andor DNA-based NGS\u003c\/p\u003e\n\u003cp\u003e11 Oncogenicity Interpretation of Gene Fusions Detected by RNA-based NGS\u003c\/p\u003e\n\u003cp\u003e12 Applications of Long-Read Sequencing for Cancer Diagnostics\u003c\/p\u003e\n\u003cp\u003e13 Liquid Biopsy and ctDNA Technical and Clinical Perspectives\u003c\/p\u003e\n\u003cp\u003e14 Panel Discussion Tissue vs Liquid Biopsy\u003c\/p\u003e\n\u003cp\u003e15 Sarcoma and Fusion Testing\u003c\/p\u003e\n\u003cp\u003e16 Molecular Diagnostics for GYN Tumors\u003c\/p\u003e\n\u003cp\u003e17 Molecular Diagnostics for Pediatric Tumors\u003c\/p\u003e\n\u003cp\u003e18 GU Cancers Molecular Markers (Only PDF, No Video)\u003c\/p\u003e\n\u003cp\u003e19 Copy Number Variation via NGS and Microarray\u003c\/p\u003e\n\u003cp\u003e20 Cytogenomics Technical Focus\u003c\/p\u003e\n\u003cp\u003e21 Cytogenomics Clinical Focus\u003c\/p\u003e\n\u003cp\u003e22 Gliomas and Methylation Profiling\u003c\/p\u003e\n\u003cp\u003e23 Germline Testing in Oncology What, When, and How\u003c\/p\u003e\n\u003cp\u003e24 Tumor-Normal Paired Sequencing Clinical Impact\u003c\/p\u003e\n\u003cp\u003e26 Melanoma Molecular Pathology\u003c\/p\u003e\n\u003cp\u003e27 Molecular Diagnostics for Breast Cancer\u003c\/p\u003e\n\u003cp\u003e29 Myeloid Neoplasms and MRD Testing\u003c\/p\u003e\n\u003cp\u003e30 Leukemia Molecular Diagnostics (B- and T-cell)\u003c\/p\u003e\n\u003cp\u003e31 Molecular Diagnostics and Lymphoma\u003c\/p\u003e\n\u003cp\u003e32 Pharmacogenomics in Oncology Management\u003c\/p\u003e\n\u003cp\u003e33 Lung Tumor Testing\u003c\/p\u003e\n\u003cp\u003eGI Cancer Case-Based Applications VIDEO + PDF Not Release\u003c\/p\u003e\n\u003cp\u003e35 Thyroid Cancer and Salivary Tumor Genomics\u003c\/p\u003e\n\u003cp\u003e36 AI in Molecular Oncology\u003c\/p\u003e\n\u003cp\u003e37 Interactive Workshop Case Report Writing and Communication\u003c\/p\u003e\n\u003cp\u003e38 The Power of Patient Partnership in Cancer Advocacy\u003c\/p\u003e\n\u003cp\u003e39 Building a Molecular Profiling Program\u003c\/p\u003e\n\u003cp\u003e40 Regulatory and Reimbursement Essentials\u003c\/p\u003e\n\u003cp\u003e41 Lab Leadership and Challenges\u003c\/p\u003e\n\u003cp\u003e42 Future Directions in Molecular Oncology\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405751013572,"sku":null,"price":71.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Harvard-Molecular-Diagnostics-Current-Roles-in-Cancer-Diagnosis-2026.jpg?v=1784215643"},{"product_id":"scripps-clinical-hematology-and-oncology-2026","title":"Scripps Clinical Hematology and Oncology 2026","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: hematologists, medical oncologists, and advanced practice providers\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eScripps Cancer Center’s Clinical Hematology and Oncology course is tailored for hematologists, oncologists, surgeons, radiation oncologists, internists, and other health care professionals seeking updates in these specialized areas. The course’s primary objective is to unite clinicians and leading experts across various fields of hematology and oncology in a collaborative and engaging environment to explore the latest clinical advancements and significant breakthroughs. This nationally accredited annual continuing medical education program stands as one of the largest hematology\/oncology conferences in the Western United States, alongside other prominent meetings such as ASH, ASCO, and the San Antonio Breast Cancer Symposium. Notably, this conference is among the few that seamlessly integrates topics from both hematology and oncology, offering a unique and comprehensive educational experience.\u003c\/p\u003e\n\u003cp\u003eCourse Date: 2026\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eExplain the clinical and molecular aspects of pathogenesis, diagnostic methods, and treatment options for a range of hematologic disorders.\u003c\/p\u003e\n\u003cp\u003eIdentify and implement evolving approaches to hematologic malignancies, with a focus on evidence-based standards of care and advancements in diagnosis and treatment.\u003c\/p\u003e\n\u003cp\u003eEvaluate and select emerging therapeutic options for managing common malignancies, while considering their appropriate indications and contraindications.\u003c\/p\u003e\n\u003cp\u003eIncorporate evolving approaches to solid tumors and breast cancer from a diagnostic, prognostic, and therapeutic perspective.\u003c\/p\u003e\n\u003cp\u003eUtilize practical insights from the clinical scenarios presented during panel discussions, focusing on evidence-based approaches to managing patients with common yet serious hematology and oncology conditions.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for hematologists, medical oncologists, and advanced practice providers who want updates on targeted therapies, immunotherapies, and cancer care.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003e02 ITP 2026 Update\u003c\/p\u003e\n\u003cp\u003e03 Transfusion Medicine for the Practicing Hem-Onc Physician\u003c\/p\u003e\n\u003cp\u003e04 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e05 Unusual Thromboses\u003c\/p\u003e\n\u003cp\u003e06 Anticoagulants and Antiplatelet Agents When to Combine and When not to\u003c\/p\u003e\n\u003cp\u003e07 VTE and Anticoagulation 2026 Update\u003c\/p\u003e\n\u003cp\u003e08 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e09 Breakout 1 Interesting Cases in Thrombosis\u003c\/p\u003e\n\u003cp\u003e10 Breakout 2 Interesting Cases in Platelet Disorders\u003c\/p\u003e\n\u003cp\u003e11 Breakout 3 Interesting Cases in Bleeding\u003c\/p\u003e\n\u003cp\u003e12 Breakout 4 Interesting Cases in Plasma Cell Dyscrasias\u003c\/p\u003e\n\u003cp\u003e13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs – Janice Mehnert, MD\u003c\/p\u003e\n\u003cp\u003e13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs – Ryan Sullivan, MD\u003c\/p\u003e\n\u003cp\u003e13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs -Allison Betof-Warner, MD, PhD\u003c\/p\u003e\n\u003cp\u003e14 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e15 Menin Inhibitors and Other New Targeted Therapies in AML\u003c\/p\u003e\n\u003cp\u003e16 Hypomethylating Agents and Beyond Cutting-Edge Approaches to MDS\u003c\/p\u003e\n\u003cp\u003e17 After IMiDs, Proteosome Inhibitors, and CD38 Antibodies Novel Approaches to RelapsedRefractory Multiple Myeloma\u003c\/p\u003e\n\u003cp\u003e18 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e19 Newer Therapeutic Options for Refractory or Relapsed Large Cell Lymphoma\u003c\/p\u003e\n\u003cp\u003e20 Non-Chemotherapy Approaches to Mantle Cell Lymphoma\u003c\/p\u003e\n\u003cp\u003e21 Progress in the Treatment of AL Amyloidosis\u003c\/p\u003e\n\u003cp\u003e22 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e23 Beyond BRCA Managing Risk in Women with Moderate-Penetrance Gene Mutations\u003c\/p\u003e\n\u003cp\u003e24 Advances in the Treatment of Metastatic Triple-Negative Breast Cancer\u003c\/p\u003e\n\u003cp\u003e25 Minimal Residual Disease, Disease Monitoring, and Therapy Selection What is the Evidence-Based role for ctDNA in Breast Cancer Therapy\u003c\/p\u003e\n\u003cp\u003e26 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e27 Neo-Adjuvant Chemo-Immunotherapy in Resectable NSCLC A New Standard of Care\u003c\/p\u003e\n\u003cp\u003e29 Comparing the Harms and Benefits of Chemo-Immunotherapy or Immunotherapy Alone in the Metastatic Setting\u003c\/p\u003e\n\u003cp\u003e30 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e31 Checkpoint Immune Therapy in the Curative Settings of GI Cancers\u003c\/p\u003e\n\u003cp\u003e32 Are TTFs and Novel Small Molecules Moving the Needle in Pancreatic Cancer\u003c\/p\u003e\n\u003cp\u003e33 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e34 De-Escalation Strategies in HPV Positive Head and Neck Cancer\u003c\/p\u003e\n\u003cp\u003e35 Cervical Cancer Updates\u003c\/p\u003e\n\u003cp\u003e36 Molecular Classification and Treatment Opportunities in Brain Tumors\u003c\/p\u003e\n\u003cp\u003e37 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e38 Optimizing Bone Health in Cancer Care During and After Treatment\u003c\/p\u003e\n\u003cp\u003e39 Management of Common Skin Related Side Effects During and After Cancer Treatment\u003c\/p\u003e\n\u003cp\u003e40 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405751177412,"sku":null,"price":65.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Scripps-Clinical-Hematology-and-Oncology-2026.jpg?v=1784215651"},{"product_id":"memorial-sloan-kettering-cancer-center-advancing-oncology-practice-2026","title":"Memorial Sloan Kettering Cancer Center Advancing Oncology Practice 2026","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: oncology advanced practice providers, nurses, and physicians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eThis two-day live virtual symposium is designed to provide a comprehensive update on advances in cancer treatment and management across the oncology care continuum. The program will highlight current evidence-based clinical practice and research initiatives; address health inequities and wellness in the oncology population; explore the evolving role of technology and social media in healthcare; and examine emerging trends in independent oncology practice and professional development. The overarching goal of this activity is to equip healthcare professionals with practical tools to deliver state-of-the-art, collaborative, team-based cancer care — ultimately improving patient outcomes and enhancing quality of life for individuals living with cancer.\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eIdentify innovative medical and surgical cancer treatment strategies for adult and pediatric cancers.\u003c\/p\u003e\n\u003cp\u003eDiscuss ethical considerations seen throughout the cancer care continuum.\u003c\/p\u003e\n\u003cp\u003eDescribe the multi-disciplinary approach and specialized teams necessary to optimize care in the oncology population.\u003c\/p\u003e\n\u003cp\u003eFormulate an optimal plan for the management of patients experiencing an oncologic emergency.\u003c\/p\u003e\n\u003cp\u003eRecognize inequities in the screening, diagnosis, and management of cancer.\u003c\/p\u003e\n\u003cp\u003eIdentify cancer risk, assessment, prevention, and treatment in patients with a hereditary predisposition.\u003c\/p\u003e\n\u003cp\u003eExplain initiatives that promote advanced practice provider practice and professional development.\u003c\/p\u003e\n\u003cp\u003eDescribe the current and future implications of artificial intelligence, social media, and advances in technology in the cancer care landscape.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for oncology advanced practice providers, nurses, and physicians who want updates on AI integration, immunotherapy, and holistic care.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003eAugmenting the Clinician- Artificial Intelligence in Oncology Decision Making\u003c\/p\u003e\n\u003cp\u003eBest Practices in Prognosis and Goals-of-Care Conversations\u003c\/p\u003e\n\u003cp\u003eBreast Cancer in the AYA Patient- Biology, Fertility, and Beyond\u003c\/p\u003e\n\u003cp\u003eBridging the Gap- Expanding Access to Comprehensive AYA Oncology Care\u003c\/p\u003e\n\u003cp\u003eCaring for Jehovah’s Witness Patients with Malignant Hematologic Diseases\u003c\/p\u003e\n\u003cp\u003eEmergencology- Managing the “Can’t Miss” Diagnoses in the Outpatient Oncology Setting\u003c\/p\u003e\n\u003cp\u003eEndometrial Cancer and a Surgical Approach\u003c\/p\u003e\n\u003cp\u003eEthical Dilemmas at the End of Life\u003c\/p\u003e\n\u003cp\u003eFrom Bedside to Bench- Expanding the APP Role in Clinical Research and Innovation\u003c\/p\u003e\n\u003cp\u003eFrom Orientation to Autonomy- The Journey to Independent Practice\u003c\/p\u003e\n\u003cp\u003eFrom Preservation to Parenthood- Uterine Transposition in Oncofertility Care\u003c\/p\u003e\n\u003cp\u003eGender-Affirming Oncology- Best Practices for Transgender Patient Care\u003c\/p\u003e\n\u003cp\u003eHealthcare Transformation Through Academic and Community-Hospitality Partnerships\u003c\/p\u003e\n\u003cp\u003eImmunotherapy Toxicities (GI-Liver) — Predict, Prevent, Protect\u003c\/p\u003e\n\u003cp\u003eInherited Risk, Informed Care- Genetics in AYA Oncology\u003c\/p\u003e\n\u003cp\u003eInnovations in Breast Reconstruction for Managing the Ptotic Breast\u003c\/p\u003e\n\u003cp\u003eLife After Cancer- Advanced Strategies for Long-Term Survivor Care\u003c\/p\u003e\n\u003cp\u003eLikes, Lies \u0026amp; Longevity- Healthcare Education in the Era of Misinformation\u003c\/p\u003e\n\u003cp\u003eOncology on the Air- Using Podcasts to Educate, Engage, and Empower\u003c\/p\u003e\n\u003cp\u003eOncology Symptom Care Without Borders- Expanding Access Beyond the Main Campus\u003c\/p\u003e\n\u003cp\u003eOncology’s Moral Crossroads- Navigating Ethical Conundrums in Cancer Care\u003c\/p\u003e\n\u003cp\u003eOne Room, Many Voices- Leveraging Shared Medical Visits in Oncology Care\u003c\/p\u003e\n\u003cp\u003eOptimizing Management of Chemotherapy-Induced Thrombocytopenia in Solid Tumors- The Role of TPO-Receptor Agonists\u003c\/p\u003e\n\u003cp\u003ePatient Perspective – The Rarest Journeys- A Patient’s Perspective on the Diagnosis and Treatment of Rare Tumors in AYA Oncology\u003c\/p\u003e\n\u003cp\u003ePrimary Palliative Care in the Community Setting\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Panel Discussion – 01\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Panel Discussion – 02\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Panel Discussion – 03\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Panel Discussion – 04\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Panel Discussion – 05\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A and Panel Discussion – 06\u003c\/p\u003e\n\u003cp\u003eRacial Disparities in the Use of Psychedelics\u003c\/p\u003e\n\u003cp\u003eRAS Therapies in Pancreas Cancer- The New Age\u003c\/p\u003e\n\u003cp\u003eReady for the Table- The APPs Impact on Preoperative Optimization and Surgical Readiness\u003c\/p\u003e\n\u003cp\u003eRecent Advancements in the Management of Gastro-Intestinal Malignancies\u003c\/p\u003e\n\u003cp\u003eRobotic Surgery Training Redefined- APP-Led Wet Labs in Surgical Oncology Fellowships\u003c\/p\u003e\n\u003cp\u003eThe Emerging Role of Immunotherapy in dMMR Colorectal Cancer\u003c\/p\u003e\n\u003cp\u003eThe Smart OR- Artificial Intelligence in Surgical Oncology\u003c\/p\u003e\n\u003cp\u003eTransplant-Associated Thrombotic Microangiopathy (TA-TMA)\u003c\/p\u003e\n\u003cp\u003eTriage and Transfer in the SCC\u003c\/p\u003e\n\u003cp\u003eVoices that Change Policy- APP Political Advocacy in Action – The Future of APP Practice in a Changing Legislative Landscape\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405751308484,"sku":null,"price":65.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-Advancing-Oncology-Practice-2026.jpg?v=1784215653"},{"product_id":"american-society-for-radiation-oncology-annual-refresher-course-2026","title":"American Society for Radiation Oncology Annual Refresher Course 2026","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: practicing radiation oncologists, radiation oncology residents, medical and clinical physicists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCourse opens: 04\/06\/2026\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThe meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this  activity, participants should be able to do the following:\u003c\/h3\u003e\n\u003cp\u003eDescribe and implement the latest radiation therapy treatment recommendations for clinical scenarios commonly encountered in clinical practice.\u003c\/p\u003e\n\u003cp\u003eSafely utilize the latest radiation technologies to improve patient care.\u003c\/p\u003e\n\u003cp\u003eDescribe the data and clinical use of protons and heavy ions in the management of patients.\u003c\/p\u003e\n\u003cp\u003eAppropriately and safely incorporate the treatment of oligometastases into clinical practice.\u003c\/p\u003e\n\u003cp\u003eDescribe the management of benign diseases with radiation.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWednesday, March 25, 2026\u003c\/p\u003e\n\u003cp\u003eWelcome and Program Introduction\u003c\/p\u003e\n\u003cp\u003eSue Yom, MD, FASTRO, UCSF\u003c\/p\u003e\n\u003cp\u003e(includes 15 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eSkin\u003c\/p\u003e\n\u003cp\u003eSpeaker: Christopher A. Barker, MD, Memorial Sloan Kettering Cancer Center\u003c\/p\u003e\n\u003cp\u003eModerator: Sue Yom, MD, FASTRO, UCSF\u003c\/p\u003e\n\u003cp\u003e(includes 20 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eHead and Neck\u003c\/p\u003e\n\u003cp\u003eSpeaker: Sean M. McBride, MD, MPH, Memorial Sloan Kettering Cancer Center\u003c\/p\u003e\n\u003cp\u003eModerator: Sue Yom, MD, FASTRO, UCSF\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003e(includes 20 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eGastrointestinal: Upper and Lower\u003c\/p\u003e\n\u003cp\u003eSpeaker: Kimberly Johung, MD, PhD, Yale School of Medicine\u003c\/p\u003e\n\u003cp\u003eModerator: Sue Yom, MD, FASTRO, UCSF\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003e(includes 20 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eGynecologic: Endometrial and Cervical\u003c\/p\u003e\n\u003cp\u003eSpeaker: Lilie Lin, MD, FASTRO, University of Texas, MD Anderson Cancer Center\u003c\/p\u003e\n\u003cp\u003eModerator: Megan E. Daly, MD, University of California Irvine,\u003c\/p\u003e\n\u003cp\u003eChao Family Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003e(includes 15 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eeContouring for Gynecologic: Vulvar and Vaginal\u003c\/p\u003e\n\u003cp\u003eSpeaker: Neil K. Taunk, MD, MS, University of Pennsylvania\u003c\/p\u003e\n\u003cp\u003eModerator: Megan E. Daly, MD, University of California Irvine,\u003c\/p\u003e\n\u003cp\u003eChao Family Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eThursday, March 26, 2026\u003c\/p\u003e\n\u003cp\u003eDay Two Welcome\u003c\/p\u003e\n\u003cp\u003eMegan E. Daly, MD, University of California Irvine,\u003c\/p\u003e\n\u003cp\u003eChao Family Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003e(includes 15 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eAdaptive Radiotherapy\u003c\/p\u003e\n\u003cp\u003eSpeaker: Lauren Henke, MD, MS, University Hospitals \/ Case Western Reserve University\u003c\/p\u003e\n\u003cp\u003eModerator: Megan E. Daly, MD, University of California Irvine,\u003c\/p\u003e\n\u003cp\u003eChao Family Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003e(includes 20 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eCentral Nervous System\u003c\/p\u003e\n\u003cp\u003eSpeaker: Michelle Kim, MD, University of Michigan\u003c\/p\u003e\n\u003cp\u003eModerator: Megan E. Daly, MD, University of California Irvine,\u003c\/p\u003e\n\u003cp\u003eChao Family Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003e(includes 20 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eBreast\u003c\/p\u003e\n\u003cp\u003eSpeaker: Jose G. Bazan, MD, MS, City of Hope Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eModerator: Megan E. Daly, MD, University of California Irvine,\u003c\/p\u003e\n\u003cp\u003eChao Family Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003e(includes 20 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eLung\u003c\/p\u003e\n\u003cp\u003eSpeaker: Nitin Ohri, MD, MS, Montefiore-Einstein Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eModerator: Megan E. Daly, MD, University of California Irvine,\u003c\/p\u003e\n\u003cp\u003eChao Family Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003e(includes 15 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eeContouring for Thoracic\u003c\/p\u003e\n\u003cp\u003eSpeaker: Katelyn Atkins, MD, PhD, Cedars-Sinai Medical Center\u003c\/p\u003e\n\u003cp\u003eModerator: Megan E. Daly, MD, University of California Irvine,\u003c\/p\u003e\n\u003cp\u003eChao Family Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eFriday, March 27, 2026\u003c\/p\u003e\n\u003cp\u003eDay Three Welcome\u003c\/p\u003e\n\u003cp\u003eSue Yom, MD, FASTRO, UCSF\u003c\/p\u003e\n\u003cp\u003e(includes 15 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eRadiopharmaceuticals\u003c\/p\u003e\n\u003cp\u003eSpeaker: Ravi Patel, MD, PhD, University of Pittsburgh Hillman Cancer Center\u003c\/p\u003e\n\u003cp\u003eModerator: Sue Yom, MD, FASTRO, UCSF\u003c\/p\u003e\n\u003cp\u003e(includes 15 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eLymphomas\u003c\/p\u003e\n\u003cp\u003eSpeaker: Andrea K. Ng, MD, MPH, FASTRO, Massachusetts General Brigham, Harvard Medical School\u003c\/p\u003e\n\u003cp\u003eModerator: Sue Yom, MD, FASTRO, UCSF\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003e(includes 20 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eGenitourinary\u003c\/p\u003e\n\u003cp\u003eSpeaker: Nicholas G. Zaorsky, MD, MS, University Hospitals \/ Case Western Reserve University\u003c\/p\u003e\n\u003cp\u003eModerator: Megan E. Daly, MD, University of California Irvine,\u003c\/p\u003e\n\u003cp\u003eChao Family Comprehensive Cancer Cente\u003c\/p\u003e\n\u003cp\u003e(includes 15 min Q\u0026amp;A)\u003c\/p\u003e\n\u003cp\u003eeContouring for Genitourinary\u003c\/p\u003e\n\u003cp\u003eSpeaker: Amar U. Kishan, MD, University of California, Los Angeles\u003c\/p\u003e\n\u003cp\u003eModerator: Megan E. Daly, MD, University of California Irvine,\u003c\/p\u003e\n\u003cp\u003eChao Family Comprehensive Cancer Cente\u003c\/p\u003e\n\u003ch3\u003eAdditional Sessions Included with onDemand:\u003c\/h3\u003e\n\u003cp\u003eGynecologic: Vulvar and Vaginal\u003c\/p\u003e\n\u003cp\u003eSpeaker: Emi J. Yoshida, MD, University of California, San Francisco\u003c\/p\u003e\n\u003cp\u003ePediatrics\u003c\/p\u003e\n\u003cp\u003eSpeaker: Ralph Ermoian, MD, University of Washington\u003c\/p\u003e\n\u003cp\u003eSarcomas\u003c\/p\u003e\n\u003cp\u003eSpeaker: B. Ashleigh Guadagnolo, MD, MPH, FASTRO, MD Anderson Cancer Center\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405752062148,"sku":null,"price":130.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/American-Society-for-Radiation-Oncology-Annual-Refresher-Course-2026.jpg?v=1784215670"},{"product_id":"harvard-psychosocial-oncology-what-to-expect-when-caring-for-an-oncology-patient-2026","title":"Harvard Psychosocial Oncology What to Expect When Caring for an Oncology Patient 2026","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: oncologists, psychiatrists, primary care physicians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePsychosocial Oncology: What to Expect When Caring for an Oncology Patient\u003c\/p\u003e\n\u003cp\u003eDeliver a comprehensive two-day, Harvard-accredited virtual conference that equips clinicians with essential skills in psychosocial oncology, from managing cancer-related mental health conditions to addressing substance use, bereavement, and supportive care needs across diverse patient populations.\u003c\/p\u003e\n\u003cp\u003eDana-Farber Cancer Institute will be offering its second annual virtual conference accredited by Harvard Medical School. This course, which has been expanded to two days based on audience feedback, will focus on the psychosocial care of patients living with cancer. With 1 out of 3 people diagnosed with cancer at some point in their life, there is an increasing need for cancer-related training among health care professionals.\u003c\/p\u003e\n\u003cp\u003eAll clinicians interested in learning more about the care of individuals living with cancer are encouraged to attend, including psychiatrists, social workers, psychologists, and primary care providers.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003cp\u003eIdentify psychosocial stressors faced by patients living with cancer.\u003c\/p\u003e\n\u003cp\u003eRecognize skills in managing the psychosocial needs of these patients.\u003c\/p\u003e\n\u003cp\u003eUnderstand the impact of cancer and cancer treatments on patients and their support systems.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eBest for oncologists, psychiatrists, social workers, and nurses who want updates on comprehensive psychosocial care for cancer patients.\u003c\/p\u003e\n\u003cp\u003eWho Should Participate\u003c\/p\u003e\n\u003cp\u003ePrimary Care Physicians, Physician Assistants, Specialty, Social workers, Psychiatrists Physicians, Psychologists, and Others\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e01 Approaching Cancer Care for the Whole Patient\u003c\/p\u003e\n\u003cp\u003e02 Overview of Cancer Treatment and Treatment Side Effects\u003c\/p\u003e\n\u003cp\u003e03 Adjustment to Illness\u003c\/p\u003e\n\u003cp\u003e04 Couples and Families\u003c\/p\u003e\n\u003cp\u003e05 Morning Q\u0026amp;A Courtney Bitz; Eileen Joyce; Damien Miran; Cristina Pozo-Kaderman; Anna Muriel\u003c\/p\u003e\n\u003cp\u003e06 Anxiety\u003c\/p\u003e\n\u003cp\u003e07 Depression\u003c\/p\u003e\n\u003cp\u003e08 Survivorship\u003c\/p\u003e\n\u003cp\u003e09 Spiritual Care (Moderated Discussion)\u003c\/p\u003e\n\u003cp\u003e10 Afternoon Q\u0026amp;A Stephanie Tung; Timothy Steinhoff; Carrie Wu; Stephen Conway; Leora Lowenthal; John Peteet; Damien Mir\u003c\/p\u003e\n\u003cp\u003e11 Psychedelics\u003c\/p\u003e\n\u003cp\u003e12 Substance usemisuse\u003c\/p\u003e\n\u003cp\u003e13 Cannabis\u003c\/p\u003e\n\u003cp\u003e14 Navigating Challenging Patients\u003c\/p\u003e\n\u003cp\u003e15 Morning Q\u0026amp;A Roxanne Sholevar; Miryam Yusufov; Ilana Braun; Stephanie Tung; Michelle Jacobo\u003c\/p\u003e\n\u003cp\u003e16 Bereavement\u003c\/p\u003e\n\u003cp\u003e16 Sue Morris Recording 2026\u003c\/p\u003e\n\u003cp\u003e17 Facilitating Cancer Support Groups\u003c\/p\u003e\n\u003cp\u003e18 Existential Distress and End of Life Issues\u003c\/p\u003e\n\u003cp\u003e19 Pediatric Psychosocial Care (Moderated Discussion)\u003c\/p\u003e\n\u003cp\u003e20 Care of Young Adults\u003c\/p\u003e\n\u003cp\u003e21 Afternoon Q\u0026amp;A Sue Morris; Tricia Hughes; Leora Lowenthal; Amanda Moment; Kate Lally; Joan Hanania; Cristina Pozo-Kaderman\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405752914116,"sku":null,"price":65.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Harvard-Psychosocial-Oncology-What-to-Expect-When-Caring-for-an-Oncology-Patient-2026.jpg?v=1784215681"},{"product_id":"memorial-sloan-kettering-cancer-center-radiologic-interpretation-in-the-oncology-population-2026","title":"Memorial Sloan Kettering Cancer Center Radiologic Interpretation in the Oncology Population 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude: videos + file sub vtt + pdfs, size: GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: radiologists, oncologists, and imaging technologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRadiologic imaging plays a critical role in the care of patients across the cancer continuum. This course provides a comprehensive overview of radiologic interpretation in oncology, covering imaging of the breast, pelvis, chest, abdomen, brain, spine, extremities, and whole body, with attention to pediatric and special populations. Modalities include X-ray, ultrasound, CT, MRI, and nuclear imaging. The program also explores innovative applications in interventional oncology and features interdisciplinary, case-based discussions with interactive audience engagement.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003cp\u003eDescribe the principles and interpretation of common imaging modalities and translate the knowledge learned to clinical practice\u003c\/p\u003e\n\u003cp\u003eIdentify the clinical indications for and selection criteria of various imaging modalities\u003c\/p\u003e\n\u003cp\u003eRecognize common abnormalities on various radiology examinations\u003c\/p\u003e\n\u003cp\u003eAddress challenges and limitations of various imaging modalities\u003c\/p\u003e\n\u003cp\u003eIdentify important considerations when interpreting radiologic imaging in special populations\u003c\/p\u003e\n\u003cp\u003eDiscuss the differential diagnosis for common radiographic findings\u003c\/p\u003e\n\u003cp\u003eExplain the role of imaging in cancer screening, staging, and surveillance\u003c\/p\u003e\n\u003cp\u003eDescribe the current and future use of artificial intelligence in radiologic imaging and interpretation\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThis course is designed for physicians, nurse practitioners, physician assistants, nurse practitioner students, physician assistant students, clinical nurse specialists, nurses, radiology assistants, and certified registered nurse anesthetists.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003eAbdomen Session Q\u0026amp;A_Discussion\u003c\/p\u003e\n\u003cp\u003eAbdominal Imaging FAQs and Clinical Pearls\u003c\/p\u003e\n\u003cp\u003eBrain and Spine Imaging FAQs and Clinical Pearls\u003c\/p\u003e\n\u003cp\u003eBrain and Spine Q\u0026amp;A_Discussion\u003c\/p\u003e\n\u003cp\u003eBreast Imaging FAQs and Clinical Pearls\u003c\/p\u003e\n\u003cp\u003eBreast, Chest Tissue, and Pelvis Q\u0026amp;A_ Discussion\u003c\/p\u003e\n\u003cp\u003eCase Studies – Breast Imaging\u003c\/p\u003e\n\u003cp\u003eCase Studies – Chest and Abdominal Imaging\u003c\/p\u003e\n\u003cp\u003eCase Studies – Neurological Imaging\u003c\/p\u003e\n\u003cp\u003eChest Imaging FAQs and Clinical Pearls\u003c\/p\u003e\n\u003cp\u003eChest Session Q\u0026amp;A_Discussion\u003c\/p\u003e\n\u003cp\u003eChest X-Ray\u003c\/p\u003e\n\u003cp\u003eCT of the Abdomen and Pelvis\u003c\/p\u003e\n\u003cp\u003eCT of the Brain\u003c\/p\u003e\n\u003cp\u003eCT of the Chest\u003c\/p\u003e\n\u003cp\u003eImproving Quality of Life in Cancer Care Through Palliative Interventional Radiology\u003c\/p\u003e\n\u003cp\u003eInnovation in Radiology Q\u0026amp;Discussion\u003c\/p\u003e\n\u003cp\u003eMRI of the Brain and Spine\u003c\/p\u003e\n\u003cp\u003ePediatric Considerations in Radiologic Interpretation\u003c\/p\u003e\n\u003cp\u003ePET Imaging\u003c\/p\u003e\n\u003cp\u003eRadiologic Interpretation in Women’s Health- Transvaginal Ultrasound and Pelvic Imaging\u003c\/p\u003e\n\u003cp\u003eThe Future of Artificial Intelligence in Radiologic Interpretation\u003c\/p\u003e\n\u003cp\u003eUltrasound, Mammography, and MRI of the Breast\u003c\/p\u003e\n\u003cp\u003eWhole Body and Extremity Q\u0026amp;Discussion\u003c\/p\u003e\n\u003cp\u003eX-Ray of the Extremity\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405753733316,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-Radiologic-Interpretation-in-the-Oncology-Population-2026.jpg?v=1784215707"},{"product_id":"memorial-sloan-kettering-cancer-center-10th-annual-msk-symposium-on-lymphoma-2026","title":"Memorial Sloan Kettering Cancer Center 10th Annual MSK Symposium on Lymphoma 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  file sub vtt +  pdfs, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: internists, hematologists, medical and radiation oncologists, hematopathologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eJoin us for the 10th anniversary edition of the MSK Symposium on Lymphoma, marking a decade of advances in lymphoma diagnosis, management, and therapy. This one-and-a-half-day symposium will explore the rapidly evolving landscape of lymphoma research and clinical practice, highlighting advances in disease biology, diagnostic approaches, and therapeutic strategies that are transforming patient outcomes.\u003c\/p\u003e\n\u003cp\u003eKeynote Lectures: Presented by internationally recognized leaders in lymphoma biology, translational research, and clinical care.\u003c\/p\u003e\n\u003cp\u003eInteractive Panel Discussions: Case-based conversations addressing evolving treatment paradigms and real-world clinical challenges.\u003c\/p\u003e\n\u003cp\u003eAllied Health Professionals Session: A dedicated session for the interprofessional care team, highlighting their essential and expanding role in lymphoma management. Please note that space is limited for this session.\u003c\/p\u003e\n\u003cp\u003eParticipants will gain insight into the scientific advances shaping lymphoma biology and pathology, and how these discoveries are being translated into clinical practice. This program brings together distinguished experts from MSK and institutions across the United States and around the world to advance education, collaboration, and patient-centered care—helping to shape the future of lymphoma care.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003cp\u003eDescribe recent advances in lymphoma diagnosis, helping navigate with recent advances in the WHO and ICC classifications\u003c\/p\u003e\n\u003cp\u003eDescribe new agents mode of actions, efficacy, side effects\u003c\/p\u003e\n\u003cp\u003eDiscuss options and recommendations for patients in the relapse refractory setting\u003c\/p\u003e\n\u003cp\u003eProvide strategies to help shared decision-making with patients regarding their treatment\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThis symposium is designed for internists, hematologists, medical and radiation oncologists, hematopathologists, scientists, and medical trainees who are involved in the diagnosis, treatment, and biomedical research of lymphoma. Participants have the option to attend in person or virtually.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003eA “Path” Toward Diagnosis- An Overview of Pathology in Lymphoma\u003c\/p\u003e\n\u003cp\u003eAdvances in Therapeutic Strategies for Mantle Cell Lymphoma\u003c\/p\u003e\n\u003cp\u003eBridging, Debulking, and Beyond- The Multifaceted Role of Radiotherapy with CAR T Cells and Bispecifics\u003c\/p\u003e\n\u003cp\u003eCAR T-Cell Therapy- Lessons Learned from the DESCAR-T Registry\u003c\/p\u003e\n\u003cp\u003eConcepts and Controversies in Aggressive B-Cell Lymphoma Classification\u003c\/p\u003e\n\u003cp\u003eCurrent Challenges in the Management of Patients with Follicular Lymphoma\u003c\/p\u003e\n\u003cp\u003eDebate- Is a Follicular Lymphoma Cure in Reach- T-Cell Engagers versus CAR T-Cell Therapy\u003c\/p\u003e\n\u003cp\u003eDiffuse Large B-Cell Lymphoma- Diagnosis and Updates on Management\u003c\/p\u003e\n\u003cp\u003eDiffuse Large B-Cell Lymphoma Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eFollicular Lymphoma Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eHodgkin Lymphoma Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eHTLV-1 Clinic Overview\u003c\/p\u003e\n\u003cp\u003eHTLV-1-Associated Lymphoma-Leukemia- Biology\u003c\/p\u003e\n\u003cp\u003eHTLV-1-Associated Lymphoma-Leukemia- Epidemiology and Natural History\u003c\/p\u003e\n\u003cp\u003eHTLV-1-Associated Lymphoma-Leukemia- Therapies\u003c\/p\u003e\n\u003cp\u003eInnovations in T-Cell Lymphoma- A Winding Road\u003c\/p\u003e\n\u003cp\u003eInsights into the Molecular Classification of Diffuse Large B-Cell Lymphoma\u003c\/p\u003e\n\u003cp\u003eIntegrative Medicine- Management of Treatment Related Side Effects\u003c\/p\u003e\n\u003cp\u003eIntroduction to Cutaneous T-Cell Lymphoma\u003c\/p\u003e\n\u003cp\u003eLessons Learned from the Development of T-Cell-Engaging Antibodies in B-Cell Lymphoma\u003c\/p\u003e\n\u003cp\u003eMantle Cell Lymphoma Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eMechanisms of Resistance to BTK Degraders\u003c\/p\u003e\n\u003cp\u003ePanel Discussion and Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003ePlenary Lecture- Designing the Next Generation of CAR T-Cell Therapies for Lymphoma\u003c\/p\u003e\n\u003cp\u003ePlenary Lecture Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eRecent Advances in the Management of Chronic Lymphocytic Leukemia\u003c\/p\u003e\n\u003cp\u003eResearch Spotlight- Bispecific B Cell Protocols at MSK and CRS management\u003c\/p\u003e\n\u003cp\u003eSkin Considerations for Cutaneous T-Cell Lymphoma\u003c\/p\u003e\n\u003cp\u003eSmall Doses, Big Impact- The Role of Very Low-Dose Radiotherapy in Potentially Curable Indolent Lymphomas\u003c\/p\u003e\n\u003cp\u003eSpecial Lecture- B-Cell Development and Lineage Stability\u003c\/p\u003e\n\u003cp\u003eSpecial Lecture- How to Interpret “Real-World” Data\u003c\/p\u003e\n\u003cp\u003eSpotlight on New Agents and MSK Clinical Trials\u003c\/p\u003e\n\u003cp\u003eSpotlight on Nodular Lymphocyte Predominant B-Cell- Hodgkin Lymphoma\u003c\/p\u003e\n\u003cp\u003eSpotlight on Recent Drugs and MSK Clinical Trials – 01\u003c\/p\u003e\n\u003cp\u003eSpotlight on Recent Drugs and MSK Clinical Trials\u003c\/p\u003e\n\u003cp\u003eT-Cell Lymphoma Panel Discussion and Q\u0026amp;A\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405753864388,"sku":null,"price":71.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-10th-Annual-MSK-Symposium-on-Lymphoma-2026.jpg?v=1784215714"},{"product_id":"memorial-sloan-kettering-cancer-center-geriatric-oncology-symposium-rapid-diagnosis-early-detection-risk-reduction-and-innovations-2026","title":"Memorial Sloan Kettering Cancer Center Geriatric Oncology Symposium Rapid Diagnosis, Early Detection, Risk Reduction, and Innovations 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  file sub vtt +  pdfs, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: oncologists, geriatricians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAging is a significant risk factor for the development of cancer, and as the U.S. population continues to age, the demand for clinicians skilled in the care of older adults with cancer will continue to grow. Yet research suggests that common geriatric syndromes and the psychosocial needs of older oncology patients are often unintentionally overlooked or under-addressed.\u003c\/p\u003e\n\u003cp\u003eThrough a multidisciplinary lens, participants will gain practical insights into clinical tools, system-level solutions, and emerging research aimed at improving outcomes and quality of life for older adults with cancer.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003cp\u003eIdentify strategies for implementing rapid diagnostic tools and workflows to accelerate timely and accurate disease detection in geriatric patients\u003c\/p\u003e\n\u003cp\u003eDiscuss the importance of early detection and risk reduction strategies tailored to older adults to optimize health outcomes\u003c\/p\u003e\n\u003cp\u003eEvaluate emerging innovations in digital health and medical technology\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eThis symposium is designed for physicians, advanced practice providers, registered nurses, CRNAs, residents, fellows, respiratory therapists, physical therapists, occupational therapists, social workers, case managers, and other healthcare professionals in medicine and surgery who provide care for the older adult.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003ch3\u003eTopics (16 Lectures):\u003c\/h3\u003e\n\u003cp\u003eCAIT Clinic Model- Updates on Risk Stratification Prior to Chemotherapy\u003c\/p\u003e\n\u003cp\u003eCase Study\u003c\/p\u003e\n\u003cp\u003eDigital Health- Updates on Current Research\u003c\/p\u003e\n\u003cp\u003eEarly Detection and Risk Reduction Q\u0026amp;A and Panel Discussion\u003c\/p\u003e\n\u003cp\u003eEHR Implementation- Lessons learned\u003c\/p\u003e\n\u003cp\u003eGood Time to Stop- Cancer Screening in High-risk Older Adults\u003c\/p\u003e\n\u003cp\u003eImplications of Sensory Changes in Oncology Care\u003c\/p\u003e\n\u003cp\u003eImproving Care for Older Adults Undergoing Surgery Implementing the ACS (GSV) Program\u003c\/p\u003e\n\u003cp\u003eKeynote Address- Caring for Patients with Multimorbidity\u003c\/p\u003e\n\u003cp\u003eMinimizing Postoperative Complications in Older Adults with Breast Cancer\u003c\/p\u003e\n\u003cp\u003eNovel Technologies and Geriatric Oncology Q\u0026amp;A and Panel Discussion\u003c\/p\u003e\n\u003cp\u003eOptimizing Care Q\u0026amp;A and Panel Discussion\u003c\/p\u003e\n\u003cp\u003ePalliative Care and Geriatrics Service- Who Does What for Patients with Serious Illnesses-\u003c\/p\u003e\n\u003cp\u003eRADAR and Older Adult with Cancer\u003c\/p\u003e\n\u003cp\u003eRapid Diagnosis Q\u0026amp;A and Panel Discussion\u003c\/p\u003e\n\u003cp\u003eReducing Risk in an Age-friendly Environment\u003c\/p\u003e\n\u003cp\u003eTelehealth and the Older Adult\u003c\/p\u003e\n\u003cp\u003eUpcoming MSK Technology Innovations\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405754060996,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-Geriatric-Oncology-Symposium-Rapid-Diagnosis-Early-Detection-Risk-Reduction-and-Innovations-2026.jpg?v=1784215718"},{"product_id":"mayo-clinic-s-9th-annual-hematology-oncology-case-based-approaches-to-patient-care-for-advanced-practice-providers-and-nurses-2026","title":"Mayo Clinic’s 9th Annual Hematology Oncology Case-Based Approaches to Patient Care for Advanced Practice Providers and Nurses 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: hematology\/oncology and internal medicine physicians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eHilton Head Island, SC US\u003c\/p\u003e\n\u003cp\u003eApril 9, 2026 to April 11, 2026\u003c\/p\u003e\n\u003cp\u003eCourse Directors: Winston Tan, M.D., Yanyan Lou, M.D., Ph.D., Nicole A. Gannon, P.A.-C., Ashton W. Boyle, P.A.-C. and Katelyn E. Keller, MPAS, P.A.-C.\u003c\/p\u003e\n\u003cp\u003eThrough a dynamic, case-based format, this symposium will address real-world challenges faced in daily clinical practice. Attendees will gain practical insights into the diagnosis, management, and supportive care of patients with a wide range of cancers. The course will emphasize clinical decision-making, multidisciplinary collaboration, and up-to-date treatment strategies to enhance the delivery of high-quality oncology care.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003ePhysicians, physician assistants, nurse practitioners, nurses, residents\/fellows, and pharmacists in the fields of hematology\/oncology and internal medicine.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this activity, participants should be able to:\u003c\/h3\u003e\n\u003cp\u003eDifferentiate between immunotherapy, targeted therapy, chemotherapy, and radiation therapy.\u003c\/p\u003e\n\u003cp\u003eSelect appropriate treatment modalities based on cancer type and disease stage.\u003c\/p\u003e\n\u003cp\u003eApply updated evidence-based strategies in the diagnosis and treatment of common hematologic and oncologic malignancies.\u003c\/p\u003e\n\u003cp\u003eAssess patient eligibility and indications for bone marrow transplantation and chimeric antigen receptor (CAR) T-cell therapy.\u003c\/p\u003e\n\u003cp\u003eIncorporate principles of palliative and supportive care into comprehensive cancer treatment plans to improve symptom management and quality of life.\u003c\/p\u003e\n\u003cp\u003eIdentify common complications and adverse effects related to immunotherapy, targeted therapy, chemotherapy, and radiation therapy, using current guidelines and clinical judgment.\u003c\/p\u003e\n\u003cp\u003eManage common complications and adverse effects related to immunotherapy, targeted therapy, chemotherapy, and radiation therapy, using current guidelines and clinical judgment.\u003c\/p\u003e\n\u003cp\u003eEnhance interdisciplinary communication and care coordination through case-based discussions and collaborative learning.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eDay 1\u003c\/p\u003e\n\u003cp\u003eThursday, April 9, 2026\u003c\/p\u003e\n\u003cp\u003e11:30 AM\u003c\/p\u003e\n\u003cp\u003e12:00 PM\u003c\/p\u003e\n\u003cp\u003eRegistration Opens, Exhibits and Lunch\u003c\/p\u003e\n\u003cp\u003e12:00 PM\u003c\/p\u003e\n\u003cp\u003e12:15 PM\u003c\/p\u003e\n\u003cp\u003eWelcome\/Introduction\u003c\/p\u003e\n\u003cp\u003eModerator: Ashton Boyle, PA-C\u003c\/p\u003e\n\u003cp\u003e12:15 PM\u003c\/p\u003e\n\u003cp\u003e12:45 PM\u003c\/p\u003e\n\u003cp\u003eDo we matter in Cancer Care? – The financial, social, and emotional impacts of APPs\u003c\/p\u003e\n\u003cp\u003eStephanie Gebhardt, ARNP\u003c\/p\u003e\n\u003cp\u003e12:45 PM\u003c\/p\u003e\n\u003cp\u003e1:15 PM\u003c\/p\u003e\n\u003cp\u003eThe Difference a Year Can Make: A Case Study of  Cholangiocarcinoma\u003c\/p\u003e\n\u003cp\u003eMicah Weber, PA-C\u003c\/p\u003e\n\u003cp\u003e1:15 PM\u003c\/p\u003e\n\u003cp\u003e1:45 PM\u003c\/p\u003e\n\u003cp\u003eLiver transplant as an option for metastatic colon cancer\u003c\/p\u003e\n\u003cp\u003eSamantha Inabinett, APRN\u003c\/p\u003e\n\u003cp\u003e1:45 PM\u003c\/p\u003e\n\u003cp\u003e2:15 PM\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A Panel\u003c\/p\u003e\n\u003cp\u003eAll Presenting Faculty\u003c\/p\u003e\n\u003cp\u003e2:15 PM\u003c\/p\u003e\n\u003cp\u003e2:45 PM\u003c\/p\u003e\n\u003cp\u003eBreak and Exhibits\u003c\/p\u003e\n\u003cp\u003e2:45 PM\u003c\/p\u003e\n\u003cp\u003e3:15 PM\u003c\/p\u003e\n\u003cp\u003eUnusual plasma cell malignancies\u003c\/p\u003e\n\u003cp\u003eTaimur Sher, MBBS, MD\u003c\/p\u003e\n\u003cp\u003e3:15 PM\u003c\/p\u003e\n\u003cp\u003e3:45 PM\u003c\/p\u003e\n\u003cp\u003eCancer-Associated Thrombosis\u003c\/p\u003e\n\u003cp\u003eJordan Davis, PA-C\u003c\/p\u003e\n\u003cp\u003e3:45 PM\u003c\/p\u003e\n\u003cp\u003e4:15 PM\u003c\/p\u003e\n\u003cp\u003eLong-Term Impacts of T-Cell Engaging Therapies: Case Insights and Clinical Considerations\u003c\/p\u003e\n\u003cp\u003eMegan Melody, MD, Tampa General Hospital\u003c\/p\u003e\n\u003cp\u003e4:15 PM\u003c\/p\u003e\n\u003cp\u003e4:45 PM\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A Panel\u003c\/p\u003e\n\u003cp\u003eAll Presenting Faculty\u003c\/p\u003e\n\u003cp\u003e4:45 PM\u003c\/p\u003e\n\u003cp\u003e4:45 PM\u003c\/p\u003e\n\u003cp\u003eAdjourn\u003c\/p\u003e\n\u003cp\u003e5:00 PM\u003c\/p\u003e\n\u003cp\u003e6:00 PM\u003c\/p\u003e\n\u003cp\u003eWelcome Reception\u003c\/p\u003e\n\u003cp\u003eDay 2\u003c\/p\u003e\n\u003cp\u003eFriday, April 10, 2026\u003c\/p\u003e\n\u003cp\u003e7:00 AM\u003c\/p\u003e\n\u003cp\u003e7:55 AM\u003c\/p\u003e\n\u003cp\u003eBreakfast and Exhibits\u003c\/p\u003e\n\u003cp\u003e7:55 AM\u003c\/p\u003e\n\u003cp\u003e8:00 AM\u003c\/p\u003e\n\u003cp\u003eIntroduction\u003c\/p\u003e\n\u003cp\u003eModerator: Nicole Gannon, PA-C\u003c\/p\u003e\n\u003cp\u003e8:00 AM\u003c\/p\u003e\n\u003cp\u003e8:30 AM\u003c\/p\u003e\n\u003cp\u003eChronic GVHD in the Real World: Practical Case Discussions for APPs and Nurses\u003c\/p\u003e\n\u003cp\u003eKatelyn Keller, PA-C\u003c\/p\u003e\n\u003cp\u003e8:30 AM\u003c\/p\u003e\n\u003cp\u003e9:00 AM\u003c\/p\u003e\n\u003cp\u003eOh My Blast – What to do if you suspect acute leukemia\u003c\/p\u003e\n\u003cp\u003eAshley Westberry, APRN\u003c\/p\u003e\n\u003cp\u003e9:00 AM\u003c\/p\u003e\n\u003cp\u003e9:30 AM\u003c\/p\u003e\n\u003cp\u003eA new Era in Myeloma: Case-Based Perspectives on Bispecific Antibodies\u003c\/p\u003e\n\u003cp\u003eAndre J. Fernandez, MPAS, P.A.-C. and Caitie J. Flott, APRN, M.S.N.\u003c\/p\u003e\n\u003cp\u003e9:30 AM\u003c\/p\u003e\n\u003cp\u003e9:45 AM\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A Panel\u003c\/p\u003e\n\u003cp\u003eAll Presenting Faculty\u003c\/p\u003e\n\u003cp\u003e9:45 AM\u003c\/p\u003e\n\u003cp\u003e10:15 AM\u003c\/p\u003e\n\u003cp\u003eBreak and Exhibits\u003c\/p\u003e\n\u003cp\u003e10:15 AM\u003c\/p\u003e\n\u003cp\u003e10:45 AM\u003c\/p\u003e\n\u003cp\u003eNovel Therapeutics in Melanoma\u003c\/p\u003e\n\u003cp\u003eLindsey Noland, PA-C\u003c\/p\u003e\n\u003cp\u003e10:45 AM\u003c\/p\u003e\n\u003cp\u003e11:15 AM\u003c\/p\u003e\n\u003cp\u003eImmunotherapy toxicities\u003c\/p\u003e\n\u003cp\u003eEmily Kelbert, PA-C\u003c\/p\u003e\n\u003cp\u003e11:15 AM\u003c\/p\u003e\n\u003cp\u003e11:45 AM\u003c\/p\u003e\n\u003cp\u003eThe Zebra Cancer: Case Based Approach to the Management of Neuroendocrine Tumors\u003c\/p\u003e\n\u003cp\u003eRachel Eiring, PA-C\u003c\/p\u003e\n\u003cp\u003e11:45 AM\u003c\/p\u003e\n\u003cp\u003e12:00 PM\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A Panel\u003c\/p\u003e\n\u003cp\u003eAll Presenting Faculty\u003c\/p\u003e\n\u003cp\u003e12:00 PM\u003c\/p\u003e\n\u003cp\u003e1:00 PM\u003c\/p\u003e\n\u003cp\u003eLunch, Exhibits \u0026amp; Abstract Session\u003c\/p\u003e\n\u003cp\u003eWinston Tan, MD\u003c\/p\u003e\n\u003cp\u003e1:00 PM\u003c\/p\u003e\n\u003cp\u003e1:30 PM\u003c\/p\u003e\n\u003cp\u003eCancer Pain Management\u003c\/p\u003e\n\u003cp\u003eChimere Bruning, PA-C\u003c\/p\u003e\n\u003cp\u003e1:30 PM\u003c\/p\u003e\n\u003cp\u003e2:00 PM\u003c\/p\u003e\n\u003cp\u003eContinuity, Coordination and Connection: Safe Transitions after Bone Marrow Transplant\u003c\/p\u003e\n\u003cp\u003eErin Taylor, RN and Nicole Gannon, PA-C\u003c\/p\u003e\n\u003cp\u003e2:00 PM\u003c\/p\u003e\n\u003cp\u003e2:30 PM\u003c\/p\u003e\n\u003cp\u003eExpecting the Unexpected: Managing Reactions in the Infusion Center\u003c\/p\u003e\n\u003cp\u003eAlex Fein, PA-C\u003c\/p\u003e\n\u003cp\u003e2:30 PM\u003c\/p\u003e\n\u003cp\u003e3:00 PM\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A Panel\u003c\/p\u003e\n\u003cp\u003eAll Presenting Faculty\u003c\/p\u003e\n\u003cp\u003e3:00 PM\u003c\/p\u003e\n\u003cp\u003e3:00 PM\u003c\/p\u003e\n\u003cp\u003eAdjourn\u003c\/p\u003e\n\u003cp\u003eDay 3\u003c\/p\u003e\n\u003cp\u003eSaturday, April 11, 2026\u003c\/p\u003e\n\u003cp\u003e7:00 AM\u003c\/p\u003e\n\u003cp\u003e7:55 AM\u003c\/p\u003e\n\u003cp\u003eBreakfast and Exhibits\u003c\/p\u003e\n\u003cp\u003e7:55 AM\u003c\/p\u003e\n\u003cp\u003e8:00 AM\u003c\/p\u003e\n\u003cp\u003eIntroduction\u003c\/p\u003e\n\u003cp\u003eModerator: Katie Keller, PA-C\u003c\/p\u003e\n\u003cp\u003e8:00 AM\u003c\/p\u003e\n\u003cp\u003e8:30 AM\u003c\/p\u003e\n\u003cp\u003eBad Medicine: Talking with Patients about Ivermectin and other Low Evidence Treatments\u003c\/p\u003e\n\u003cp\u003eKate McLaughlin, APRN\u003c\/p\u003e\n\u003cp\u003e8:30 AM\u003c\/p\u003e\n\u003cp\u003e9:00 AM\u003c\/p\u003e\n\u003cp\u003eManaging Cardiovascular Complications of Cancer Therapy: Insights from Clinical Cases\u003c\/p\u003e\n\u003cp\u003eAlyssa McPherson, APRN\u003c\/p\u003e\n\u003cp\u003e9:00 AM\u003c\/p\u003e\n\u003cp\u003e9:30 AM\u003c\/p\u003e\n\u003cp\u003eCellular Therapies for Autoimmune Disease\u003c\/p\u003e\n\u003cp\u003eErnesto Ayala, M.D.\u003c\/p\u003e\n\u003cp\u003e9:30 AM\u003c\/p\u003e\n\u003cp\u003e10:00 AM\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A Panel\u003c\/p\u003e\n\u003cp\u003eAll Presenting Faculty\u003c\/p\u003e\n\u003cp\u003e10:00 AM\u003c\/p\u003e\n\u003cp\u003e10:30 AM\u003c\/p\u003e\n\u003cp\u003eBreak and Exhibits\u003c\/p\u003e\n\u003cp\u003e10:30 AM\u003c\/p\u003e\n\u003cp\u003e11:00 AM\u003c\/p\u003e\n\u003cp\u003eOral Chemotherapy\u003c\/p\u003e\n\u003cp\u003eMorgan Leavins, Pharm.D., R.Ph.\u003c\/p\u003e\n\u003cp\u003e11:00 AM\u003c\/p\u003e\n\u003cp\u003e11:30 AM\u003c\/p\u003e\n\u003cp\u003eApproach to GI Malignancies in the Hospital\u003c\/p\u003e\n\u003cp\u003eJeremy Jones, MD\u003c\/p\u003e\n\u003cp\u003e11:30 AM\u003c\/p\u003e\n\u003cp\u003e12:00 PM\u003c\/p\u003e\n\u003cp\u003eLessons Learned: The Stresses and Successes of a Long-Term Hem\/Onc APP Career\u003c\/p\u003e\n\u003cp\u003eNicole Gannon, PA-C\u003c\/p\u003e\n\u003cp\u003e12:00 PM\u003c\/p\u003e\n\u003cp\u003e12:30 PM\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A Panel\u003c\/p\u003e\n\u003cp\u003eAll Presenting Faculty\u003c\/p\u003e\n\u003cp\u003e12:30 PM\u003c\/p\u003e\n\u003cp\u003e12:40 PM\u003c\/p\u003e\n\u003cp\u003eClosing Remarks\/Post Test\u003c\/p\u003e\n\u003cp\u003e12:40 PM\u003c\/p\u003e\n\u003cp\u003e12:40 PM\u003c\/p\u003e\n\u003cp\u003eAdjourn\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405754749124,"sku":null,"price":249.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Mayo-Clinics-9th-Annual-Hematology-Oncology-Case-Based-Approaches-to-Patient-Care-for-Advanced-Practice-Providers-and-Nurses-2026.jpg?v=1784215736"},{"product_id":"harvard-gastroenterology-2026","title":"Harvard Gastroenterology 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + file sub vtt +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: internists, hospitalists, primary care physicians, gastroenterologists, hepatologists, oncologists, geriatricians, and obstetricians\/gynecologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eThe Comprehensive 2026 Gastroenterology Update\u003c\/p\u003e\n\u003cp\u003eGastroenterology 2026 is a live online course, using live streaming, electronic Q\u0026amp;A, and other remote learning technologies.\u003c\/p\u003e\n\u003cp\u003eThis program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians.\u003c\/p\u003e\n\u003cp\u003ePractical, Results-Driven Education\u003c\/p\u003e\n\u003ch3\u003eHighlights of the 2026 program include:\u003c\/h3\u003e\n\u003cp\u003eThe newest guidelines for the use of biologics in IBD\u003c\/p\u003e\n\u003cp\u003eTherapeutic drug monitoring in IBD treatment\u003c\/p\u003e\n\u003cp\u003eManagement of the older adult with IBD\u003c\/p\u003e\n\u003cp\u003eUpdated guidelines for treatment of C. difficile infection\u003c\/p\u003e\n\u003cp\u003eManaging GI complications of immunotherapy and anti-neoplastic therapies\u003c\/p\u003e\n\u003cp\u003eImproved management of IBS\u003c\/p\u003e\n\u003cp\u003eTips for managing fecal incontinence\u003c\/p\u003e\n\u003cp\u003eManagement of refractory GERD\u003c\/p\u003e\n\u003cp\u003eOptimal surveillance in hereditary GI cancer syndromes\u003c\/p\u003e\n\u003cp\u003eCurrent treatment of H. pylori\u003c\/p\u003e\n\u003cp\u003eUpdated treatment of HBV and HCV\u003c\/p\u003e\n\u003cp\u003eManagement of steatotic liver disease in 2026\u003c\/p\u003e\n\u003cp\u003eHow to diagnose and manage cirrhosis\u003c\/p\u003e\n\u003cp\u003eHow to improve your adenoma detection rate (ADR)\u003c\/p\u003e\n\u003cp\u003eSteps to ensure delivery of high-quality colonoscopic care\u003c\/p\u003e\n\u003cp\u003eTechniques to effectively control acute GI bleeding\u003c\/p\u003e\n\u003cp\u003eEndoscopic management of obesity\u003c\/p\u003e\n\u003cp\u003eWhen FMT is indicated for treatment\u003c\/p\u003e\n\u003cp\u003eNew strategies to treat common GI problems\u003c\/p\u003e\n\u003cp\u003eA comprehensive update of national guidelines\u003c\/p\u003e\n\u003cp\u003eEducation to Optimize Your Patient Outcomes\u003c\/p\u003e\n\u003ch3\u003eThe evidence-based recommendations provided in this program cover strategies to improve care and outcomes for patients with:\u003c\/h3\u003e\n\u003cp\u003eIBD\u003c\/p\u003e\n\u003cp\u003eGI complications of immunotherapy\u003c\/p\u003e\n\u003cp\u003eMicroscopic colitis\u003c\/p\u003e\n\u003cp\u003eSteatotic liver disease\u003c\/p\u003e\n\u003cp\u003eBarrett’s esophagus\u003c\/p\u003e\n\u003cp\u003eEosinophilic esophagitis\u003c\/p\u003e\n\u003cp\u003eC. difficile colitis\u003c\/p\u003e\n\u003cp\u003eH. pylori infection\u003c\/p\u003e\n\u003cp\u003eAlcohol-related liver disease\u003c\/p\u003e\n\u003cp\u003eAutoimmune hepatitis\u003c\/p\u003e\n\u003cp\u003eIBS\u003c\/p\u003e\n\u003cp\u003eRefractory GERD\u003c\/p\u003e\n\u003cp\u003eAcute pancreatitis\u003c\/p\u003e\n\u003cp\u003eChronic pancreatitis\u003c\/p\u003e\n\u003cp\u003eCeliac disease\u003c\/p\u003e\n\u003cp\u003eGI bleeding\u003c\/p\u003e\n\u003cp\u003eHigh risk for colorectal cancer\u003c\/p\u003e\n\u003cp\u003eRecent Advances and Innovations\u003c\/p\u003e\n\u003ch3\u003eClinicians can rely on this program for education on:\u003c\/h3\u003e\n\u003cp\u003eBiological therapies for IBD: how to choose which agent to start with? How to monitor during treatment? What is the role for therapeutic drug monitoring? When to switch? What new agents are now available?\u003c\/p\u003e\n\u003cp\u003eGI complications of immunotherapy — a common and heterogeneous disorder: how to approach and treat effectively?\u003c\/p\u003e\n\u003cp\u003eEosinophilic esophagitis: how to decide between drug therapy and dietary therapy?\u003c\/p\u003e\n\u003cp\u003eThe stool microbiome: understanding the science behind clinical applications\u003c\/p\u003e\n\u003cp\u003eCeliac disease: making sense of the multiple serologic tests—new therapeutic strategies are on the horizon\u003c\/p\u003e\n\u003cp\u003eAdenoma detection rates: critical to measure and how to incorporate strategies, including AI, to increase your rate\u003c\/p\u003e\n\u003cp\u003eEndoscopic approaches to managing obesity\u003c\/p\u003e\n\u003cp\u003eUpdated treatments for HBV and HCV\u003c\/p\u003e\n\u003cp\u003eThis program also offers a glimpse into the future of gastroenterology with engaging lectures given by world-renowned experts on inspiring and cutting-edge topics.\u003c\/p\u003e\n\u003ch3\u003e2. Learning Objectives Upon completion of this course, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eInterpret major advances in the field of gastroenterology.\u003c\/p\u003e\n\u003cp\u003eIncorporate the most up-to-date diagnostic approaches to GI disorders.\u003c\/p\u003e\n\u003cp\u003eIdentify therapeutic options for GI disorders in an evidence-based manner.\u003c\/p\u003e\n\u003cp\u003eManage patients with both common and rare GI disorders using established guidelines.\u003c\/p\u003e\n\u003ch3\u003e3. Target Audience Who Should Participate:\u003c\/h3\u003e\n\u003cp\u003eGastroenterologists\u003c\/p\u003e\n\u003cp\u003eInternists\u003c\/p\u003e\n\u003cp\u003eHospitalists\u003c\/p\u003e\n\u003cp\u003eSurgeons\u003c\/p\u003e\n\u003cp\u003eNurse Practitioners\u003c\/p\u003e\n\u003cp\u003ePhysician Assistants …and other medical professionals seeking a comprehensive update in Gastroenterology.\u003c\/p\u003e\n\u003cp\u003eBest for internists, hospitalists, primary care physicians, gastroenterologists, hepatologists, oncologists, geriatricians, and obstetricians\/gynecologists.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003eMonday, June 8, 2026\u003c\/p\u003e\n\u003cp\u003eWelcome\u003c\/p\u003e\n\u003cp\u003eDr. Daniel Chung\u003c\/p\u003e\n\u003cp\u003eWhich Initial Therapy to Choose in Crohn’s Disease?\u003c\/p\u003e\n\u003cp\u003eDr. Joshua Korzenik\u003c\/p\u003e\n\u003cp\u003eWhich Initial Therapy to Choose in Ulcerative Colitis?\u003c\/p\u003e\n\u003cp\u003eDr. Ashwin Ananthakrishnan\u003c\/p\u003e\n\u003cp\u003ePutting It Together: Illustrative IBD Case Presentations\u003c\/p\u003e\n\u003cp\u003eDr. Kristin Burke\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Ashwin Ananthakrishnan, Joshua Korzenik, and Kristin Burke\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eManagement of the Older Adult with IBD\u003c\/p\u003e\n\u003cp\u003eDr. Bharati Kochar\u003c\/p\u003e\n\u003cp\u003eIBD in Pregnancy\u003c\/p\u003e\n\u003cp\u003eDr. Loren Rabinowitz\u003c\/p\u003e\n\u003cp\u003eTherapeutic Drug Monitoring in IBD\u003c\/p\u003e\n\u003cp\u003eDr. Adam Cheifetz\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Adam Cheifetz, Bharati Kochar, and Loren Rabinowitz\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eHow to Manage Microscopic Colitis\u003c\/p\u003e\n\u003cp\u003eDr. Hamed Khalili\u003c\/p\u003e\n\u003cp\u003eGI Complications of Immunotherapy\u003c\/p\u003e\n\u003cp\u003eDr. Michael Dougan\u003c\/p\u003e\n\u003cp\u003eGI Complications of Antineoplastic Therapy\u003c\/p\u003e\n\u003cp\u003eDr. Shilpa Grover\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Michael Dougan, Hamed Khalili, and Shilpa Grover\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eHigh-Risk Cancer Surveillance in GI Cancer Syndromes\u003c\/p\u003e\n\u003cp\u003eDr. Daniel Chung\u003c\/p\u003e\n\u003cp\u003eCRC Screening and How to Improve Your ADR\u003c\/p\u003e\n\u003cp\u003eDr. Ramona Lim\u003c\/p\u003e\n\u003cp\u003eBeyond Screening: What to Recommend to Reduce Colorectal Cancer Risk\u003c\/p\u003e\n\u003cp\u003eDr. Andrew Chan\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Daniel Chung, Ramona Lim, and Andrew Chan\u003c\/p\u003e\n\u003cp\u003eDay 2\u003c\/p\u003e\n\u003cp\u003eTuesday, June 9, 2026\u003c\/p\u003e\n\u003cp\u003eBarrett’s Esophagus: Whom and How to Treat?\u003c\/p\u003e\n\u003cp\u003eDr. Douglas Pleskow\u003c\/p\u003e\n\u003cp\u003eEsophageal Motility Disorders Made Easy\u003c\/p\u003e\n\u003cp\u003eDr. Barbara Nath\u003c\/p\u003e\n\u003cp\u003eManagement of Refractory GERD\u003c\/p\u003e\n\u003cp\u003eDr. Norman Nishioka\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Douglas Pleskow, Barbara Nath, and Norman Nishioka\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eComprehensive Approach to Eosinophilic Esophagitis\u003c\/p\u003e\n\u003cp\u003eDr. Walter Chan\u003c\/p\u003e\n\u003cp\u003eCeliac Disease and Gluten Sensitivity: 2026 Practitioner Updates\u003c\/p\u003e\n\u003cp\u003eDr. Ciaran Kelly\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Walter Chan and Ciaran Kelly\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eMaking the Diagnosis of IBS\u003c\/p\u003e\n\u003cp\u003eDr. Kyle Staller\u003c\/p\u003e\n\u003cp\u003eModern Strategies to Treat IBS\u003c\/p\u003e\n\u003cp\u003eDr. Vikram Rangan\u003c\/p\u003e\n\u003cp\u003eTips to Managing Fecal Incontinence\u003c\/p\u003e\n\u003cp\u003eDr. Kyle Staller\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Kyle Staller and Vikram Rangan\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eOptimizing the Management of Gastroparesis\u003c\/p\u003e\n\u003cp\u003eDr. Trisha Pasricha\u003c\/p\u003e\n\u003cp\u003eHow to Evaluate Small Intestinal Bacterial Overgrowth\u003c\/p\u003e\n\u003cp\u003eDr. Judy Nee\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Judy Nee and Trisha Pasricha\u003c\/p\u003e\n\u003cp\u003eDay 3\u003c\/p\u003e\n\u003cp\u003eWednesday, June 10, 2026\u003c\/p\u003e\n\u003cp\u003eCholestatic Liver Diseases: What’s New in PBC and PSC\u003c\/p\u003e\n\u003cp\u003eDr. Daniel Pratt\u003c\/p\u003e\n\u003cp\u003eUpdate on Autoimmune Hepatitis\u003c\/p\u003e\n\u003cp\u003eDr. Alan Bonder\u003c\/p\u003e\n\u003cp\u003eCurrent Approaches to the Treatment of HBV and HCV\u003c\/p\u003e\n\u003cp\u003eDr. Michael Curry\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Daniel Pratt, Alan Bonder, and Michael Curry\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eAlcohol-Associated Liver Disease\u003c\/p\u003e\n\u003cp\u003eDr. Gyongyi Szabo\u003c\/p\u003e\n\u003cp\u003eThe Management of MASLD\u003c\/p\u003e\n\u003cp\u003eDr. Kathleen Corey\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Gyongyi Szabo and Kathleen Corey\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eHow to Workup a Liver Lesion\u003c\/p\u003e\n\u003cp\u003eDr. Karin Andersson\u003c\/p\u003e\n\u003cp\u003eDiagnosis and Routine Management of Cirrhosis\u003c\/p\u003e\n\u003cp\u003eDr. Michelle Lai\u003c\/p\u003e\n\u003cp\u003eManaging Advanced Liver Disease\u003c\/p\u003e\n\u003cp\u003eDr. Anna Rutherford\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Anna Rutherford and Karin Andersson\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eBest Management Strategies in Acute Pancreatitis\u003c\/p\u003e\n\u003cp\u003eDr. David Jin\u003c\/p\u003e\n\u003cp\u003eUpdates in Chronic Pancreatitis\u003c\/p\u003e\n\u003cp\u003eDr. Sunil Sheth\u003c\/p\u003e\n\u003cp\u003eControversies in the Management of Cystic Lesions of the Pancreas\u003c\/p\u003e\n\u003cp\u003eDr. Carlos Fernandez-del Castillo\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. David Jin, Sunil Sheth, and Carlos Fernandez-del Castillo\u003c\/p\u003e\n\u003cp\u003eDay 4\u003c\/p\u003e\n\u003cp\u003eThursday, June 11, 2026\u003c\/p\u003e\n\u003cp\u003eTips to Removing the Difficult Colon Polyp\u003c\/p\u003e\n\u003cp\u003eDr. Tyler Berzin\u003c\/p\u003e\n\u003cp\u003eQuality in Colonoscopy: What to Measure and Why It Matters\u003c\/p\u003e\n\u003cp\u003eDr. Mandeep Sawhney\u003c\/p\u003e\n\u003cp\u003eEndoscopy and the Anticoagulated Patient\u003c\/p\u003e\n\u003cp\u003eDr. Kunal Jajoo\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Tyler Berzin, Mandeep Sawhney, and Kunal Jajoo\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eAcute GI Bleeding and Other GI Emergencies\u003c\/p\u003e\n\u003cp\u003eDr. Linda Lee\u003c\/p\u003e\n\u003cp\u003eAdvances in Endoscopic Surgery for Foregut Disorders\u003c\/p\u003e\n\u003cp\u003eDr. Kumar Krishnan\u003c\/p\u003e\n\u003cp\u003eEndoscopic Approaches to Manage Obesity\u003c\/p\u003e\n\u003cp\u003eDr. Christopher Thompson\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Christopher Thompson, Kumar Krishnan, and Linda Lee\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eWhat’s New in C. Difficile Colitis\u003c\/p\u003e\n\u003cp\u003eDr. Jessica Allegretti\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A with Dr. Allegretti\u003c\/p\u003e\n\u003cp\u003eNew Insights into the Gut Microbiome and Disease\u003c\/p\u003e\n\u003cp\u003eDr. Ramnik Xavier\u003c\/p\u003e\n\u003cp\u003eCurrent Approach to Diagnosis and Treatment of Helicobacter pylori\u003c\/p\u003e\n\u003cp\u003eDr. Jay Luther\u003c\/p\u003e\n\u003cp\u003eGI Cases to Remember\u003c\/p\u003e\n\u003cp\u003eDr. Douglas Horst\u003c\/p\u003e\n\u003cp\u003ePanel Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eDrs. Douglas Horst, Ramnik Xavier, and Jay Luther\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405755732164,"sku":null,"price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Harvard-Gastroenterology-2026.jpg?v=1784215759"},{"product_id":"digestive-disease-week-2026","title":"Digestive Disease Week 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  file sub vtt +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: gastroenterologists, hepatologists, general surgeons, oncologists, bariatric specialists, allergists, and internal medicine physicians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this course, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eEvaluate the current and potential applications of artificial intelligence in endoscopic practice, histology, and IBD severity assessment.\u003c\/p\u003e\n\u003cp\u003eApply updated, evidence-based strategies to the endoscopic management of acute GI bleeding, pancreatobiliary diseases, and complex colorectal polyps.\u003c\/p\u003e\n\u003cp\u003eIncorporate noninvasive tools (NITs) to optimize the diagnosis, staging, and monitoring of MASH\/MASLD, and select appropriate treatments such as resmetirom or GLP-1 RAs.\u003c\/p\u003e\n\u003cp\u003eAssess and select early-intervention therapies, combination treatments, and treat-to-target strategies to manage Inflammatory Bowel Disease (IBD) effectively.\u003c\/p\u003e\n\u003cp\u003eEvaluate emerging endoscopic and surgical treatments for obesity-related GI diseases, including endobariatrics and Endoscopic Sleeve Gastroplasty (ESG).\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThis educational activity is intended for gastroenterologists, hepatologists, surgeons, basic scientists, nurse practitioners, physician assistants, and nurses who are involved in the management of digestive and liver diseases.\u003c\/p\u003e\n\u003cp\u003eBest for gastroenterologists, hepatologists, general surgeons, oncologists, bariatric specialists, allergists, and internal medicine physicians.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003e* WARNING: The main topics are summarized below; there are 403 topics in total.\u003c\/p\u003e\n\u003cp\u003eThe Impact of AI on the Endoscopic Practice in Gastroenterology: Hype and Reality\u003c\/p\u003e\n\u003cp\u003eAI-Enabled Diagnostics and Intestinal Ultrasound in IBD Monitoring\u003c\/p\u003e\n\u003cp\u003eEosinophilic Esophagitis (EoE): New Targeted Immunology and Epithelial Cytokines\u003c\/p\u003e\n\u003cp\u003eEarly Intervention and Combination Therapies in Crohn’s Disease and Ulcerative Colitis\u003c\/p\u003e\n\u003cp\u003eEndobariatrics and ESG: Integration within a Multidisciplinary Model\u003c\/p\u003e\n\u003cp\u003eAdvances in Colon Polyp Detection and Endoscopic vs. Surgical Resection\u003c\/p\u003e\n\u003cp\u003eInnovations and Updates in Pancreato-Biliary Endoscopy\u003c\/p\u003e\n\u003cp\u003eEUS-Guided Gallbladder Drainage with AXIOS™ Stent\u003c\/p\u003e\n\u003cp\u003eDiagnosis, Staging, and Management of MASH and MASLD\u003c\/p\u003e\n\u003cp\u003eSystemic Inflammation and Organ Failure in Acute Pancreatitis\u003c\/p\u003e\n\u003cp\u003eTumor Immune Microenvironment in Colorectal Liver Metastases\u003c\/p\u003e\n\u003cp\u003ePharmacological and Psychological Approaches to Disorders of Gut-Brain Interaction (DGBI)\u003c\/p\u003e\n\u003cp\u003eUpdates in Hepatitis B and C Management and Care Delivery\u003c\/p\u003e\n\u003cp\u003eModern Surgical Strategies Against Pancreatic Cancer\u003c\/p\u003e\n\u003cp\u003eEvolving Technologies: Robotic Scope Control and Suture-Based Innovation\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405756715204,"sku":null,"price":149.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Digestive-Disease-Week-2026.webp?v=1784215769"},{"product_id":"scientific-symposiums-international-practical-surgical-pathology-diagnostic-pearls-in-head-and-neck-soft-tissue-genitourinary-and-hepatobiliary-pathology-2026","title":"Scientific Symposiums International Practical Surgical Pathology Diagnostic Pearls in Head and Neck, Soft Tissue, Genitourinary and Hepatobiliary Pathology 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + file sub vtt + pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: pathologists, otolaryngologists, head and neck surgeons, orthopedic oncologists, urologists, hepatologists, gastroenterologists, and surgical oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe “Practical Surgical Pathology: Diagnostic Pearls in Head and Neck, Soft Tissue, Genitourinary, and Hepatobiliary Pathology” is an intensive program presented by Scientific Symposiums International. This course is specifically designed to provide practicing surgical pathologists with practical approaches, diagnostic pearls, and essential updates for navigating challenging cases across four complex subspecialties. Through expert-led lectures and case-based discussions, the program emphasizes the integration of routine morphology with the latest World Health Organization (WHO) classifications, immunohistochemical panels, and molecular testing to prevent common diagnostic pitfalls and improve patient care.\u003c\/p\u003e\n\u003ch3\u003eLearning Objectives Upon completion of this educational activity, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eApply updated diagnostic criteria and WHO classifications to accurately identify complex neoplasms in the head and neck, soft tissue, genitourinary tract, and hepatobiliary system.\u003c\/p\u003e\n\u003cp\u003eDistinguish benign entities and morphologic mimics from true malignancies to avoid over-diagnosis and under-diagnosis in daily surgical pathology practice.\u003c\/p\u003e\n\u003cp\u003eSelect and interpret the most effective immunohistochemical stains and molecular tests for resolving difficult differential diagnoses.\u003c\/p\u003e\n\u003cp\u003eRecognize newly defined and emerging tumor entities across the four featured pathology subspecialties.\u003c\/p\u003e\n\u003cp\u003eFormulate precise, clinically relevant pathology reports that provide actionable information for medical and surgical management.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThis course is primarily designed for practicing surgical pathologists, clinical pathologists, pathology residents, and fellows who wish to update their diagnostic skills and stay current with the latest advancements in surgical pathology.\u003c\/p\u003e\n\u003cp\u003eBest for pathologists, otolaryngologists, head and neck surgeons, orthopedic oncologists, urologists, hepatologists, gastroenterologists, and surgical oncologists.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003eHead and Neck Pathology\u003c\/p\u003e\n\u003cp\u003eDiagnostic Pitfalls in Salivary Gland Tumors: Navigating the Overlaps\u003c\/p\u003e\n\u003cp\u003eSquamous Cell Carcinoma and Its Variants in the Upper Aerodigestive Tract\u003c\/p\u003e\n\u003cp\u003eThyroid Pathology: Updates in NIFTP and Indeterminate Nodules\u003c\/p\u003e\n\u003cp\u003eHuman Papillomavirus (HPV) Related Neoplasms of the Head and Neck\u003c\/p\u003e\n\u003cp\u003eSpindle Cell Lesions of the Head and Neck\u003c\/p\u003e\n\u003cp\u003eSoft Tissue Pathology\u003c\/p\u003e\n\u003cp\u003eLipomatous Tumors: From Benign to Atypical to Malignant\u003c\/p\u003e\n\u003cp\u003eVascular Tumors of Soft Tissue: Diagnostic Pearls and Pitfalls\u003c\/p\u003e\n\u003cp\u003eSpindle Cell Sarcomas: A Practical Morphologic and Molecular Approach\u003c\/p\u003e\n\u003cp\u003eRound Cell Tumors: An Algorithmic Approach to Diagnosis\u003c\/p\u003e\n\u003cp\u003eCutaneous Soft Tissue Lesions Frequently Encountered in Practice\u003c\/p\u003e\n\u003cp\u003eGenitourinary Pathology\u003c\/p\u003e\n\u003cp\u003eProstate Cancer Grading: Current Consensus and Controversies\u003c\/p\u003e\n\u003cp\u003eUrothelial Carcinoma and Its Divergent Differentiations\u003c\/p\u003e\n\u003cp\u003eRenal Cell Carcinoma: Emerging Entities and WHO Updates\u003c\/p\u003e\n\u003cp\u003eTesticular Germ Cell Tumors: Diagnostic Challenges\u003c\/p\u003e\n\u003cp\u003eBenign Mimics of Malignancy in the Genitourinary Tract\u003c\/p\u003e\n\u003cp\u003eHepatobiliary Pathology\u003c\/p\u003e\n\u003cp\u003eMedical Liver Biopsies: A Pattern-Based Approach for the Surgical Pathologist\u003c\/p\u003e\n\u003cp\u003eHepatocellular Carcinoma vs. Cholangiocarcinoma vs. Metastatic Disease\u003c\/p\u003e\n\u003cp\u003eBiliary Tract Neoplasia and Precursor Lesions\u003c\/p\u003e\n\u003cp\u003eFatty Liver Disease: Steatosis, Steatohepatitis, and Fibrosis Scoring\u003c\/p\u003e\n\u003cp\u003eDrug-Induced Liver Injury (DILI) and Autoimmune Hepatitis\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405757010116,"sku":null,"price":156.0,"currency_code":"USD","in_stock":true}]},{"product_id":"confederation-of-european-otorhinolaryngology-head-and-neck-surgery-8th-congress-of-european-orl-hns-2026","title":"Confederation of European Otorhinolaryngology Head and Neck Surgery 8th Congress of European ORL-HNS 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + file sub vtt, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: otorhinolaryngologists, head and neck surgeons, audiologists, plastic surgeons, oncologists, pediatricians, and allergists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe Confederation of European Otorhinolaryngology – Head and Neck Surgery (CEORL-HNS) Congress is the premier European scientific event dedicated to the advancement of Otorhinolaryngology and Head and Neck Surgery. It brings together leading experts, clinicians, and researchers from across the globe to share groundbreaking research, innovative surgical techniques, and updated clinical guidelines. The congress aims to foster international collaboration, showcase the latest technological advancements in the field, and elevate the standard of patient care across all ENT subspecialties.\u003c\/p\u003e\n\u003ch3\u003eLearning Objectives Upon completion of this educational activity, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eIntegrate the latest evidence-based medical and surgical guidelines into the daily practice of otorhinolaryngology.\u003c\/p\u003e\n\u003cp\u003eEvaluate and implement new technologies, including robotic-assisted surgery, 3D navigation systems, and advanced endoscopic approaches for complex pathologies.\u003c\/p\u003e\n\u003cp\u003eApply multidisciplinary approaches to the management of head and neck cancers, sleep-disordered breathing, and neurotologic conditions.\u003c\/p\u003e\n\u003cp\u003eIdentify, manage, and prevent complications in challenging cases across pediatric ORL, rhinology, otology, and facial plastic surgery.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThe congress is intended for practicing otorhinolaryngologists, head and neck surgeons, facial plastic surgeons, audiologists, speech-language pathologists, researchers, and trainees (residents and fellows) seeking to update their clinical knowledge and surgical skills.\u003c\/p\u003e\n\u003cp\u003eBest for otorhinolaryngologists, head and neck surgeons, audiologists, plastic surgeons, oncologists, pediatricians, and allergists.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003eWARNING: The conference only recorded videos of the designated meeting rooms, not all the meeting rooms as in the original schedule.\u003c\/p\u003e\n\u003cp\u003eCongress of European ORL-HNS 2026 Congresshall.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Tu.01 How To Close Primary Csf Leaks.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Tu.01 Eustachian Tube Dysfunction.mp4\u003c\/p\u003e\n\u003cp\u003eFp.Mo.06 Oncologic Surgery And Outcomes.mp4\u003c\/p\u003e\n\u003cp\u003eFp.Mo.05 Cholesteatoma Endoscopy Mastoid Obliteration.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Mo.06 Tips And Pearls In Thyroid Surgery.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Mo.06 Challenges In Complex Sinonasal And Skull Base Tumor Resections And Their Management.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Mo.05 How To Achieve R0 Resection In Sinonasal Malignancy.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Mo.05 Septoplasty In Children.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Mo.21 Managing Complicated Epistaxis Cases.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Mo.21 Unilateral Vocal Fold Paralysis Options From Augmentation And Thyroplasty To Laryngeal Reinnervations.mp4\u003c\/p\u003e\n\u003cp\u003eFp.Mo.02 New Diagnostics Tools And Screening.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Mo.21 Button Batteries.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Mo.18 Residents Quiz.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Mo.05 To Cut Or Not To Cut. The Psychology Of Surgery.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Mo.02 Basic Fess, Unmet Issues Discussed Through Peculiar Clinical Cases.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Tu.02 A New Platform For Training In Vestibular Medicine.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Tu.18 Mastoid Obliteration In Canal Wall Up And Canal Wall Down Procedures Why, When, And How.mp4\u003c\/p\u003e\n\u003cp\u003eCongress of European ORL-HNS 2026 G3.mp4\u003c\/p\u003e\n\u003cp\u003eFp.Tu.06 Infections In Otology, Ci In Meningitis.mp4\u003c\/p\u003e\n\u003cp\u003eFp.Tu.05 Precision Strategies And Rare Tumours.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Tu.06 Principles Of Csf Leak And Skull Base Reconstruction.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Tu.06 Endoscopic Middle Ear Surgery.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Tu.22 Ent Emergencies In Children.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Tu.22 Congenital Neck Masses.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Tu.22 Congenital Anosmia.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Tu.21 Superior Canal Dehiscence When And How To Do Surgery.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Tu.21 Reconstruction Of Facial Defects.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Tu.05 Current Concepts In Opc Management.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Tu.05 Novel Concepts Of Oral Cavity Cancer Treatment The Interplay Of Surgery And Immunotherapy.mp4\u003c\/p\u003e\n\u003cp\u003eFp.Tu.02 Therapeutics, Ablation And Voice Rehabilitation.mp4\u003c\/p\u003e\n\u003cp\u003eFp.Tu.01 Advances In Chronic Rhinosinusitis, Inflammation And Microbiology.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Tu.18 Developing Skills To Lead In Paediatric Airway Surgery.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Tu.02 How To Avoid Complications In Airway Surgery.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Mo.18 Balancing Aesthetic And Functional Results In Rhinoplasty.mp4\u003c\/p\u003e\n\u003cp\u003eCongress of European ORL-HNS 2026 G4.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Mo.18 How To Become A Laser Laryngeal Surgeon Tips And Tricks.mp4\u003c\/p\u003e\n\u003cp\u003eFp.Su.05 Biomarkers And Immunology.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Su.22 Refinement In Head And Neck Reconstruction.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Su.22 Snoring Analysis Today.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Su.21 Modern Imaging In Otology.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Su.05 Meatoplasty Techniques How I Do It.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Su.21 Middle Ear Mechanics And Passive Prostheses.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Su.05 Prevention And Treatment Of Complications Of Otitis Media.mp4\u003c\/p\u003e\n\u003cp\u003eFp.Su.02 Diagnostics Pathophysiology \u0026amp; Innovation.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Su.21 Training In Otology And Neurotology.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Su.05 Choosing The Right Patient For Biological Treatment In Crs.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Su.18 Establishing A National Ai Research Collaborative In Ent.mp4\u003c\/p\u003e\n\u003cp\u003eFp.Su.01 Awards.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Su.02 Mastering The Recurrent Laryngeal Nerve And The Parathyroid Gland In Locally Advanced Thyroid Cancer.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Su.17 Managing Complications In Endoscopic Sinus And Skull Base Surgery.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Su.18 The Delivery Room Has Called For A Pediatric Otolaryngologist What Should I Know.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Su.02 How To Avoid And Manage Complications During Basic Fess.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Su.01 How To Use Artificial Intelligence In Rhinology.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Su.01 Ossiculoplasty From Bench To Bedside Translating Biomechanics Into Surgical Precision.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Su.22 Cricopharyngeal Dysfunction.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Su.06 Optimizing Care For The Geriatric Laryngopharynx.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Wd.01 Multimodal Approaches For Better Results Surgery, Medicine And Immunotherapy In Rhinitis And Chronic Rhinosinusitis.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Mo.02 Indications And Novel Concepts In Surgical Treatment Of Vertigo.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Mo.01 Salvage Surgery Practical Tips And Pitfalls To Avoid.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Mo.17 Carcinoma Of Unknown Primary What Is The Best Approach.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Wd.06 An Update On Treatment And Complications Of Temporal Bone Lesions Pgl’S And Beyond.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Wd.22 Auditory Implants For Life.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Wd.21 Everything About Sphenoid Sinus.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Mo.01 Third Window Syndrome.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Wd.05 New Trends In Vestibular Schwannoma Management.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Wd.05 Subtotal Petrosectomy How I Do It.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Wd.02 Chatgpt In Ent Surgery Transforming Practice And Enhancing Surgeon Quality Of Life.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Wd.02 Surgical Management Of Bilateral Vocal Fold Paralysis.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Wd.17 Novel Robotic Platforms And Concepts In The Treatment Of Head And Neck Cancers.mp4\u003c\/p\u003e\n\u003cp\u003eRt.Wd.01 Therapeutic Goals In Crs.mp4\u003c\/p\u003e\n\u003cp\u003eClosing Ceremonies.mp4\u003c\/p\u003e\n\u003cp\u003eFp.Su.06 Airway.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Wd.02 The History, Evolution And Practical Application Of Airway Dilation.mp4\u003c\/p\u003e\n\u003cp\u003eKl.Wd.06 Predictive And Prognostic Biomarkers In Hnscc.mp4\u003c\/p\u003e\n\u003cp\u003eIc.Su.17 Novel Options For Management Of Benign Sinonasal Tumours.mp4\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405757436100,"sku":null,"price":65.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Confederation-of-European-Otorhinolaryngology-Head-and-Neck-Surgery-8th-Congress-of-European-ORL-HNS-2026.jpg?v=1784215790"},{"product_id":"european-association-of-dermato-oncology-14th-european-school-of-dermato-oncology-2026","title":"European Association of Dermato-Oncology 14th European School of Dermato-Oncology 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + file sub vtt +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: dermatologists, medical oncologists, surgical oncologists, radiation oncologists, dermatopathologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe EADO initiates for the fourteenth time a course dedicated to fundamentals in skin cancer targeted to specialists and residents in the final phase of their resident program. They will benefit a comprehensive and updated course to improve their decision-making process for the management of all types and stages of skin cancer, from diagnosis, primary treatment and adjuvant treatment, to the management of loco-regional disease and distant metastatic disease.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThis 2-day educational course targets doctors who are actively involved in the treatment of skin cancer. Dermatologists or other specialists who have completed specialist training, or residents in the final year of their training program, are likely to gain the most from this course.\u003c\/p\u003e\n\u003cp\u003eBest for dermatologists, medical oncologists, surgical oncologists, radiation oncologists, and dermatopathologists.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this program, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eUnderstand the fundamental epidemiology, genetic predispositions, and molecular biology driving the pathogenesis of various skin cancers.\u003c\/p\u003e\n\u003cp\u003eApply advanced non-invasive diagnostic techniques, such as dermoscopy and reflectance confocal microscopy, to accurately identify and differentiate cutaneous malignancies.\u003c\/p\u003e\n\u003cp\u003eOptimize the use of modern systemic treatments, including immune checkpoint inhibitors and targeted therapies, while effectively recognizing and managing their specific adverse events.\u003c\/p\u003e\n\u003cp\u003eNavigate the complex diagnostic and therapeutic pathways for rare cutaneous tumors, including Merkel cell carcinoma and cutaneous lymphomas.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCOURSE 1 What should you know about the mode of action of Immune Checkpoint Inhibition and Targeted Therapies\u003c\/p\u003e\n\u003cp\u003eCOURSE 2 AI-assisted diagnostics for skin cancer standards and innovations\u003c\/p\u003e\n\u003cp\u003eCOURSE 3 Access to drug innovations in Europe\u003c\/p\u003e\n\u003cp\u003eCOURSE 4 Adjuvant therapies across skin cancer\u003c\/p\u003e\n\u003cp\u003eCOURSE 5 Neoadjuvant therapies across skin cancers the new standards-of-care\u003c\/p\u003e\n\u003cp\u003eCOURSE 6 European guideline changes for skin cancer patients\u003c\/p\u003e\n\u003cp\u003eCOURSE 7 Common adverse events of skin cancer drugs (ICI, TT, HHI, chemo, etc)\u003c\/p\u003e\n\u003cp\u003eCOURSE 8 Challenging side effects of skin cancer drugs expert panel discussion of 4 cases\u003c\/p\u003e\n\u003cp\u003eCOURSE 9 Challenging clinical situations in melanoma and keratinocyte cancers\u003c\/p\u003e\n\u003cp\u003eCOURSE 10 What should you know about running a clinical trial\u003c\/p\u003e\n\u003cp\u003eOpening Session\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405757468868,"sku":null,"price":65.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/European-Association-of-Dermato-Oncology-14th-European-School-of-Dermato-Oncology-2026.jpg?v=1784215792"},{"product_id":"international-myeloma-society-myeloma-cure-summit-definitions-metrics-and-milestones-2026","title":"International Myeloma Society Myeloma Cure Summit Definitions, Metrics, and Milestones 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + file sub vtt +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: Hematologists, Medical Oncologists, Immunologists, Radiologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003cp\u003eTo evaluate key parameters in myeloma, including the depth and durability of minimal residual disease (MRD) negativity.\u003c\/p\u003e\n\u003cp\u003eTo assess the roles of advanced imaging and mass spectrometry in defining a cure.\u003c\/p\u003e\n\u003cp\u003eTo understand immune reconstitution, time off therapy, and the restoration of normal function.\u003c\/p\u003e\n\u003cp\u003eTo explore the potential reversion to an MGUS-like state under the guidance of leading investigators and clinicians.\u003c\/p\u003e\n\u003cp\u003eTo examine patient sub-group considerations, such as age and disease risk, to determine who is most likely to be cured.\u003c\/p\u003e\n\u003cp\u003eTo identify specific therapies and concepts that are potentially able to increase cure fractions.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThe IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.\u003c\/p\u003e\n\u003cp\u003eBest for Hematologists, Medical Oncologists, Immunologists, Radiologists, and Clinical Researchers.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003eFebruary 20, 2026\u003c\/p\u003e\n\u003cp\u003eFebruary 21, 2026\u003c\/p\u003e\n\u003cp\u003ePanel\/Participants: Kenneth Anderson, Shaji Kumar, Maria-Victoria Mateos, Nikhil Munshi, Philippe Moreau, Noopur Raje, Jesus San Miguel\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405757763780,"sku":null,"price":52.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/International-Myeloma-Society-Myeloma-Cure-Summit-Definitions-Metrics-and-Milestones-2026.jpg?v=1784215799"},{"product_id":"harvard-ai-in-clinical-medicine-2026","title":"Harvard AI in Clinical Medicine 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + file sub vtt +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: pathologists, endocrinologists, ophthalmologists, nurses, gastroenterologists, intensivists, radiologists, surgeons, anesthesiologists, oncologists, pulmonologists, cardiologists, and psychiatrists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eNew technologies are available now to help you impact your practice. AI medical scribes, new research tools and diagnostic tests, and personalized treatment options are just a few applications of AI that are beginning to have a direct impact on clinicians and the patients they serve.\u003c\/p\u003e\n\u003cp\u003eUp until now, most health care providers have not received formal training in artificial intelligence. Now is the time for physicians, nurses, advanced practice providers, and all allied health professionals to prepare for how AI is changing medical care.\u003c\/p\u003e\n\u003cp\u003eThis live online course focuses on cutting edge and exciting new applications of AI, including foundational principles and lessons learned that you will be able to take directly back to your practice. Over three days, you will hear from medical society leaders, academic leaders, and innovators from academia and industry.\u003c\/p\u003e\n\u003ch3\u003e2. Learning Objectives Upon completion of this course, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eDiscuss the ethical considerations and potential biases in AI algorithms, especially in decision-making processes related to patient care, diagnosis, and treatment planning.\u003c\/p\u003e\n\u003cp\u003eAssess the long-term quality and accuracy of AI technologies and their impact on patient care.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eWho Should Participate: Clinicians treating patients in any type of setting including, physicians, nurses, nurse practitioners, and clinical leaders.\u003c\/p\u003e\n\u003cp\u003eBest for pathologists, endocrinologists, ophthalmologists, nurses, gastroenterologists, intensivists, radiologists, surgeons, anesthesiologists, oncologists, pulmonologists, cardiologists, and psychiatrists.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003eKeynote: Paging Dr. A.I.: How AI is Changing the Face of Clinical Care\u003c\/p\u003e\n\u003cp\u003eLearning the AI Lingo: Machine Learning, Deep Learning, and Large Language Models\u003c\/p\u003e\n\u003cp\u003eA Look Into the Black Box: Technical Background for Clinicians\u003c\/p\u003e\n\u003cp\u003eMedical Data as the Backbone of AI\u003c\/p\u003e\n\u003cp\u003eChatbots in Health Care: A Historical Expedition\u003c\/p\u003e\n\u003cp\u003eAI Learning Revolution: Transforming Medical Education\u003c\/p\u003e\n\u003cp\u003eAmbient Scribes\u003c\/p\u003e\n\u003cp\u003eAn AI designed drug for IPF: from preclinical development to phase II in under 3 years\u003c\/p\u003e\n\u003cp\u003ePrecision Medicine: AI and Personalized Treatment in Oncology\u003c\/p\u003e\n\u003cp\u003eKeynote: Ethics and AI in Healthcare\u003c\/p\u003e\n\u003cp\u003eAI for Pioneering Leadership in the Digital Era\u003c\/p\u003e\n\u003cp\u003eLaw and Regulation in AI\u003c\/p\u003e\n\u003cp\u003eTelemetry\/Mhealth for early detection of heart failure exacerbation\u003c\/p\u003e\n\u003cp\u003eBrain computer interfaces and decoding speech\u003c\/p\u003e\n\u003cp\u003eCan Chat bots improve mental health?\u003c\/p\u003e\n\u003cp\u003eBias in Risk Stratification for allocation and policy\u003c\/p\u003e\n\u003cp\u003eRobust, Fair and private AI\u003c\/p\u003e\n\u003cp\u003eAlgorithmic bias in clinical scores and implications for AI\u003c\/p\u003e\n\u003cp\u003eBut I Want it Now!: Barriers to Clinical AI Implementation\u003c\/p\u003e\n\u003cp\u003eHow Can I Help You? Clinical Decision Support in the EHR\u003c\/p\u003e\n\u003cp\u003eImplementing AI in your small practice\u003c\/p\u003e\n\u003cp\u003eHidden risks of AI in your practice\u003c\/p\u003e\n\u003cp\u003eMoney Talks: How AI Can Help You Improve Your Bottom Line\u003c\/p\u003e\n\u003cp\u003eAI and Reducing Healthcare Provider Burnout\u003c\/p\u003e\n\u003cp\u003eWhy AI may be good for our health but hurt our wallets\u003c\/p\u003e\n\u003cp\u003eStudy Hall – Clinical Applications: Pathology\u003c\/p\u003e\n\u003cp\u003eStudy Hall – Clinical Applications: Endocrinology\u003c\/p\u003e\n\u003cp\u003eStudy Hall – Clinical Applications: Ophthalmology\u003c\/p\u003e\n\u003cp\u003eStudy Hall – Clinical Applications: Nursing\u003c\/p\u003e\n\u003cp\u003eStudy Hall – Clinical Applications: Gastroenterology\u003c\/p\u003e\n\u003cp\u003eStudy Hall – Clinical Applications: Critical Care\u003c\/p\u003e\n\u003cp\u003eStudy Hall – Clinical Applications: Radiology\u003c\/p\u003e\n\u003cp\u003eStudy Hall – Clinical Applications: Surgery or Anesthesia\u003c\/p\u003e\n\u003cp\u003eVirtual demonstrations: Ambient Scribe from Abridge\u003c\/p\u003e\n\u003cp\u003eVirtual demonstrations: Leveraging clinician’s expertise with Agentic AI\u003c\/p\u003e\n\u003cp\u003eVirtual demonstrations: Evidence search using OpenEvidence\u003c\/p\u003e\n\u003cp\u003eVirtual demonstrations: Doctronic\u003c\/p\u003e\n\u003cp\u003eVirtual demonstrations: Uptodate Expert AI\u003c\/p\u003e\n\u003cp\u003eVirtual demonstrations: Glasshealth’s clinical decision support platform\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405757862084,"sku":null,"price":390.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Harvard-AI-in-Clinical-Medicine-2026.jpg?v=1784215801"},{"product_id":"international-myeloma-society-7th-immune-effector-cell-therapies-in-multiple-myeloma-workshop-2026","title":"International Myeloma Society 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + file sub vtt +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: hematologists, medical oncologists, immunologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this workshop, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eEvaluate the latest clinical updates and real-world data for various CAR T cell therapies (Ide-cel, Cilta-cel, Anito-cel, GC012F) and bispecific antibodies (Teclistamab, Talquetamab, Elranatamab, Linvoseltamab).\u003c\/p\u003e\n\u003cp\u003eAnalyze novel therapeutic approaches, including trispecific antibodies, combination therapies, and dual-targeted CAR T cells.\u003c\/p\u003e\n\u003cp\u003eIdentify and manage toxicities associated with T cell engaging therapies, such as CAR-T-associated delayed neurotoxicity and immune effector cell enterocolitis.\u003c\/p\u003e\n\u003cp\u003eUnderstand the genomic drivers and microenvironmental factors contributing to response and resistance in BCMA and GPRC5D-targeted therapies.\u003c\/p\u003e\n\u003cp\u003eApply practical strategies for optimizing the administration and sequencing of immune therapies in clinical settings.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThe IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.\u003c\/p\u003e\n\u003cp\u003eBest for hematologists, medical oncologists, immunologists, clinical researchers, and scientists.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003eSESSION 1: CLINICAL UPDATES ON CART CELLS\u003c\/p\u003e\n\u003cp\u003eIde-cel and Cilta-cel: Latest Updates and Ongoing Trials\u003c\/p\u003e\n\u003cp\u003eLatest Real World Data for CAR T Cells\u003c\/p\u003e\n\u003cp\u003eUpdate on Anito-cel and GC012F\u003c\/p\u003e\n\u003cp\u003eGPRC5D CAR T Cells: Latest Updates and Ongoing Trials\u003c\/p\u003e\n\u003cp\u003eDual-targeted CAR T Cell Approaches\u003c\/p\u003e\n\u003cp\u003eUpdate on Allogeneic CAR T Cell Approaches\u003c\/p\u003e\n\u003cp\u003eSESSION 2: CLINICAL UPDATES ON BISPECIFIC ANTIBODIES\u003c\/p\u003e\n\u003cp\u003eTeclistamab and Talquetamab for Relapsed MM: Latest Updates and Ongoing Trials\u003c\/p\u003e\n\u003cp\u003eElranatamab and Linvoseltamab for Relapsed MM: Latest Updates and Ongoing Trials\u003c\/p\u003e\n\u003cp\u003eReal World Data for Bispecific Antibodies\u003c\/p\u003e\n\u003cp\u003eEtentamig and Cevostamab: Latest Updates and Ongoing Trials\u003c\/p\u003e\n\u003cp\u003eSESSION 3: NOVEL APPROACHES IN THE CLINIC\u003c\/p\u003e\n\u003cp\u003eTrispecific Antibodies for Myeloma\u003c\/p\u003e\n\u003cp\u003eCombining Bispecific Abs with CAR T Cells\u003c\/p\u003e\n\u003cp\u003eFixed Duration Bispecific Antibody Therapy\u003c\/p\u003e\n\u003cp\u003eAugmenting T Cell Therapies with Proteasome Inhibitors\u003c\/p\u003e\n\u003cp\u003eTriPRIL CAR T Cells\u003c\/p\u003e\n\u003cp\u003eBispecific with Anti-CD38 Antibody\u003c\/p\u003e\n\u003cp\u003eSESSION 4: TOXICITIES OF T CELL ENGAGING THERAPIES\u003c\/p\u003e\n\u003cp\u003ePre-treatment Parameters Predicting CAR T Cell Toxicities\u003c\/p\u003e\n\u003cp\u003eElevated ALC and CAR T Cell Toxicities\u003c\/p\u003e\n\u003cp\u003eManaging CAR-T-associated Delayed Neurotoxicity\u003c\/p\u003e\n\u003cp\u003eCAR T-related Lymphomas: Clinical and Mechanistic Insights\u003c\/p\u003e\n\u003cp\u003eSESSION 5: PRACTICAL CONSIDERATIONS FOR IMMUNE THERAPIES\u003c\/p\u003e\n\u003cp\u003eSequencing BCMA-directed Therapies: How to Choose?\u003c\/p\u003e\n\u003cp\u003eOptimizing Outpatient Bispecific Ab and CAR T Cell Administration\u003c\/p\u003e\n\u003cp\u003eManaging Extramedullary Disease with T cell-redirecting Therapies\u003c\/p\u003e\n\u003cp\u003eT Cell Therapies for CNS Myeloma\u003c\/p\u003e\n\u003cp\u003eImpact of CHIP on Outcomes after CAR T Cell Therapy\u003c\/p\u003e\n\u003cp\u003eSESSION 6: UNDERSTANDING RESPONSE AND RESISTANCE TO T CELL THERAPIES\u003c\/p\u003e\n\u003cp\u003eGenomic Drivers of Resistance to BCMA-targeted Therapies\u003c\/p\u003e\n\u003cp\u003eMechanisms of Antigen Escape following GPRC5D-targeted Therapies\u003c\/p\u003e\n\u003cp\u003eImmune Correlates of Response to BCMA CAR T Cells\u003c\/p\u003e\n\u003cp\u003eMicroenvironmental Factors Impacting Response\/resistance\u003c\/p\u003e\n\u003cp\u003eImmune Correlates of Resistance to Bispecific Antibodies\u003c\/p\u003e\n\u003cp\u003eSESSION 7: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 1\u003c\/p\u003e\n\u003cp\u003eEvaluating Immune Fitness Across the Stages of MM Progression\u003c\/p\u003e\n\u003cp\u003eTargeting S100A8\/9 to Enhance T Cell Therapies\u003c\/p\u003e\n\u003cp\u003eOvercoming T Cell Exhaustion\u003c\/p\u003e\n\u003cp\u003eModulating the Microbiome to Enhance CAR T Cell Therapy\u003c\/p\u003e\n\u003cp\u003eSESSION 8: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 2\u003c\/p\u003e\n\u003cp\u003eNovel T Cell Therapy Targets for Myeloma\u003c\/p\u003e\n\u003cp\u003eCAR T Cells Against CD70\u003c\/p\u003e\n\u003cp\u003eTargeting Intra-cellular Targets\u003c\/p\u003e\n\u003cp\u003eEZH1\/2 inhibition to augment cellular therapy\u003c\/p\u003e\n\u003cp\u003eSESSION 9: CHALLENGING CASES IN IMMUNE EFFECTOR CELL THERAPY\u003c\/p\u003e\n\u003cp\u003eCAR T Cell Therapy in a Patient with Plasma Cell Leukemia\u003c\/p\u003e\n\u003cp\u003eImmune Effector Cell Enterocolitis: A Novel Clonal Lymphoproliferative Disorder?\u003c\/p\u003e\n\u003cp\u003eFatal HLH Following GPRC5D×CD3 Therapy: Lessons from Genetic and Infectious Co-factors\u003c\/p\u003e\n\u003cp\u003eSESSION 10: IN VIVO APPROACHES\u003c\/p\u003e\n\u003cp\u003eScience of In Vivo CAR T Cell Therpay\u003c\/p\u003e\n\u003cp\u003eBedside CAR T Cell Production\u003c\/p\u003e\n\u003cp\u003eIn Vivo Bispecific Therapy\u003c\/p\u003e\n\u003cp\u003eClinical Results of In Vivo CAR T Cell Therapy\u003c\/p\u003e\n\u003cp\u003eClinical Results of In Vivo CAR T Cell Therapy Part II\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405757993156,"sku":null,"price":52.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/International-Myeloma-Society-7th-Immune-Effector-Cell-Therapies-in-Multiple-Myeloma-Workshop-2026.jpg?v=1784215803"},{"product_id":"memorial-sloan-kettering-cancer-center-psychopharmacology-in-cancer-care-2025","title":"Memorial Sloan Kettering Cancer Center Psychopharmacology in Cancer Care 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: oncologists, hematologists, psychiatrists, palliative care physicians, neurologists, pain medicine specialists, internists, family medicine physicians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecialties – Behavioral Care, Critical Care, General and Family Practice, Geriatric Medicine, Hematology, Integrative Medicine, Internal Medicine, Medical Oncology, Neurology, Nurse Anesthetist, Nurse Practitioner, Nursing, Pain Medicine, Psychiatry, Psychology, Social Work\u003c\/p\u003e\n\u003cp\u003eOverview\u003c\/p\u003e\n\u003cp\u003eClinicians have numerous tools at their disposal to help adult cancer patients dealing with symptoms of depression, anxiety, and other cancer sequelae. Psychiatric medications are most frequently prescribed to cancer patients by oncologists and general practitioners, however psychiatric syndromes are often underdiagnosed and undertreated. Few oncology practices have dedicated psychiatric consultants familiar with the nuances of Psycho-Oncology. Even when patients receive psychotropic medications appropriately, they may have problems that arise before their next oncology visit or before they see the person who prescribed their psychiatric medications. Psychologists, nurses, and social workers play an essential role in identifying psychological and physical symptoms as well as both beneficial and problematic medication effects as they provide frontline psychosocial interventions and support for cancer patients.\u003c\/p\u003e\n\u003cp\u003eThis highly regarded annual course, co-sponsored by the MSK Psycho-Oncology Education and Training Institute (POETI), is designed to support non-prescribing psycho-oncology clinicians and psychiatrists new to Psycho-pharmaco-oncology. Oncologists, palliative care providers, advanced practice nurses, and oncology nurses will also find it invaluable.\u003c\/p\u003e\n\u003cp\u003eThe program emphasizes effective psychopharmacological interventions for key disorders and symptoms, including anxiety, depression, delirium, sleep dsisturbances, pain, fatigue, and changes in weight or appetite. Expert faculty will provide updates on the use of novel interventions including ketamine, medical marijuana, and psilocybin for depression, anxiety, and pain. Additionally, the vital role of clinical social work in delivering psychosocial support will be examined.\u003c\/p\u003e\n\u003cp\u003eAttendees will receive access to an online syllabus after the course, which will include select PDFs of the faculty presentations (slides) and recorded videos.\u003c\/p\u003e\n\u003cp\u003eObjectives\u003c\/p\u003e\n\u003ch3\u003eBy attending this program, learners will be able to:\u003c\/h3\u003e\n\u003cp\u003eDescribe basic psycho-pharmaco-oncology principles for understanding and treating anxiety, depression and delirium in people with cancer.\u003c\/p\u003e\n\u003cp\u003eIdentify the use of novel interventions including ketamine, medical marijuana, and psilocybin for depression, anxiety, and pain in people with cancer.\u003c\/p\u003e\n\u003cp\u003eDiscuss basic psycho-pharmaco-oncology principles for understanding and improving quality of life and psychiatric palliative care in people with cancer, including managing cognitive changes, insomnia, fatigue, poor appetite and weight loss, and pain.\u003c\/p\u003e\n\u003cp\u003eThe 2025 Psychopharmacology in Cancer Care course by Memorial Sloan Kettering Cancer Center (MSKCC) is designed for physicians and healthcare professionals involved in oncology, psychiatry, palliative care, and psycho-oncology.\u003c\/p\u003e\n\u003ch3\u003eThis course is particularly beneficial for:\u003c\/h3\u003e\n\u003cp\u003eOncologists \u0026amp; Hematologists managing psychiatric symptoms in cancer patients.\u003c\/p\u003e\n\u003cp\u003ePsychiatrists \u0026amp; Psychologists specializing in psycho-oncology.\u003c\/p\u003e\n\u003cp\u003ePalliative Care Physicians addressing depression, anxiety, and delirium in cancer care.\u003c\/p\u003e\n\u003cp\u003eInternal Medicine \u0026amp; Family Medicine Physicians prescribing psychiatric medications for cancer patients.\u003c\/p\u003e\n\u003cp\u003eNeurologists \u0026amp; Pain Medicine Specialists focusing on psychiatric aspects of pain management.\u003c\/p\u003e\n\u003cp\u003eAdvanced Practice Nurses \u0026amp; Nurse Practitioners supporting psycho-oncology care.\u003c\/p\u003e\n\u003cp\u003eSocial Workers \u0026amp; Psychosocial Professionals involved in psychiatric palliative care.\u003c\/p\u003e\n\u003cp\u003eThe course covers depression, anxiety, delirium, sleep disturbances, fatigue, pain, weight changes, and emerging treatments like ketamine, medical marijuana, and psilocybin\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAnxiety Disorders.mp4\u003c\/p\u003e\n\u003cp\u003eAnxiety Disorders.pdf\u003c\/p\u003e\n\u003cp\u003eCancer and Cancer-Treatment Related Cognitive Changes.mp4\u003c\/p\u003e\n\u003cp\u003eCancer and Cancer-Treatment Related Cognitive Changes.pdf\u003c\/p\u003e\n\u003cp\u003eCancer-Related Fatigue.mp4\u003c\/p\u003e\n\u003cp\u003eCancer-Related Fatigue.pdf\u003c\/p\u003e\n\u003cp\u003eCaring for the Whole Patient- The Role of Clinical Social Work in Psychosocial Support.mp4\u003c\/p\u003e\n\u003cp\u003eCaring for the Whole Patient- The Role of Clinical Social Work in Psychosocial Support.pdf\u003c\/p\u003e\n\u003cp\u003eDelirium.mp4\u003c\/p\u003e\n\u003cp\u003eDelirium.pdf\u003c\/p\u003e\n\u003cp\u003eDepressive Disorders.mp4\u003c\/p\u003e\n\u003cp\u003eDepressive Disorders.pdf\u003c\/p\u003e\n\u003cp\u003eHandouts.pdf\u003c\/p\u003e\n\u003cp\u003eKetamine and Esketamine for Depression.mp4\u003c\/p\u003e\n\u003cp\u003eKetamine and Esketamine for Depression.pdf\u003c\/p\u003e\n\u003cp\u003eNovel Psychopharmacologic Interventions in Oncology.mp4\u003c\/p\u003e\n\u003cp\u003eNovel Psychopharmacologic Interventions in Oncology.pdf\u003c\/p\u003e\n\u003cp\u003ePain.mp4\u003c\/p\u003e\n\u003cp\u003ePain.pdf\u003c\/p\u003e\n\u003cp\u003ePsychopharm2025_Brochure.pdf\u003c\/p\u003e\n\u003cp\u003eSleep Disorders.mp4\u003c\/p\u003e\n\u003cp\u003eSleep Disorders.pdf\u003c\/p\u003e\n\u003cp\u003eWeight and Appetite Loss.mp4\u003c\/p\u003e\n\u003cp\u003eWeight and Appetite Loss.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405758812356,"sku":null,"price":26.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-Psychopharmacology-in-Cancer-Care-2025.jpg?v=1784215825"},{"product_id":"cleveland-clinic-24th-annual-ash-review-2025","title":"Cleveland Clinic 24th Annual ASH Review 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: hematologists, medical oncologists, radiation oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eBy Participating, You Will Be Able To:\u003c\/h3\u003e\n\u003cp\u003eDescribe the implications for new diagnostic and therapeutic approaches to hematologic diseases.\u003c\/p\u003e\n\u003cp\u003eDiscuss the impact of research and new treatments on patient management.\u003c\/p\u003e\n\u003cp\u003eWho Should Attend?\u003c\/p\u003e\n\u003cp\u003ePhysicians\u003c\/p\u003e\n\u003cp\u003ePhysician Assistants\u003c\/p\u003e\n\u003cp\u003eResident\/Fellow\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAdvances in Sickle Cell Disease.mp4\u003c\/p\u003e\n\u003cp\u003eAgenda.pdf\u003c\/p\u003e\n\u003cp\u003eArtificial Intelligence in Classical Hematology.mp4\u003c\/p\u003e\n\u003cp\u003eChronic Myeloid Leukemia.mp4\u003c\/p\u003e\n\u003cp\u003eHodgkin Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eLymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eMyelodysplastic Syndromes.mp4\u003c\/p\u003e\n\u003cp\u003ePlasma Cell Dyscrasias.mp4\u003c\/p\u003e\n\u003cp\u003ePlatelet Disorders.mp4\u003c\/p\u003e\n\u003cp\u003eThrombosis in Cancer Patients.mp4\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405758943428,"sku":null,"price":13.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Cleveland-Clinic-24th-Annual-ASH-Review-2025.jpg?v=1784215827"},{"product_id":"american-society-of-clinical-oncology-annual-meeting-2025","title":"American Society of Clinical Oncology Annual Meeting 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: oncologists, hematologists, pathologists, radiologists, surgical, and radiation oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago, Illinois, under the theme “Driving Knowledge to Action: Building a Better Future”.\u003c\/p\u003e\n\u003ch3\u003eHere are some key highlights:\u003c\/h3\u003e\n\u003cp\u003eOver 5,400 presentations covered cutting-edge research, clinical trials, and treatment innovations across a wide range of cancers.\u003c\/p\u003e\n\u003cp\u003eBreast, lung, ovarian, and colorectal cancers were among the most featured tumor types.\u003c\/p\u003e\n\u003cp\u003eAstraZeneca and Daiichi Sankyo presented promising results from the DESTINY-Breast09 study, suggesting a potential new standard of care for HER2-positive metastatic breast cancer.\u003c\/p\u003e\n\u003cp\u003eGilead and Merck \u0026amp; Co made headlines with their TROP-2–targeted therapy Trodelvy combined with Keytruda, showing strong results in triple-negative breast cancer.\u003c\/p\u003e\n\u003cp\u003eAmgen’s Imdelltra showed significant benefit in small cell lung cancer, a notoriously tough-to-treat disease.\u003c\/p\u003e\n\u003cp\u003eIn ovarian cancer, the ROSELLA trial and OVATION-2 study offered encouraging data for patients with resistant or advanced disease\u003c\/p\u003e\n\u003ch3\u003eThe target audience for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is impressively broad, reflecting the multidisciplinary nature of cancer care. It includes:\u003c\/h3\u003e\n\u003cp\u003eMedical, surgical, and radiation oncologists\u003c\/p\u003e\n\u003cp\u003eHematologists, pathologists, and radiologists\u003c\/p\u003e\n\u003cp\u003ePrimary care physicians and internal medicine specialists\u003c\/p\u003e\n\u003cp\u003eGynecologic, thoracic, colorectal, and urologic surgeons\u003c\/p\u003e\n\u003cp\u003ePulmonologists, dermatologists, and oral surgeons\u003c\/p\u003e\n\u003cp\u003eOncology nurse practitioners, nurses, and physician assistants\u003c\/p\u003e\n\u003cp\u003eResidents, fellows, and medical students\u003c\/p\u003e\n\u003cp\u003eAllied health professionals involved in oncology care and research\u003c\/p\u003e\n\u003cp\u003eThe meeting is designed to foster collaboration across specialties, highlight the latest in clinical and translational research, and support continuing education for professionals at all stages of their careers\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e*Note: Agenda\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405765169348,"sku":null,"price":110.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/American-Society-of-Clinical-Oncology-Annual-Meeting-2025.png?v=1784215845"},{"product_id":"meetings-by-mail-cleveland-clinic-updates-in-primary-immunodeficiency-2025","title":"Meetings By Mail Cleveland Clinic Updates in Primary Immunodeficiency 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: allergy \u0026amp; immunology physicians, rheumatologists, hematologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRelease date: June 5, 2025\u003c\/p\u003e\n\u003cp\u003eTopics include: humoral deficiency, complexities in IEI, advances in diagnostics, complement defects, mannose binding lectin, immunoglobulin replacement therapy, antibiotic prophylaxis, bone marrow transplant, gene therapy, recurrent or secondary infections, vaccines and much more!\u003c\/p\u003e\n\u003ch3\u003eThe Updates in Primary Immunodeficiency 2025 symposium is designed for healthcare professionals with an interest in allergy, immunology, rheumatology, hematology, and related fields. The target audience includes:\u003c\/h3\u003e\n\u003cp\u003ePhysicians\u003c\/p\u003e\n\u003cp\u003ePhysician assistants\u003c\/p\u003e\n\u003cp\u003eNurse practitioners\u003c\/p\u003e\n\u003cp\u003eFellows and residents\u003c\/p\u003e\n\u003cp\u003ePhysicians are part of the target audience for the Updates in Primary Immunodeficiency 2025 symposium. This course is designed for healthcare professionals, including physicians, physician assistants, nurse practitioners, fellows, and residents, with an interest in allergy, immunology, rheumatology, hematology, and related fields\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAgenda.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405765693636,"sku":null,"price":19.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Meetings-By-Mail-Cleveland-Clinic-Updates-in-Primary-Immunodeficiency-2025.jpg?v=1784215849"},{"product_id":"medical-education-resources-internal-medicine-for-primary-care-cardio-neuro-onc-pulm-2025","title":"Medical Education Resources Internal Medicine for Primary Care Cardio Neuro Onc Pulm 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: primary care physicians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLisbon, Portugal – InterContinental Lisbon\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThis program is targeted to office-based primary care providers and other health professionals with updates in primary care medicine\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this program, participants should be better able to:\u003c\/h3\u003e\n\u003cp\u003eImplement treatment strategies reflective of recent guidelines and current evidence basedmedicine for heart failure\u003c\/p\u003e\n\u003cp\u003eRecognize the clinical manifestations of valvular heart disease\u003c\/p\u003e\n\u003cp\u003eList pharmacologic options for stroke prevention in patients with atrial fibrillation and the benefits ofeach\u003c\/p\u003e\n\u003cp\u003ePerform a cardiovascular workup\u003c\/p\u003e\n\u003cp\u003eDiscuss evidence-based management options for Alzheimer’s disease\u003c\/p\u003e\n\u003cp\u003eEvaluate weakness and recognize cardinal features of Parkinson’s disease as well as othermovement disorders\u003c\/p\u003e\n\u003cp\u003eUtilize history and physical examination to distinguish weakness from non-specific symptoms\u003c\/p\u003e\n\u003cp\u003eDescribe the differential diagnosis of headaches and migraines\u003c\/p\u003e\n\u003cp\u003eDiagnose and manage patients with asthma\u003c\/p\u003e\n\u003cp\u003eDesign treatment strategies reflective of current evidence-based medicine for common respiratoryinfections\u003c\/p\u003e\n\u003cp\u003eDescribe the current therapeutic management of COPD\u003c\/p\u003e\n\u003cp\u003eDiscuss diagnosis and screening strategies as well as treatment plans for lung nodules and lungcancer\u003c\/p\u003e\n\u003cp\u003eIdentify clinical practices shown to prevent cancer\u003c\/p\u003e\n\u003cp\u003eDiscuss the diagnostic approach to the patient with suspected cancer\u003c\/p\u003e\n\u003cp\u003eEvaluate and manage risks of the cancer survivor\u003c\/p\u003e\n\u003cp\u003eDescribe the mechanism of action of new antiplatelet agents\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eMonday, June 2, 2025\u003c\/p\u003e\n\u003cp\u003e7:00 am Registration\u003c\/p\u003e\n\u003cp\u003eRooms booked as part of the MER room block include breakfast in the hotel dining room. Participants booked outside of the MER room block, please make breakfast arrangements on your own.\u003c\/p\u003e\n\u003cp\u003eOffice Management of Heart Failure\u003c\/p\u003e\n\u003cp\u003eEtiologies and stages of heart failure; Differentiating heart failure with reduced EF (HFrEF) and heart failure with preserved EF (HFpEF); Work-up and pharmacological treatment options; Cardiac amyloidosis; Importance of end-of-life care\u003c\/p\u003e\n\u003cp\u003ePrimary Care Approach to Valvular Heart Disease\u003c\/p\u003e\n\u003cp\u003eCoffee Break\u003c\/p\u003e\n\u003cp\u003eUpdate on Atrial Fibrillation for the Primary Care Provider\u003c\/p\u003e\n\u003cp\u003eNew methods of detection, rate vs rhythm control, new options for stroke prevention\u003c\/p\u003e\n\u003cp\u003eAlzheimer’s \u0026amp; Other Dementias\u003c\/p\u003e\n\u003cp\u003eDefinition; statistics; neurological changes of normal aging; pathology; etiological theories; vascular dementias; investigations; social issues; symptomatic treatment; research therapies\u003c\/p\u003e\n\u003cp\u003eParkinson’s Disease \u0026amp; Other Movement Disorders\u003c\/p\u003e\n\u003cp\u003eEpidemiology; cardinal features; secondary features; pathology; neurochemistry; differential diagnosis; treatment; complication; other movement disorders; neuroleptic- induced movement disorders; chorea\u003c\/p\u003e\n\u003cp\u003e12:40 pm\u003c\/p\u003e\n\u003cp\u003eSession Adjourns\u003c\/p\u003e\n\u003cp\u003eTuesday, June 3, 2025\u003c\/p\u003e\n\u003cp\u003e7:00 am Registration\u003c\/p\u003e\n\u003cp\u003eRooms booked as part of the MER room block include breakfast in the hotel dining room. Participants booked outside of the MER room block, please make breakfast arrangements on your own.\u003c\/p\u003e\n\u003cp\u003eEvaluating Weakness\u003c\/p\u003e\n\u003cp\u003eUsing the history and physical examination to distinguish weakness from non-specific symptoms; characteristics of neurological diseases that produce weakness; presentations of representative diseases of the nervous system\u003c\/p\u003e\n\u003cp\u003eHeadaches \u0026amp; Migraines\u003c\/p\u003e\n\u003cp\u003eBasic headache mechanisms; headache history: characteristics, precipitating factors, medical conditions; migraine: common tension, classic, treatment, complicated, cluster, sinus; trigeminal neuralgia; Giant Cell Arteritis; brain tumor; subarachnoid hemorrhage; emergency room treatment\u003c\/p\u003e\n\u003cp\u003eCoffee Break\u003c\/p\u003e\n\u003cp\u003eCardiac Testing for the Non-cardiologist\u003c\/p\u003e\n\u003cp\u003eUncomplicating the menu choices; Selecting the right test for the right patient and making sense of the results\u003c\/p\u003e\n\u003cp\u003eAsthma\u003c\/p\u003e\n\u003cp\u003eThe medical impact of asthma; fundamental role of inflammation, with possible scarring and irreversible loss of lung function; practical points of diagnosis; goal setting management based on levels of severity; risk factors for mortality and treatment in the acute setting; management options for the difficult to control asthmatic patient\u003c\/p\u003e\n\u003cp\u003eControversies in the Treatment of Common Respiratory Infections\u003c\/p\u003e\n\u003cp\u003eAcute and chronic bronchitis; pneumonia (community versus hospital-acquired); role of the Pneumonia Severity Index score in determining indication for hospitalization; cost- effective use of antibiotics; clinical significance of drug resistance; guidelines for management\u003c\/p\u003e\n\u003cp\u003e12:40 pm\u003c\/p\u003e\n\u003cp\u003eSession Adjourns\u003c\/p\u003e\n\u003cp\u003eWednesday, June 4, 2025\u003c\/p\u003e\n\u003cp\u003e7:00 am Registration\u003c\/p\u003e\n\u003cp\u003eRooms booked as part of the MER room block include breakfast in the hotel dining room. Participants booked outside of the MER room block, please make breakfast arrangements on your own.\u003c\/p\u003e\n\u003cp\u003eCOPD\u003c\/p\u003e\n\u003cp\u003eDefinition; pathophysiology; early detection and intervention; risk reduction; management update including new modalities (including lung volume reduction surgery) and the role of inhaled corticosteroids and domiciliary oxygen\u003c\/p\u003e\n\u003cp\u003eLung Cancer Screening \u0026amp; Pulmonary Nodules\u003c\/p\u003e\n\u003cp\u003eAppropriate use of the new lung cancer screening recommendations; Fleischner Society guidelines and American College of Chest Physician Lung Cancer guidelines; approach to definitive evaluation and management strategies\u003c\/p\u003e\n\u003cp\u003eCoffee Break\u003c\/p\u003e\n\u003cp\u003eCancer Prevention\u003c\/p\u003e\n\u003cp\u003eApproach to the Patient with Suspected Cancer\u003c\/p\u003e\n\u003cp\u003e11:40 am\u003c\/p\u003e\n\u003cp\u003eSession Adjourns\u003c\/p\u003e\n\u003cp\u003eThursday, June 5, 2025\u003c\/p\u003e\n\u003cp\u003e7:00 am Registration\u003c\/p\u003e\n\u003cp\u003eRooms booked as part of the MER room block include breakfast in the hotel dining room. Participants booked outside of the MER room block, please make breakfast arrangements on your own.\u003c\/p\u003e\n\u003cp\u003eManagement of Cancer Survivors\u003c\/p\u003e\n\u003cp\u003e9:30 am\u003c\/p\u003e\n\u003cp\u003eConference Adjourns\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405765759172,"sku":null,"price":84.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Medical-Education-Resources-Internal-Medicine-for-Primary-Care-Cardio-Neuro-Onc-Pulm-2025.jpg?v=1784215851"},{"product_id":"memorial-sloan-kettering-cancer-center-radiologic-interpretation-in-the-oncology-population-for-advanced-practice-providers-2025","title":"Memorial Sloan Kettering Cancer Center Radiologic Interpretation in the Oncology Population for Advanced Practice Providers 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: oncologists, radiation oncologists, surgical oncologists, radiologists and interventional radiologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecialties\u003c\/p\u003e\n\u003cp\u003eSpecialties – Bone Marrow Transplant, Breast Medical Oncology, Critical Care, Emergency Medicine, Gastroenterology, Gastrointestinal Oncology, Genitourinary Oncology, Gynecologic Oncology, Head and Neck Oncology, Hematology, Hepatology, Hospice and Palliative Medicine, Hospitalist, Immigrant Health and Cancer Disparities, Infectious Diseases, Integrative Medicine, Internal Medicine, Interventional Radiology, Leukemia, Lymphoma, Medical Oncology, Neuro-Oncology, Neuropathology, Neuroradiology, Nuclear Medicine, Nurse Anesthetist, Nurse Practitioner, Nursing, Oncology and Hematology, Pediatric Oncology, Pediatrics, Physician Assistant, Pulmonology, Radiation Oncology, Solid Tumor Oncology, Surgical Oncology, Thoracic Medical Oncology\u003c\/p\u003e\n\u003cp\u003eOverview\u003c\/p\u003e\n\u003cp\u003eRadiologic imaging plays a critical role in the care of all oncology patients, yet a knowledge gap in radiologic interpretation exists among Advanced Practice Providers (APPs). This one-day virtual program offers a comprehensive overview of radiologic interpretation, specifically designed for the oncology population. Topics include imaging of the breast, pelvis, chest, abdomen, brain, spine, extremities, and whole body. Key imaging modalities such as X-ray, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and nuclear imaging will be covered.\u003c\/p\u003e\n\u003cp\u003eThe program also addresses unique radiologic considerations for pediatric and transgender populations, as well as innovative applications of imaging in interventional oncology. To enhance learning and engagement, interdisciplinary case studies will be integrated throughout, utilizing interactive tools to reinforce key concepts. Additionally, attendees will gain access to an online syllabus after the course concludes, which will include recorded videos of the faculty presentations.\u003c\/p\u003e\n\u003cp\u003eObjectives\u003c\/p\u003e\n\u003ch3\u003eAt the conclusion of this course, learners will be able to:\u003c\/h3\u003e\n\u003cp\u003eGain knowledge of the principles and interpretation of common imaging modalities and translate the knowledge learned to clinical practice\u003c\/p\u003e\n\u003cp\u003eIdentify the clinical indications for and selection criteria of various imaging modalities\u003c\/p\u003e\n\u003cp\u003eRecognize common abnormalities on various radiology examinations\u003c\/p\u003e\n\u003cp\u003eAddress challenges and limitations of various imaging modalities\u003c\/p\u003e\n\u003cp\u003eIdentify important considerations when interpreting radiologic imaging in special populations\u003c\/p\u003e\n\u003cp\u003eDiscuss the differential diagnosis for common radiographic findings\u003c\/p\u003e\n\u003cp\u003eExplain the role of imaging in cancer screening, staging, and surveillance\u003c\/p\u003e\n\u003cp\u003eDescribe the use of real time radiologic imaging and interpretation in interventional oncology\u003c\/p\u003e\n\u003ch3\u003eThe 2025 Radiologic Interpretation in the Oncology Population for Advanced Practice Providers course by Memorial Sloan Kettering Cancer Center is primarily designed for Advanced Practice Providers (APPs), but it also welcomes physicians from a wide range of specialties involved in oncology care. These include:\u003c\/h3\u003e\n\u003cp\u003eMedical oncologists\u003c\/p\u003e\n\u003cp\u003eRadiation oncologists\u003c\/p\u003e\n\u003cp\u003eSurgical oncologists\u003c\/p\u003e\n\u003cp\u003eRadiologists and interventional radiologists\u003c\/p\u003e\n\u003cp\u003eNeuro-oncologists and neuroradiologists\u003c\/p\u003e\n\u003cp\u003ePediatric oncologists\u003c\/p\u003e\n\u003cp\u003eInternal medicine and hospitalist physicians\u003c\/p\u003e\n\u003cp\u003eEmergency medicine and critical care physicians\u003c\/p\u003e\n\u003cp\u003ePhysicians in hepatology, hematology, and gastroenterology\u003c\/p\u003e\n\u003cp\u003eThe course focuses on enhancing radiologic interpretation skills across imaging modalities like X-ray, CT, MRI, ultrasound, and nuclear imaging, with applications in cancer screening, staging, and surveillance\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAbdomen Session Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eAbdominal Imaging FAQs and Clinical Pearls.mp4\u003c\/p\u003e\n\u003cp\u003eAbdominal Imaging FAQs and Clinical Pearls.pdf\u003c\/p\u003e\n\u003cp\u003eBrain and Spine Imaging FAQ and Clinical Pearls.mp4\u003c\/p\u003e\n\u003cp\u003eBrain and Spine Imaging FAQ and Clinical Pearls.pdf\u003c\/p\u003e\n\u003cp\u003eBrain and Spine Session Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eBreast Imaging FAQ and Clinical Pearls.mp4\u003c\/p\u003e\n\u003cp\u003eBreast Imaging FAQ and Clinical Pearls.pdf\u003c\/p\u003e\n\u003cp\u003eBreast, Chest Tissue, and Pelvis Session Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eCASE STUDY- Abdomen.mp4\u003c\/p\u003e\n\u003cp\u003eCASE STUDY- Brain and Spine.mp4\u003c\/p\u003e\n\u003cp\u003eCASE STUDY- CHEST.mp4\u003c\/p\u003e\n\u003cp\u003eCASE STUDY- Transgender Considerations.mp4\u003c\/p\u003e\n\u003cp\u003eChest Imaging FAQ and Clinical Pearls.mp4\u003c\/p\u003e\n\u003cp\u003eChest Imaging FAQ and Clinical Pearls.pdf\u003c\/p\u003e\n\u003cp\u003eChest Session Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eChest X-Ray.mp4\u003c\/p\u003e\n\u003cp\u003eChest X-Ray.pdf\u003c\/p\u003e\n\u003cp\u003eCT of the Abdomen and Pelvis.mp4\u003c\/p\u003e\n\u003cp\u003eCT of the Abdomen and Pelvis.pdf\u003c\/p\u003e\n\u003cp\u003eCT of the Brain.mp4\u003c\/p\u003e\n\u003cp\u003eCT of the Brain.pdf\u003c\/p\u003e\n\u003cp\u003eCT of the Chest.mp4\u003c\/p\u003e\n\u003cp\u003eCT of the Chest.pdf\u003c\/p\u003e\n\u003cp\u003eInterventional Oncology Session Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eMRI of the Brain.mp4\u003c\/p\u003e\n\u003cp\u003eMRI of the Brain.pdf\u003c\/p\u003e\n\u003cp\u003eMRI of the Spine.mp4\u003c\/p\u003e\n\u003cp\u003ePediatric Considerations in Abdominal Imaging.mp4\u003c\/p\u003e\n\u003cp\u003ePediatric Considerations in Abdominal Imaging.pdf\u003c\/p\u003e\n\u003cp\u003ePediatric Considerations in Chest Imaging.mp4\u003c\/p\u003e\n\u003cp\u003ePediatric Considerations in Chest Imaging.pdf\u003c\/p\u003e\n\u003cp\u003ePET Scans.mp4\u003c\/p\u003e\n\u003cp\u003ePET Scans.pdf\u003c\/p\u003e\n\u003cp\u003ePOCUS CASE STUDIES- Effusion, Tamponade, and Pancreatitis.mp4\u003c\/p\u003e\n\u003cp\u003ePOCUS CASE STUDIES- Effusion, Tamponade, and Pancreatitis.pdf\u003c\/p\u003e\n\u003cp\u003eRadiologic Imaging through the Cancer Care Continuum- A Case Study Approach.mp4\u003c\/p\u003e\n\u003cp\u003eRadiologic Interpretation in Women’s Health- Transvaginal US and Pelvic Imaging.mp4\u003c\/p\u003e\n\u003cp\u003eRadiologic Interpretation in Women’s Health- Transvaginal US and Pelvic Imaging.pdf\u003c\/p\u003e\n\u003cp\u003eRadiologicInterpretation2025_Brochure.pdf\u003c\/p\u003e\n\u003cp\u003eRetinoblastoma- Image Guided Intraarterial Chemotherapy.mp4\u003c\/p\u003e\n\u003cp\u003eRetinoblastoma- Image Guided Intraarterial Chemotherapy.pdf\u003c\/p\u003e\n\u003cp\u003eSpecial Considerations in the Transgender Populations.mp4\u003c\/p\u003e\n\u003cp\u003eSpecial Considerations in the Transgender Populations.pdf\u003c\/p\u003e\n\u003cp\u003eThe ABCs of Interventional Radiology- Catheters, Drains, and Stents… Oh My!.mp4\u003c\/p\u003e\n\u003cp\u003eThe ABCs of Interventional Radiology- Catheters, Drains, and Stents… Oh My!.pdf\u003c\/p\u003e\n\u003cp\u003eUltrasound, Mammography, and MRI of the Breast.mp4\u003c\/p\u003e\n\u003cp\u003eWhole Body and Extremity Session Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eX-Ray of the Extremity.mp4\u003c\/p\u003e\n\u003cp\u003eX-Ray of the Extremity.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405768184004,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-Radiologic-Interpretation-in-the-Oncology-Population-for-Advanced-Practice-Providers-2025.jpg?v=1784215876"},{"product_id":"cedars-sinai-11th-annual-cedars-sinai-update-in-obstetrics-gynecology-conference-2025","title":"Cedars Sinai 11th Annual Cedars-Sinai Update in Obstetrics \u0026 Gynecology Conference 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: obstetricians, gynecologists, endocrinologists, family \u0026amp; general medicine physicians, oncologists, surgeons, urologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eSpecialties – Endocrinology \u0026amp; Metabolism, Family \/ General Medicine, Obstetrics \u0026amp; Gynecology, Oncology, Surgery, Urology\u003c\/p\u003e\n\u003cp\u003eProfessions – Nurse, Nurse (Advanced Practice NP CRNA CNM CNS), Other (non-physician), Physician, Researcher (non-physician), Researcher (physician)\u003c\/p\u003e\n\u003cp\u003eOverview\u003c\/p\u003e\n\u003cp\u003eObjectives\u003c\/p\u003e\n\u003cp\u003eApply the latest recommendations from national organizations on thyroid disease in pregnancy.\u003c\/p\u003e\n\u003cp\u003eUnderstand the environmental factors in the causation of adverse birth outcomes, as well as the policy, clinical, and research strategies for adaptation and mitigation of these factors.\u003c\/p\u003e\n\u003ch3\u003eThis conference is particularly beneficial for:\u003c\/h3\u003e\n\u003cp\u003eObstetricians \u0026amp; Gynecologists seeking updates on thyroid disease in pregnancy, environmental impacts on birth outcomes, and HPV home testing.\u003c\/p\u003e\n\u003cp\u003eEndocrinologists \u0026amp; Metabolism Specialists interested in hormone replacement therapy (HRT) updates.\u003c\/p\u003e\n\u003cp\u003eFamily \u0026amp; General Medicine Physicians looking for multidisciplinary approaches to women’s health.\u003c\/p\u003e\n\u003cp\u003eOncologists \u0026amp; Surgeons focusing on cervical cancer screening and treatment strategies.\u003c\/p\u003e\n\u003cp\u003eUrologists \u0026amp; Researchers involved in women’s health and reproductive medicine.\u003c\/p\u003e\n\u003cp\u003eThe event will feature expert-led discussions, evidence-based clinical updates, and networking opportunities with leading professionals in the field.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eContraception Update.mp4\u003c\/p\u003e\n\u003cp\u003eContraception Update.pdf\u003c\/p\u003e\n\u003cp\u003eDisclosure and Accredidation Information_11th Annual Cedars-Sinai Update in Obstetrics and Gynecology Conference.pdf\u003c\/p\u003e\n\u003cp\u003eEnvironmental Impacts on Delivery Outcomes.mp4\u003c\/p\u003e\n\u003cp\u003eEnvironmental Impacts on Delivery Outcomes.pdf\u003c\/p\u003e\n\u003cp\u003eExercise in Pregnancy.mp4\u003c\/p\u003e\n\u003cp\u003eExercise in Pregnancy.pdf\u003c\/p\u003e\n\u003cp\u003eFetal Growth IUGR Update.mp4\u003c\/p\u003e\n\u003cp\u003eFetal Growth IUGR Update.pdf\u003c\/p\u003e\n\u003cp\u003eHome Testing for HPV.mp4\u003c\/p\u003e\n\u003cp\u003eHome Testing for HPV.pdf\u003c\/p\u003e\n\u003cp\u003eMaking Pelvic Pain Less Painful.mp4\u003c\/p\u003e\n\u003cp\u003eMaking Pelvic Pain Less Painful.pdf\u003c\/p\u003e\n\u003cp\u003eWelcome.pdf\u003c\/p\u003e\n\u003cp\u003eWomen with IBD- navigating hormones, health and healing.mp4\u003c\/p\u003e\n\u003cp\u003eWomen with IBD- navigating hormones, health and healing.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405769035972,"sku":null,"price":52.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Cedars-Sinai-11th-Annual-Cedars-Sinai-Update-in-Obstetrics-Gynecology-Conference-2025-scaled.jpg?v=1784215891"},{"product_id":"cedars-sinai-6th-annual-cedars-sinai-gastrointestinal-tumor-conference-2025","title":"Cedars Sinai 6th Annual Cedars-Sinai Gastrointestinal Tumor Conference 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: gastroenterologists, oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eSpecialties – Endocrinology \u0026amp; Metabolism, Family \/ General Medicine, Gastroenterology, Medical Genetics, Nuclear Medicine, Oncology, Pain Management, Palliative Care, Pathology \u0026amp; Laboratory Medicine, Radiation Oncology, Radiology\u003c\/p\u003e\n\u003cp\u003eProfessions – Nurse, Nurse (Advanced Practice NP CRNA CNM CNS), Occupational Therapist, Other (non-physician), Pharmacist, Physician, Researcher (non-physician)\u003c\/p\u003e\n\u003cp\u003eOverview\u003c\/p\u003e\n\u003cp\u003eObjectives\u003c\/p\u003e\n\u003cp\u003eAnalyze advances in biomarkers and therapies to evaluate and synthesize treatment options for patients with gastroesophageal cancers.\u003c\/p\u003e\n\u003cp\u003eUse AJCC or other appropriate staging in clinical practice, including the use of appropriate prognostic indicators and evidence based national guidelines for treatment planning\u003c\/p\u003e\n\u003cp\u003eEvaluate the basic science of immune therapy for GI malignancies and the implications for transfer from bench to bedside\u003c\/p\u003e\n\u003cp\u003eIncrease knowledge of therapy for neuroendocrine tumors and biomarker identification of novel therapies\u003c\/p\u003e\n\u003cp\u003eIdentify and implement optimal strategies for managing therapy related side effects and toxicities in patients treated with therapeutic agents\u003c\/p\u003e\n\u003cp\u003eAnticipate the needs, problems, and issues of cancer survivors and develop an individualized wellness plan in partnership with cancer survivors, their families and the healthcare team\u003c\/p\u003e\n\u003cp\u003eGastroenterology\u003c\/p\u003e\n\u003cp\u003eOncology (especially GI oncology)\u003c\/p\u003e\n\u003cp\u003eRadiation oncology\u003c\/p\u003e\n\u003cp\u003ePathology and laboratory medicine\u003c\/p\u003e\n\u003cp\u003eEndocrinology \u0026amp; metabolism\u003c\/p\u003e\n\u003cp\u003eFamily and general medicine\u003c\/p\u003e\n\u003cp\u003eMedical genetics\u003c\/p\u003e\n\u003cp\u003eNuclear medicine\u003c\/p\u003e\n\u003cp\u003ePain management and palliative care\u003c\/p\u003e\n\u003cp\u003eRadiology\u003c\/p\u003e\n\u003cp\u003eThe conference emphasizes precision medicine, immunotherapy, and biomarker strategies for cancers of the pancreas, liver, and gastroesophagus. It’s a valuable opportunity for physicians to gain cutting-edge insights and apply them directly to clinical decision-making\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below\u003c\/p\u003e\n\u003cp\u003eApril 5 Full Live.mp4\u003c\/p\u003e\n\u003cp\u003eAgenda.pdf\u003c\/p\u003e\n\u003cp\u003eCedars Sinai Health System.pdf\u003c\/p\u003e\n\u003cp\u003eHow I treat liver metastases (surgical).pdf\u003c\/p\u003e\n\u003cp\u003eMolecular Landscape in CRC- Shaping the Future.pdf\u003c\/p\u003e\n\u003cp\u003eOvercoming obstacles to optimize care in Neuroendocrine tumors.pdf\u003c\/p\u003e\n\u003cp\u003eSocial Media in Oncology.pdf\u003c\/p\u003e\n\u003cp\u003eTargeting KRAS in GI malignancies.pdf\u003c\/p\u003e\n\u003cp\u003eThe Challenges of Treating Pancreatic Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eUpdate in Surgical Management of Pancreatic Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eUpdates on the Management of Gastric Cancer.pdf\u003c\/p\u003e\n\u003cp\u003eWelcome and Introduction.pdf\u003c\/p\u003e\n\u003ch3\u003e* Detail:\u003c\/h3\u003e\n\u003cp\u003eSaturday, April 5, 2025\u003c\/p\u003e\n\u003cp\u003eDisclosure and Accredidation Information\u003c\/p\u003e\n\u003cp\u003eRegistration Check In and Exhibits\u003c\/p\u003e\n\u003cp\u003eRecording\u003c\/p\u003e\n\u003cp\u003eWelcome and Introduction\u003c\/p\u003e\n\u003cp\u003eCedars Sinai Health System\u003c\/p\u003e\n\u003cp\u003eDavid Hoffman, MD\u003c\/p\u003e\n\u003cp\u003eTargeting KRAS in GI malignancies\u003c\/p\u003e\n\u003cp\u003eIgnacio Garrido-Laguna, MD, PhD, MBA\u003c\/p\u003e\n\u003cp\u003eMolecular Landscape in CRC: Shaping the Future\u003c\/p\u003e\n\u003cp\u003eJason A. Zell, DO, MPH\u003c\/p\u003e\n\u003cp\u003eUpdates on the Management of Gastric Cancer\u003c\/p\u003e\n\u003cp\u003eDani Castillo, MD\u003c\/p\u003e\n\u003cp\u003eThe Challenges of Treating Pancreatic Cancer\u003c\/p\u003e\n\u003cp\u003eVincent J. Picozzi, MD\u003c\/p\u003e\n\u003cp\u003eUpdate in Surgical Management of Pancreatic Cancer\u003c\/p\u003e\n\u003cp\u003eNicholas Nissen, MD\u003c\/p\u003e\n\u003cp\u003eBreak and Exhibits\u003c\/p\u003e\n\u003cp\u003ePanel Discussion: GI Cancer Cases\u003c\/p\u003e\n\u003cp\u003eKambiz Kosari, MD\u003c\/p\u003e\n\u003cp\u003eKatelyn Atkins, MD, PhD\u003c\/p\u003e\n\u003cp\u003eJeremy Lorber, MD\u003c\/p\u003e\n\u003cp\u003eHow I treat liver metastases (surgical)\u003c\/p\u003e\n\u003cp\u003eAlexandra Gangi, MD\u003c\/p\u003e\n\u003cp\u003eOvercoming obstacles to optimize care in Neuroendocrine tumors\u003c\/p\u003e\n\u003cp\u003eEmily Bergsland, MD\u003c\/p\u003e\n\u003cp\u003ePick Up Lunch and Exhibits\u003c\/p\u003e\n\u003cp\u003eSocial Media in Oncology\u003c\/p\u003e\n\u003cp\u003eSumanta Pal, MD, FASCO\u003c\/p\u003e\n\u003cp\u003eClosing Remarks\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405770215620,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Cedars-Sinai-6th-Annual-Cedars-Sinai-Gastrointestinal-Tumor-Conference-2025-scaled.jpg?v=1784215908"},{"product_id":"memorial-sloan-kettering-cancer-center-9th-annual-msk-symposium-on-lymphoma-2025","title":"Memorial Sloan Kettering Cancer Center 9th Annual MSK Symposium on Lymphoma 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: internists, oncologists, hematologists as well as medical and radiation oncologists, hematopathologists, scientists, and medical trainees\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecialties\u003c\/p\u003e\n\u003cp\u003eSpecialties – Anatomic Pathology, Bone Marrow Transplant, Cellular Therapeutics, Clinical Pathology, Geriatric Medicine, Hematology, Hematopathology, Immunotherapy, Internal Medicine, Laboratory Medicine, Leukemia, Lymphoma, Medical Oncology, Molecular Pathology, Nuclear Medicine, Oncology and Hematology, Radiation Oncology\u003c\/p\u003e\n\u003cp\u003eOverview\u003c\/p\u003e\n\u003cp\u003eThis annual symposium provides a comprehensive overview of the latest advancements in the evolving field of lymphoma. Renowned national and international experts present cutting-edge discoveries in lymphoma biology, state-of-the-art diagnostic techniques, and innovative treatment strategies. The program highlights the clinical management of common lymphoma subtypes while also examining groundbreaking drug developments that are redefining patient care. Attendees will gain valuable insights into the latest findings in lymphoma biology and pathology, exploring how these breakthroughs are being translated into practical, impactful solutions for clinical practice.\u003c\/p\u003e\n\u003cp\u003eThe target audience for this symposium includes internists, oncologists, hematologists as well as medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in the diagnosis, treatment, and biomedical research of lymphoma. Participants have the choice of attending either in-person or virtually.\u003c\/p\u003e\n\u003cp\u003eWe look forward to welcoming colleagues and esteemed faculty from around the world to exchange insights and advance the future of lymphoma care.\u003c\/p\u003e\n\u003cp\u003eObjectives\u003c\/p\u003e\n\u003ch3\u003eAt the conclusion of this symposium, attendees will be able to:\u003c\/h3\u003e\n\u003cp\u003eDescribe recent advances in lymphoma classification\u003c\/p\u003e\n\u003cp\u003eDescribe new agents mode of actions, efficacy, side effects\u003c\/p\u003e\n\u003cp\u003eDiscuss options and recommendations for patients in the relapse refractory setting\u003c\/p\u003e\n\u003cp\u003eProvide adequate information to help shared decision with patients regarding their treatment\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAdvances in Biology.mp4\u003c\/p\u003e\n\u003cp\u003eAdvances in Biology.pdf\u003c\/p\u003e\n\u003cp\u003eAdvancing Therapeutic Options in the Relapse Setting.mp4\u003c\/p\u003e\n\u003cp\u003eAdvancing Therapeutic Options in the Relapse Setting.pdf\u003c\/p\u003e\n\u003cp\u003eB-Cell Dynamics in the Germinal Center.mp4\u003c\/p\u003e\n\u003cp\u003eB-Cell Dynamics in the Germinal Center.pdf\u003c\/p\u003e\n\u003cp\u003eBiology of Hodgkin Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eBiology of Hodgkin Lymphoma.pdf\u003c\/p\u003e\n\u003cp\u003eCAR T-Cell Therapy for B Cell Lymphoma- Approach to Management and Care in the Outpatient Setting.mp4\u003c\/p\u003e\n\u003cp\u003eCAR T-Cell Therapy for B Cell Lymphoma- Approach to Management and Care in the Outpatient Setting.pdf\u003c\/p\u003e\n\u003cp\u003eCellular Therapies for Treating Mantle Cell Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eCellular Therapies for Treating Mantle Cell Lymphoma.pdf\u003c\/p\u003e\n\u003cp\u003eEpidemiology and Outcomes of Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eEpidemiology and Outcomes of Lymphoma.pdf\u003c\/p\u003e\n\u003cp\u003eGerminal Center Biology.pdf\u003c\/p\u003e\n\u003cp\u003eHistologic Transformation of Follicular Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eHistologic Transformation of Follicular Lymphoma.pdf\u003c\/p\u003e\n\u003cp\u003eLessons and Challenges.mp4\u003c\/p\u003e\n\u003cp\u003eLessons and Challenges.pdf\u003c\/p\u003e\n\u003cp\u003eLymphoma Survivorship- Optimizing Quality of Life and Monitoring Long Term Side Effects of Treatment.mp4\u003c\/p\u003e\n\u003cp\u003eLymphoma Survivorship- Optimizing Quality of Life and Monitoring Long Term Side Effects of Treatment.pdf\u003c\/p\u003e\n\u003cp\u003eLymphoma2025_Brochure.pdf\u003c\/p\u003e\n\u003cp\u003eManagement of Fertility in Patients with Hodgkin’s and Non-Hodgkin Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eManagement of Fertility in Patients with Hodgkin’s and Non-Hodgkin Lymphoma.pdf\u003c\/p\u003e\n\u003cp\u003eManagement of Older Patients.mp4\u003c\/p\u003e\n\u003cp\u003eManagement of Older Patients.pdf\u003c\/p\u003e\n\u003cp\u003eMantle Cell Lymphoma in Ambulatory Setting- Focus on Supportive Care and Adverse Event Management.mp4\u003c\/p\u003e\n\u003cp\u003eMantle Cell Lymphoma in Ambulatory Setting- Focus on Supportive Care and Adverse Event Management.pdf\u003c\/p\u003e\n\u003cp\u003eNew Antibodies Engaging Immune Cells.mp4\u003c\/p\u003e\n\u003cp\u003eNew Antibodies Engaging Immune Cells.pdf\u003c\/p\u003e\n\u003cp\u003eNew Drugs on the Horizon for Follicular Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eNew Drugs on the Horizon for Follicular Lymphoma.pdf\u003c\/p\u003e\n\u003cp\u003eNotch and Marginal Zone Biology.mp4\u003c\/p\u003e\n\u003cp\u003eNotch and Marginal Zone Biology.pdf\u003c\/p\u003e\n\u003cp\u003eOptimizing Patient Selection in 2025.mp4\u003c\/p\u003e\n\u003cp\u003eOptimizing Patient Selection in 2025.pdf\u003c\/p\u003e\n\u003cp\u003ePanel Discussion- Advances in Therapeutic Strategies for Mantle Cell Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003ePanel Discussion- Aggressive B-Cell Lymphoma \u0026amp; Car T-Cell Therapies in Large B-Cell Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003ePanel Discussion- Aggressive B-Cell Lymphoma- Addressing Remaining Gaps on the Path to a Definitive Cure.mp4\u003c\/p\u003e\n\u003cp\u003ePanel Discussion- Current Challenges in the Management of Patients with Follicular Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003ePanel Discussion- Empowering APPs and Nurses.mp4\u003c\/p\u003e\n\u003cp\u003ePanel Discussion- Hodgkin Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003ePanel Discussion- Improving Outcomes of Patients with T-Cell Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003ePanel Discussion- The Dark Side of B-Cells.mp4\u003c\/p\u003e\n\u003cp\u003eProgress in Large B-Cell Lymphoma Management.mp4\u003c\/p\u003e\n\u003cp\u003eProgress in Large B-Cell Lymphoma Management.pdf\u003c\/p\u003e\n\u003cp\u003eRadiation Therapy and CAR T.mp4\u003c\/p\u003e\n\u003cp\u003eRecent Insights Into Mantle Cell Lymphoma Biology.mp4\u003c\/p\u003e\n\u003cp\u003eRecent Insights Into Mantle Cell Lymphoma Biology.pdf\u003c\/p\u003e\n\u003cp\u003eResearch Spotlight- Updates of Active Hodgkin’s Lymphoma Protocols at Memorial Sloan Kettering.mp4\u003c\/p\u003e\n\u003cp\u003eResearch Spotlight- Updates of Active Hodgkin’s Lymphoma Protocols at Memorial Sloan Kettering.pdf\u003c\/p\u003e\n\u003cp\u003eSingle Cell Analysis of B-Cell Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eSingle Cell Analysis of B-Cell Lymphoma.pdf\u003c\/p\u003e\n\u003cp\u003eTreatment Initiation Versus Active Surveillance.mp4\u003c\/p\u003e\n\u003cp\u003eTreatment Initiation Versus Active Surveillance.pdf\u003c\/p\u003e\n\u003cp\u003eUpdate on Burkitt Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eUpdate on Burkitt Lymphoma.pdf\u003c\/p\u003e\n\u003cp\u003eUpdate on Primary Mediastinal B-Cell Lymphoma.mp4\u003c\/p\u003e\n\u003cp\u003eUpdate on Primary Mediastinal B-Cell Lymphoma.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405772181700,"sku":null,"price":58.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-9th-Annual-MSK-Symposium-on-Lymphoma-2025.jpg?v=1784215926"},{"product_id":"harvard-neurology-for-the-non-neurologist-2025","title":"Harvard Neurology for the Non-Neurologist 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: primary care physicians, general practice providers (primary care, family medicine), internists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAdditional In-Person Live Workshop: June 12, 2025 | Mass General Brigham, Assembly Row, Somerville, MA\u003c\/p\u003e\n\u003cp\u003eNeurology for the Non-Neurologist was founded by Dr. Marty Samuels 30+ years ago and we are hoping to continue his legacy for years to come! This is a comprehensive live CME course that will provide attendees with the opportunity to improve knowledge, competence, and performance in the major sub-specialty areas of modern clinical neurology. The activity will incorporate presentations, Q\u0026amp;A, multiple-choice questions, and opportunities for the learners to interact with experts in the field. The course will provide updates on the rapidly changing field of clinical neurology. With the knowledge and competence gained, the learner will improve their ability to skillfully diagnose and manage those patients who present with neurological symptoms and disorders.\u003c\/p\u003e\n\u003cp\u003eTarget audience\u003c\/p\u003e\n\u003cp\u003eThis activity is intended for Specialty Physicians, Primary Care Physicians, APPs (PA and NP), General Practice Providers (primary care, family medicine), Internal Medicine, Emergency Medicine, Oncology, Geriatrics, Psychiatry, and Neurosurgery.\u003c\/p\u003e\n\u003cp\u003eLearning objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of the activity, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eRecognize how to diagnose common neurological problems such as headache, Parkinson’s disease, ischemic stroke, and dementia.\u003c\/p\u003e\n\u003cp\u003eCite an approach to the most common neurological symptoms including headache, vision changes, weakness, dizziness, and cognitive changes.\u003c\/p\u003e\n\u003cp\u003eApply optimal care to patients with neurological problems who do not require referral to a neurologist.\u003c\/p\u003e\n\u003cp\u003eIdentify ways to provide self-management support to patients with chronic neurological conditions such as multiple sclerosis, Parkinson’s disease, or dementia.\u003c\/p\u003e\n\u003cp\u003eRecognize and manage neurological emergencies such as ischemic stroke and meningitis\/encephalitis.\u003c\/p\u003e\n\u003cp\u003eDiscuss the roles of members of a multi-disciplinary team, and how each contributes to optimizing outcomes for neurology patients, especially those undergoing rehabilitation or living with chronic disease (e.g. PT, OT, SLP, PM\u0026amp;R, etc).\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eJune 9 Agenda.pdf\u003c\/p\u003e\n\u003cp\u003eJune 9 Approach to the Dizzy Patient Manali Sheth, MD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 9 Approach to the Dizzy Patient Manali Sheth, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 9 Approach to the Dizzy Patient Manali Sheth, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 9 Clinical Neuroanatomy for the Non-Neurologist Galina Gheihman, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 9 Headache Angeliki Vgontzas, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 9 Headache Angeliki Vgontzas, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 9 Introduction to Neuropathies and Radiculopathies Meabh O’Hare, MD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 9 Introduction to Neuropathies and Radiculopathies Meabh O’Hare, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 9 Introduction to Neuropathies and Radiculopathies Meabh O’Hare, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 9 Neuroimaging for the Non-Neurologist What to Order and When Joshua P. Klein, MD, PhD.pptx\u003c\/p\u003e\n\u003cp\u003eJune 9 Optional Asynchronous Sessions Introduction to Myasthenia Gravis and Muscle Diseases (40 minutes) Joome Suh, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 9 Optional Asynchronous Sessions Introduction to Myasthenia Gravis and Muscle Diseases (40 minutes) Joome Suh, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 9 Test Your Knowledge.pdf\u003c\/p\u003e\n\u003cp\u003eJune 9 The Neurological Exam for the Non-Neurologist Tamara Kaplan, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 10 Agenda.pdf\u003c\/p\u003e\n\u003cp\u003eJune 10 Back and Neck Pain Shamik Bhattacharyya, MD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Back and Neck Pain Shamik Bhattacharyya, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Back and Neck Pain Shamik Bhattacharyya, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 10 Living With MS Supporting Quality of Life Tamara Kaplan, MD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Living With MS Supporting Quality of Life Tamara Kaplan, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Living With MS Supporting Quality of Life Tamara Kaplan, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 10 Optional Asynchronous Sessions Acute Stroke Management (40 minutes) Sam Snider, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Optional Asynchronous Sessions Acute Stroke Management (40 minutes) Sam Snider, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 10 Optional Asynchronous Sessions Basics of Seizure Management (30 minutes) Jong Woo Lee, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Optional Asynchronous Sessions Tackling Neurology Below the Belt Uroneurology \u0026amp; Sexual Dysfunction Tamara B. Kaplan MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Optional Asynchronous Sessions Tackling Neurology Below the Belt Uroneurology \u0026amp; Sexual Dysfunction Tamara B. Kaplan MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 10 Optional Asynchronous Sessions What’s New in MS (15 minutes) Sarah B. Conway, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Optional Asynchronous Sessions What’s New in MS (15 minutes) Sarah B. Conway, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 10 Recognizing and Managing Acute Stroke Simona Nedelcu, MD, PhD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Recognizing and Managing Acute Stroke Simona Nedelcu, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Recognizing and Managing Acute Stroke Simona Nedelcu, MD, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 10 Secondary Stroke Prevention Alexis Roy, MD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Secondary Stroke Prevention Alexis Roy, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Secondary Stroke Prevention Alexis Roy, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 10 Seizure Mimicks Jong Woo Lee, MD, PhD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Seizure Mimicks Jong Woo Lee, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Seizure Mimicks Jong Woo Lee, MD, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 10 Test Your Knowledge.pdf\u003c\/p\u003e\n\u003cp\u003eJune 10 Vision Loss Differential Diagnosis Sarah B. Conway, MD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Vision Loss Differential Diagnosis Sarah B. Conway, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 10 Vision Loss Differential Diagnosis Sarah B. Conway, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 11 Agenda.pdf\u003c\/p\u003e\n\u003cp\u003eJune 11 Common Neurologic Complications of Cancer \u0026amp; Their Management Eudocia Q. Lee, MD, MPH Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Common Neurologic Complications of Cancer \u0026amp; Their Management Eudocia Q. Lee, MD, MPH.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Common Neurologic Complications of Cancer \u0026amp; Their Management Eudocia Q. Lee, MD, MPH.pdf\u003c\/p\u003e\n\u003cp\u003eJune 11 Evaluating Cognitive Disorders and Dementia Seth Gale, MD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Evaluating Cognitive Disorders and Dementia Seth Gale, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Evaluating Cognitive Disorders and Dementia Seth Gale, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 11 Functional Neurologic Disorders Angela O’Neal, MD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Functional Neurologic Disorders Angela O’Neal, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Functional Neurologic Disorders Angela O’Neal, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 11 Optional Asynchronous Sessions Can’t Miss Neurological Infections (35 minutes) George K. Harrold, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Optional Asynchronous Sessions Can’t Miss Neurological Infections (35 minutes) George K. Harrold, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 11 Optional Asynchronous Sessions Complications of New Alzheimer’s Disease Treatments (30 minutes) Sheena Baratono, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Optional Asynchronous Sessions Complications of New Alzheimer’s Disease Treatments (30 minutes) Sheena Baratono, MD, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 11 Optional Asynchronous Sessions What You Need to Know about Women’s Neurology (35 minutes) Kenda Alhadid, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Optional Asynchronous Sessions What You Need to Know about Women’s Neurology (35 minutes) Kenda Alhadid, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 11 Parkinson’s Disease and other Movement Disorders Emily A. Ferenczi, MD, PhD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Parkinson’s Disease and other Movement Disorders Emily A. Ferenczi, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Parkinson’s Disease and other Movement Disorders Emily A. Ferenczi, MD, PhD.pptx\u003c\/p\u003e\n\u003cp\u003eJune 11 Sports Neurology Claus Reinsberger, MD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Sports Neurology Claus Reinsberger, MD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Sports Neurology Claus Reinsberger, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 11 Test Your Knowledge.pdf\u003c\/p\u003e\n\u003cp\u003eJune 11 Three Mystery Cases Test Your Knowledge! Galina Gheihman, MD; Tamara Kaplan, MD and Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Three Mystery Cases Test Your Knowledge! Galina Gheihman, MD; Tamara Kaplan, MD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 11 Treatment \u0026amp; Management of Alzheimer’s Disease Sheena Baratono, MD, PhD Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Treatment \u0026amp; Management of Alzheimer’s Disease Sheena Baratono, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eJune 11 Treatment \u0026amp; Management of Alzheimer’s Disease Sheena Baratono, MD, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eJune 12 Agenda.pdf\u003c\/p\u003e\n\u003cp\u003eJune 12 Directions-to-Mass-General-Brigham-at-Assembly-Row.pdf\u003c\/p\u003e\n\u003cp\u003eJune 12 Naclerio-HMS NNN approach to weakness slides.pdf\u003c\/p\u003e\n\u003cp\u003eJune 12 Neurology for Non-Neurologist-Dizziness_DB.pdf\u003c\/p\u003e\n\u003cp\u003eNeurology 2025 Faculty.pdf\u003c\/p\u003e\n\u003cp\u003eNNN Agenda 2025.pdf\u003c\/p\u003e\n\u003cp\u003ePage 1 – Front Page Course Intro.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405773459652,"sku":null,"price":130.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Harvard-Neurology-for-the-Non-Neurologist-2025.jpg?v=1784215939"},{"product_id":"memorial-sloan-kettering-cancer-center-translating-evidence-into-practice-2025","title":"Memorial Sloan Kettering Cancer Center Translating Evidence into Practice 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecialties – Critical Care, General Surgery, Hospitalist, Medical Oncology, Nursing, Oncology and Hematology, Pediatric Oncology, Pharmacology and Medication Management, Surgical Oncology\u003c\/p\u003e\n\u003cp\u003eOverview\u003c\/p\u003e\n\u003cp\u003eThis innovative annual forum, tailored for healthcare professionals across all disciplines, showcases the translation of evidence into practice. This year’s program features over 20 innovative quality improvement projects and practice initiatives. You’ll hear directly from project leads as they share their strategies for successfully driving meaningful change at their institutions. Each presentation will highlight successful examples of utilizing high-quality evidence to achieve impactful improvements in practice and outcomes.\u003c\/p\u003e\n\u003cp\u003eWe’re honored to welcome Deborah Baker from Johns Hopkins Health Systems as this year’s keynote speaker, who will deliver an exciting presentation on Developing Nurse Clinician Scientists: Translating Evidence to Improve Practice and Nurse Autonomy.\u003c\/p\u003e\n\u003ch3\u003ePodium Presentations will cover five key topic areas, including:\u003c\/h3\u003e\n\u003cp\u003eTechnology and Innovation\u003c\/p\u003e\n\u003cp\u003eExample Presentation: Staff Dash – A Data-Driven Dashboard to Inform Staffing Decisions\u003c\/p\u003e\n\u003cp\u003eSymptom Management through Supportive and Integrative Therapies\u003c\/p\u003e\n\u003cp\u003eExample Presentation: Implementing a Standardized Writing Form to Monitor Dysgraphia for the Immune Effector Cell-Associated Encephalopathy (ICE) Score\u003c\/p\u003e\n\u003cp\u003eLeadership and Professional Development\u003c\/p\u003e\n\u003cp\u003eExample Presentation: Improving Scheduling Efficiency in the Setting of Staff Turnover and Increased Surgical Volume in the Post-Anesthesia Care Unit Using Census Data Trends\u003c\/p\u003e\n\u003cp\u003eInterprofessional\/Interdisciplinary Collaboration\u003c\/p\u003e\n\u003cp\u003eExample Presentation: Criteria Utilization to Optimize Physical Therapy Services in Acute Care Oncology Postoperative Thoracic Populations\u003c\/p\u003e\n\u003cp\u003eRisk Mitigation Strategies in Oncologic Population\u003c\/p\u003e\n\u003cp\u003eExample Presentation: Use of Antiseptic Barrier Caps to Reduce Central Line-Associated Bloodstream Infections in Stem Cell Transplant and Cellular Therapy Patients\u003c\/p\u003e\n\u003ch3\u003eFinally, a Rapid-Fire Poster Session will cover a range of topics such as:\u003c\/h3\u003e\n\u003cp\u003e— Standardizing the Process for Checking Investigational Oral Medications to Improve Patient Safety in Clinical Trials\u003c\/p\u003e\n\u003cp\u003e— Transdisciplinary Post-CAR-T Therapy Coordination and Education in Non-Oncology Areas\u003c\/p\u003e\n\u003cp\u003eRegistered attendees will receive access to an online syllabus after the conference, which will include select PDFs of the faculty presentations (slides) and recorded videos.\u003c\/p\u003e\n\u003cp\u003eThis conference is designed for healthcare professionals of all disciplines including nurses, advanced practice providers, physicians, pharmacists, dieticians, social work, physical therapists, occupational therapists, respiratory therapists or any other licensed clinical practitioner interested in learning more about evidence-based healthcare and how to integrate it into their practice.\u003c\/p\u003e\n\u003cp\u003eObjectives\u003c\/p\u003e\n\u003ch3\u003eAt the conclusion of this program, learners will be able to:\u003c\/h3\u003e\n\u003cp\u003eIdentify methods used to gather high-quality evidence in order to make a practice change\u003c\/p\u003e\n\u003cp\u003eRecognize successful implementation strategies for change management\u003c\/p\u003e\n\u003cp\u003eDiscuss strategies used to translate research into daily practice\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAdministration and Monitoring Practices for Drugs at Higher Risk for Infusion Reaction.mp4\u003c\/p\u003e\n\u003cp\u003eAdministration and Monitoring Practices for Drugs at Higher Risk for Infusion Reaction.pdf\u003c\/p\u003e\n\u003cp\u003eCAUTI Reduction by Updating Hazardous Urinary Incontinence Management.mp4\u003c\/p\u003e\n\u003cp\u003eCAUTI Reduction by Updating Hazardous Urinary Incontinence Management.pdf\u003c\/p\u003e\n\u003cp\u003eCriteria Utilization to Optimize Physical Therapy Services in Acute Care Oncology Postoperative Thoracic Populations.mp4\u003c\/p\u003e\n\u003cp\u003eCriteria Utilization to Optimize Physical Therapy Services in Acute Care Oncology Postoperative Thoracic Populations.pdf\u003c\/p\u003e\n\u003cp\u003eDancing the Line- Reducing Toe Out to Toe in Time.mp4\u003c\/p\u003e\n\u003cp\u003eDancing the Line- Reducing Toe Out to Toe in Time.pdf\u003c\/p\u003e\n\u003cp\u003eDeveloping Nurse Clinician Scientists- Translating Evidence to Improve Practice and Nurse Autonomy.mp4\u003c\/p\u003e\n\u003cp\u003eDeveloping Nurse Clinician Scientists- Translating Evidence to Improve Practice and Nurse Autonomy.pdf\u003c\/p\u003e\n\u003cp\u003eEarly Palliative Care in Patients Receiving CAR T cells.mp4\u003c\/p\u003e\n\u003cp\u003eEarly Palliative Care in Patients Receiving CAR T cells.pdf\u003c\/p\u003e\n\u003cp\u003eEBP2025_Brochure.pdf\u003c\/p\u003e\n\u003cp\u003eImplementing a Standardized Writing Form to Monitor Dysgraphia for the Immune Effector Cell-Associated Encephalopathy (ICE) Score.mp4\u003c\/p\u003e\n\u003cp\u003eImplementing a Standardized Writing Form to Monitor Dysgraphia for the Immune Effector Cell-Associated Encephalopathy (ICE) Score.pdf\u003c\/p\u003e\n\u003cp\u003eImproving Scheduling Efficiency in the Setting of Staff Turnover and Increased Surgical Volume in The PostAnesthesia Care Unit Using Census Data Trends.mp4\u003c\/p\u003e\n\u003cp\u003eImproving Scheduling Efficiency in the Setting of Staff Turnover and Increased Surgical Volume in The PostAnesthesia Care Unit Using Census Data Trends.pdf\u003c\/p\u003e\n\u003cp\u003eInterprofessional Interdisciplinary Collaboration Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eLeadership and Professional Development Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eMindfulness Breathing in Oncology Nursing.mp4\u003c\/p\u003e\n\u003cp\u003eMindfulness Breathing in Oncology Nursing.pdf\u003c\/p\u003e\n\u003cp\u003eNurse Initiated Nutritional Screening and Referral System.mp4\u003c\/p\u003e\n\u003cp\u003eNurse Initiated Nutritional Screening and Referral System.pdf\u003c\/p\u003e\n\u003cp\u003eNurse-Led Pre-Procedure Teaching Program to Improve Patient Access.mp4\u003c\/p\u003e\n\u003cp\u003eNurse-Led Pre-Procedure Teaching Program to Improve Patient Access.pdf\u003c\/p\u003e\n\u003cp\u003ePromoting the Use of Continuous Vital Signs Monitoring (CVSM) Technology for Early Recognition of Clinical Deterioration in Non-ICU Adult Hospitalized Patients.mp4\u003c\/p\u003e\n\u003cp\u003ePromoting the Use of Continuous Vital Signs Monitoring (CVSM) Technology for Early Recognition of Clinical Deterioration in Non-ICU Adult Hospitalized Patients.pdf\u003c\/p\u003e\n\u003cp\u003eRapid-Fire Poster Session.mp4\u003c\/p\u003e\n\u003cp\u003eRapid-Fire Poster Session.pdf\u003c\/p\u003e\n\u003cp\u003eReducing Needlestick Injuries- Updating Our Blood-Collection Set.mp4\u003c\/p\u003e\n\u003cp\u003eReducing Needlestick Injuries- Updating Our Blood-Collection Set.pdf\u003c\/p\u003e\n\u003cp\u003eRisk Mitigation Strategies in Oncologic Population Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eStaff Dash- A Data-Driven Dashboard to Inform Staffing Decisions.mp4\u003c\/p\u003e\n\u003cp\u003eStaff Dash- A Data-Driven Dashboard to Inform Staffing Decisions.pdf\u003c\/p\u003e\n\u003cp\u003eSymptom Management through Supportive and Integrative Therapies Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eTechnology and Innovation Q\u0026amp;A.mp4\u003c\/p\u003e\n\u003cp\u003eUse of Antiseptic Barrier Caps to Reduce Central Line Associated Blood Stream Infections in Stem Cell Transplant and Cellular Therapy Patients.mp4\u003c\/p\u003e\n\u003cp\u003eUse of Antiseptic Barrier Caps to Reduce Central Line Associated Blood Stream Infections in Stem Cell Transplant and Cellular Therapy Patients.pdf\u003c\/p\u003e\n\u003cp\u003eWhen Nothing Exists- Establishing Consensus for a Dilation Protocol for Underserved Populations.mp4\u003c\/p\u003e\n\u003cp\u003eWhen Nothing Exists- Establishing Consensus for a Dilation Protocol for Underserved Populations.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405774540996,"sku":null,"price":32.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-Translating-Evidence-into-Practice-2025.jpg?v=1784215954"},{"product_id":"harvard-5th-annual-update-in-neuro-oncology-2025","title":"Harvard 5th Annual Update in Neuro-Oncology 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: neurologists, oncologists, radiation oncologists, neurosurgeons, neurologists, neuroradiologists, and neuropathologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eNeuro-oncology is a rapidly evolving multi-disciplinary field, which involves the medical, radiation, and surgical management of pediatric and adult patients with primary and metastatic tumors of the central nervous system (CNS) and peripheral nervous system (PNS). The field of neuro-oncology also encompasses neurogenetic syndromes, like neurofibromatosis, associated with nervous system tumors and various neurological complications of cancer and cancer treatments. In addition, modern molecular neuropathology and neuroradiology concepts are essential for accurate diagnosis and classification.\u003c\/p\u003e\n\u003cp\u003eThe target audience consists of providers and trainees involved in the care of adult and pediatric neuro-oncology patients (neurologists, oncologists, radiation oncologists, neurosurgeons, neurologists, neuroradiologists, and neuropathologists). The course will also be of high relevance to nurse practitioners, physician assistants, psychologists, pharmacists, nurses, and industry professionals.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003cp\u003eDefine the role of molecular biomarkers in the accurate diagnosis and classification of pediatric and adult CNS and PNS tumors.\u003c\/p\u003e\n\u003cp\u003eDetermine standard and novel treatment approaches to pediatric and adult CNS and PNS tumors.\u003c\/p\u003e\n\u003cp\u003eRecognize and manage neurological complications associated with new cancer therapies.\u003c\/p\u003e\n\u003cp\u003eDescribe and manage long-term complications of CNS and PNS tumors and their treatment.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWednesday, July 23, 2025\u003c\/p\u003e\n\u003cp\u003eThursday, July 24, 2025\u003c\/p\u003e\n\u003cp\u003eFriday, July 25, 2025\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405774672068,"sku":null,"price":91.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Harvard-5th-Annual-Update-in-Neuro-Oncology-2025.jpg?v=1784215959"},{"product_id":"harvard-breast-cancer-new-horizons-current-controversies-2025","title":"Harvard Breast Cancer New Horizons, Current Controversies 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: surgical, and radiation oncologists, breast surgeons\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBreast Cancer: New Horizons, Current Controversies is a comprehensive educational curriculum that encompasses the full range of breast cancer care. Topics include mechanisms of disease, improvements in diagnostic methods, treatment innovations, and management of breast cancer survivors. The primary goal of the course is to improve the knowledge, competence, and clinical skills of health care professionals who specialize in oncology. As such, the curriculum is well suited for medical, surgical, and radiation oncologists; breast and general surgeons; internists; physician assistants; nurse practitioners; oncology nurses; and other clinicians involved in the care of breast cancer patients.\u003c\/p\u003e\n\u003cp\u003eThis year, we will be again offering an in-person program as well as a livestream for those who still do not feel comfortable traveling to Boston. Continuing with the livestream allows participants to engage with our faculty from the convenience of their own community, be it in Boston or across the globe. This hybrid format worked very well last year and is appropriate given both the range of potential attendees and persistent uncertainty over travel and large group gatherings.\u003c\/p\u003e\n\u003ch3\u003eThe timing of the course for summer 2025 is particularly fortuitous owing to the extraordinary progress happening in breast cancer. In the last two years, we have seen transformative breakthroughs in all types of breast cancer treatment:\u003c\/h3\u003e\n\u003cp\u003eFDA approval of novel antibody-drug conjugates for the treatment of advanced hormone receptor-positive, HER2-positive, and triple-negative breast cancer, with new data showing benefit of these agents in tumor types beyond their initial application.\u003c\/p\u003e\n\u003cp\u003eFDA approval of the AKT pathway inhibitor capivasertib in combination with fulvestrant for patients with hormone receptor-positive, PIK3CA\/AKT\/PTEN-mutant metastatic breast cancer and reported phase III data of another agent in this class (inavolisib).\u003c\/p\u003e\n\u003cp\u003eFDA approval of the CDK4\/6 inhibitor abemaciclib in high-risk, early-stage hormone receptor-positive breast cancer, and mature data showing compelling benefits including overall survival for this class of drugs in advanced breast cancer, as well as preliminary reports of a second agent in this class (ribociclib) with adjuvant efficacy.\u003c\/p\u003e\n\u003cp\u003eFDA approval of a novel antibody-drug conjugate for patients with a HER2-low metastatic breast cancer.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003cp\u003eApply knowledge of recent clinical data together with current expert recommendations to patient selection for new and emerging therapies for advanced breast cancer.\u003c\/p\u003e\n\u003cp\u003eSelect appropriate risk assessment modalities, where applicable, and make evidence-based therapeutic selections for women who are candidates for neoadjuvant or adjuvant therapy and know the limitations of genomic testing.\u003c\/p\u003e\n\u003cp\u003eApply recent clinical data and expert recommendations to the management of women with breast cancer who are treated with mastectomy, including integration of surgical methods, breast reconstruction options, and post-mastectomy radiation if needed.\u003c\/p\u003e\n\u003cp\u003eAssess current practices regarding symptom management during active treatment and in survivorship and consider the needs for fertility and lifestyle counseling among patients with breast cancer and survivors and improve current practices if needed.\u003c\/p\u003e\n\u003cp\u003eEvaluate the genetic and personal risk factors of breast cancer and utilize appropriate genetic testing for hereditary breast cancer.\u003c\/p\u003e\n\u003cp\u003eParticipant Types\u003c\/p\u003e\n\u003cp\u003eNurse Practitioners, Primary Care Physicians, Physician Assistants, Nurses, Pharmacists, and Specialty Physicians\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eTheme: Advances in Radiation Therapy, Pathology, and Breast Cancer Management\u003c\/p\u003e\n\u003cp\u003eWelcoming Remarks\u003c\/p\u003e\n\u003cp\u003eSpeaker: Harold Burstein\u003c\/p\u003e\n\u003cp\u003eSession I: Radiation Oncology\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003e50 Years of Radiation Therapy\u003c\/p\u003e\n\u003cp\u003eAbram Recht\u003c\/p\u003e\n\u003cp\u003eStandard Radiation Therapy: The Long and the Short\u003c\/p\u003e\n\u003cp\u003eJulia Wong\u003c\/p\u003e\n\u003cp\u003eThe Future of Breast Radiation Therapy\u003c\/p\u003e\n\u003cp\u003eAtif Khan\u003c\/p\u003e\n\u003cp\u003eRadiopharmaceuticals\u003c\/p\u003e\n\u003cp\u003eHeather Jacene\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eAbram Recht, Atif Khan, Julia Wong, Heather Jacene\u003c\/p\u003e\n\u003cp\u003eSession II: Pathology\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eLobular Breast Cancer\u003c\/p\u003e\n\u003cp\u003eStuart Schnitt\u003c\/p\u003e\n\u003cp\u003ectDNA: The Evolving Role for Molecular Diagnostics\u003c\/p\u003e\n\u003cp\u003eStefania Morganti\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eStuart Schnitt, Stefania Morganti\u003c\/p\u003e\n\u003cp\u003eSpecial Lecture\u003c\/p\u003e\n\u003cp\u003eSpeaker(s): Sydney Smith \u0026amp; Julie Bosworth\u003c\/p\u003e\n\u003cp\u003eTopic: What’s New in Supportive Care: Management of Gastrointestinal Side Effects\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eEssentials of Germline Genetics\u003c\/p\u003e\n\u003cp\u003eJudy Garber\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eJulie Bosworth, Sydney Smith, Judy Garber\u003c\/p\u003e\n\u003cp\u003eSchwartz Rounds: A Complex Case\u003c\/p\u003e\n\u003cp\u003eSpeaker: Ann Partridge\u003c\/p\u003e\n\u003cp\u003eTumor Board: Early Breast Cancer\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eHarold Burstein, Faina Nakhlis, Julia Wong, Brittany Bychkovsky, Adrienne Waks, Filipa Lynce, Elizabeth Mittendorf\u003c\/p\u003e\n\u003cp\u003eSession III: HER2 Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eNew Approaches in Early Stage HER2 Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eAdrienne Waks\u003c\/p\u003e\n\u003cp\u003eThe Progress Continues: Late Stage HER2 Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eSarah Sammons\u003c\/p\u003e\n\u003cp\u003eCan We Cure Metastatic Breast Cancer?\u003c\/p\u003e\n\u003cp\u003eNancy Lin\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eSara Tolaney, Sarah Sammons, Nancy Lin, Adrienne Waks\u003c\/p\u003e\n\u003cp\u003eSpecial Lecture\u003c\/p\u003e\n\u003cp\u003eSpeaker(s): Erica Warner, Filipa Lynce, Antonio Giordano, Jennifer Ligibel\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eRacial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype\u003c\/p\u003e\n\u003cp\u003eErica Warner\u003c\/p\u003e\n\u003cp\u003eInflammatory Breast Cancer\u003c\/p\u003e\n\u003cp\u003eFilipa Lynce\u003c\/p\u003e\n\u003cp\u003eEarly Drug Discovery in Breast Cancer\u003c\/p\u003e\n\u003cp\u003eAntonio Giordano\u003c\/p\u003e\n\u003cp\u003eLifestyle\/Diet\/Exercise in Breast Cancer Patients\u003c\/p\u003e\n\u003cp\u003eJennifer Ligibel\u003c\/p\u003e\n\u003cp\u003eReception\u003c\/p\u003e\n\u003cp\u003eTheme: Surgical Interventions and Advanced Breast Cancer Treatment\u003c\/p\u003e\n\u003cp\u003eSession IV: Surgery\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eOncoplastic Reconstruction: Common Indications and Outcomes\u003c\/p\u003e\n\u003cp\u003eIndranil Sinha\u003c\/p\u003e\n\u003cp\u003eThe Axilla After Neoadjuvant Therapy: How Much Is Too Much?\u003c\/p\u003e\n\u003cp\u003eElizabeth Mittendorf\u003c\/p\u003e\n\u003cp\u003eImplications of the SOUND Trial\u003c\/p\u003e\n\u003cp\u003eOlga Kantor\u003c\/p\u003e\n\u003cp\u003eCryoblation Instead of Surgery\u003c\/p\u003e\n\u003cp\u003eFrancys Verdial\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eBarbara Smith, Indranil Sinha, Olga Kantor, Francys Verdial, Elizabeth Mittendorf\u003c\/p\u003e\n\u003cp\u003eSchlager Lecture: Immunotherapy in Early Breast Cancer: Today and Tomorrow\u003c\/p\u003e\n\u003cp\u003eSpeaker: Marleen Kok\u003c\/p\u003e\n\u003cp\u003eSession V: Triple Negative Breast Cancer (TNBC)\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eSmall TNBCs: How Small Is Small Enough?\u003c\/p\u003e\n\u003cp\u003eSteven Isakoff\u003c\/p\u003e\n\u003cp\u003eAntibody Drug Conjugates in TNBC and Refractory ER Positive Metastatic Breast Cancer\u003c\/p\u003e\n\u003cp\u003eAna Garrido-Castro\u003c\/p\u003e\n\u003cp\u003eImmunotherapy in TNBC\u003c\/p\u003e\n\u003cp\u003eGuilherme Nader Marta\u003c\/p\u003e\n\u003cp\u003eManaging Endocrine Side Effects of Immunotherapy\u003c\/p\u003e\n\u003cp\u003eElad Sharon\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eSteven Isakoff, Ana Garrido-Castro, Guilherme Nader Marta, Elad Sharon\u003c\/p\u003e\n\u003cp\u003eTumor Board: Advanced Breast Cancer\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eRachel Freedman, Barbara Smith, Sarah Sammons, Erica Mayer, Laura Spring, Leticia Varella, Guilherme Nader Marta, Daniel Abravanel\u003c\/p\u003e\n\u003cp\u003eSession VI: ER Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eNew Approaches in Early ER Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eErica Mayer\u003c\/p\u003e\n\u003cp\u003ePI3K Inhibitors in Metastatic Breast Cancer: Choosing the Right Target\u003c\/p\u003e\n\u003cp\u003eDejan Juric\u003c\/p\u003e\n\u003cp\u003eAdvanced ER Positive Breast Cancer: A Surfeit of Choices\u003c\/p\u003e\n\u003cp\u003eSeth Wander\u003c\/p\u003e\n\u003cp\u003eEmerging Antibody Drug Conjugates in ER Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003ePaolo Tarantino\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eErica Mayer, Seth Wander, Paolo Tarantino, Dejan Juric\u003c\/p\u003e\n\u003cp\u003eCDK4\/6: Which One? For Whom? – Debate\u003c\/p\u003e\n\u003cp\u003eSpeakers: Shana Berwick, Laura Spring\u003c\/p\u003e\n\u003cp\u003eASCO Highlights\u003c\/p\u003e\n\u003cp\u003eSpeaker: Harold Burstein\u003c\/p\u003e\n\u003cp\u003eClosing Remarks\u003c\/p\u003e\n\u003cp\u003eSpeaker: Harold Burstein\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405776244932,"sku":null,"price":78.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Harvard-Breast-Cancer-New-Horizons-Current-Controversies-2025.jpg?v=1784215978"},{"product_id":"cold-spring-harbor-laboratory-advances-in-brain-tumor-research-therapy-2025","title":"Cold Spring Harbor Laboratory Advances in Brain Tumor Research \u0026 Therapy 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: neuroscientists, neuro-oncologists, clinical researchers\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat You Will Learn\u003c\/p\u003e\n\u003cp\u003eEmerging insights in clinical care, imaging, pathology, surgery, radiation oncology, and therapeutic innovation for brain tumors\u003c\/p\u003e\n\u003cp\u003eFoundational and translational knowledge in cancer genetics, pediatric brain tumors, and mechanisms of tumor development and progression\u003c\/p\u003e\n\u003cp\u003eAdvances in gliomas, meningiomas, medulloblastoma, ependymoma, DIPG, and brain metastases\u003c\/p\u003e\n\u003cp\u003eCutting-edge research in mouse models, genomics, proteogenomics, metabolism, the tumor microenvironment, angiogenesis, immunology, and preclinical drug development\u003c\/p\u003e\n\u003cp\u003eStrategies for clinical translation including trial design, overcoming blood-brain barrier challenges, and optimizing therapeutic interventions\u003c\/p\u003e\n\u003cp\u003eEvent Details\u003c\/p\u003e\n\u003cp\u003eEvent: Cold Spring Harbor Laboratory – Advances in Brain Tumor Research \u0026amp; Therapy 2025\u003c\/p\u003e\n\u003cp\u003eHighlights: Small-group setting promoting mutual exchange between early-career investigators and established experts; hosted keynotes and diverse speaker lineup from top institutions\u003c\/p\u003e\n\u003cp\u003eWho Should Attend\u003c\/p\u003e\n\u003cp\u003eNeuroscientists, neuro-oncologists, clinical researchers, graduate students, postdocs, and clinicians who focus on brain tumor biology, translating basic science, and advancing therapeutic strategies.\u003c\/p\u003e\n\u003cp\u003eWhy Attend\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eClinical Aspects of Brain Tumors\u003c\/p\u003e\n\u003cp\u003ePathology \/ Imaging \/ Population biology \/ Quality of Life \/ Surgery \/ Radiation oncology \/ Medical therapies\u003c\/p\u003e\n\u003cp\u003eGenetics and Developmental Biology\u003c\/p\u003e\n\u003cp\u003eCancer Genetics \/ Pediatric brain tumors \/ Cancer neuroscience\u003c\/p\u003e\n\u003cp\u003eGliomas and Nervous System Disorders\u003c\/p\u003e\n\u003cp\u003eGliomas \/ Meningiomas \/ Ependymomas \/ Medulloblastomas \/ ATRT \/ Brain metastases \/ Diffuse Intrinsic Pontine Glioma (DIPG)\u003c\/p\u003e\n\u003cp\u003eMouse Models and Genomics\u003c\/p\u003e\n\u003cp\u003eMouse models\/ Genomics \/ Proteogenomics \/ Large datasets\u003c\/p\u003e\n\u003cp\u003eMetabolism\u003c\/p\u003e\n\u003cp\u003eMetabolic reprogramming \/ RNA biology \/ Lipid biology\u003c\/p\u003e\n\u003cp\u003eMicroenvironment, Angiogenesis and Immunology\u003c\/p\u003e\n\u003cp\u003eAngiogenesis \/ Engineered T cell vs checkpoint inhibition \/ Monocytes\u003c\/p\u003e\n\u003cp\u003eDrug Development and Preclinical Studies\u003c\/p\u003e\n\u003cp\u003eDrug design \/ Drug screening \/ Preclinical modeling \/ Blood brain barrier\u003c\/p\u003e\n\u003cp\u003eTherapeutics and Clinical Trials\u003c\/p\u003e\n\u003cp\u003eTrial design \/ Heterogeneity\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405777785028,"sku":null,"price":143.0,"currency_code":"USD","in_stock":true}]},{"product_id":"cleveland-clinic-breast-cancer-update-review-of-breast-cancer-symposia-2025","title":"Cleveland Clinic Breast Cancer Update Review of Breast Cancer Symposia 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: medical oncologists, radiation oncologists, and surgical oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCondensed Insights from Leading Breast Cancer Conferences for Clinical Application\u003c\/p\u003e\n\u003cp\u003eScheduled for February 12, 2025, this one-day live event distills key findings from major breast cancer symposia, designed to translate emerging evidence into practical strategies across the full spectrum of care.\u003c\/p\u003e\n\u003cp\u003eWhat You’ll Gain\u003c\/p\u003e\n\u003cp\u003eUp-to-date insights in surgical management, hormonal therapies, radiation techniques, and biomarker-driven treatment planning\u003c\/p\u003e\n\u003cp\u003eIn-depth exploration of high-risk screening, advanced imaging modalities, and risk prediction frameworks\u003c\/p\u003e\n\u003cp\u003eExpert-led case discussions and panel Q\u0026amp;A to support immediate clinical translation\u003c\/p\u003e\n\u003cp\u003eWho Should Attend\u003c\/p\u003e\n\u003cp\u003eMedical oncologists, radiation oncologists, and surgical oncologists focused on breast cancer care\u003c\/p\u003e\n\u003cp\u003eAdvanced practice providers, nurses, and pharmacists involved in multidisciplinary treatment pathways\u003c\/p\u003e\n\u003cp\u003eOncology fellows and residents seeking clinically relevant updates and decision-making tools\u003c\/p\u003e\n\u003cp\u003eBreast care program leaders and educators building institutional guidelines and protocols\u003c\/p\u003e\n\u003cp\u003eWhy This Program Stands Out\u003c\/p\u003e\n\u003cp\u003eFocused on translating symposium findings into actionable clinical guidance\u003c\/p\u003e\n\u003cp\u003eEncompasses a full range of breast cancer care domains—diagnosis, treatment, prevention, and survivorship\u003c\/p\u003e\n\u003cp\u003eInteractive and case-based format ensures learning is immediate, applicable, and impactful\u003c\/p\u003e\n\u003cp\u003eOne-day format makes this an efficient, high-value update for busy cancer care professionals\u003c\/p\u003e\n\u003cp\u003eElevate Your Breast Cancer Practice with Current Insights\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1 High Risk Screening and Imaging Modalities.mp4\u003c\/p\u003e\n\u003cp\u003e2 Surgical Update.mp4\u003c\/p\u003e\n\u003cp\u003e6 Radiation Oncology Update.mp4\u003c\/p\u003e\n\u003cp\u003e7 Biomarkers, Predictive and Prognostic Models.mp4\u003c\/p\u003e\n\u003cp\u003e8 Aspects of Survivorship Care.mp4\u003c\/p\u003e\n\u003cp\u003eAgenda.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405778866372,"sku":null,"price":26.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Cleveland-Clinic-Breast-Cancer-Update-Review-of-Breast-Cancer-Symposia-2025.jpg?v=1784216023"},{"product_id":"george-washington-university-hematology-and-medical-oncology-best-practices-on-demand-2025","title":"George Washington University Hematology and Medical Oncology Best Practices On Demand 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  audios + pdfs, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: hematology\/oncology certification exams\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCourse Features\u003c\/p\u003e\n\u003ch3\u003eAll registered attendees receive:\u003c\/h3\u003e\n\u003cp\u003eInstruction by the nation’s leading clinician-educators\u003c\/p\u003e\n\u003cp\u003eAccess to Course Electronic Syllabus and Slide Handouts\u003c\/p\u003e\n\u003cp\u003eAll content can be conveniently accessed from your computer, mobile device, or smartphone\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eAt the conclusion of the Hematology and Oncology Best Practices course, the successful learner will be able to:\u003c\/h3\u003e\n\u003cp\u003eHematology\u003c\/p\u003e\n\u003cp\u003eUnderstand both established information and recent clinical advances in immunohematology, bone marrow transplantation, and hematopoietic growth factors\u003c\/p\u003e\n\u003cp\u003eUnderstand both established information and recent clinical advances in coagulopathies, anticoagulant and thrombolytic therapies\u003c\/p\u003e\n\u003cp\u003eUnderstand blood and marrow morphology and hematopathology\u003c\/p\u003e\n\u003cp\u003eUnderstand red cell disorders\u003c\/p\u003e\n\u003cp\u003eHematologic Malignancies\u003c\/p\u003e\n\u003cp\u003eUnderstand the most recent advances in the pharmacology and toxicology of anti-neoplastic drugs\u003c\/p\u003e\n\u003cp\u003eBe familiar with the diagnosis, evaluation, and management of hematologic malignancies\u003c\/p\u003e\n\u003cp\u003eIdentify strategies for taking the board examinations\u003c\/p\u003e\n\u003cp\u003eOncology\u003c\/p\u003e\n\u003cp\u003eUnderstand the epidemiology of malignant diseases and management of the medical complications of malignancy\u003c\/p\u003e\n\u003cp\u003eComprehend the principles of management of gynecologic and other genito-urinary malignancies\u003c\/p\u003e\n\u003cp\u003eIdentify the latest advances in cancers of the lung, the breast, and the gastrointestinal tract\u003c\/p\u003e\n\u003cp\u003eRecognize principles of new developments in biologic therapy of cancer\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e2025 HEMONC Best Practices Course Syllabus FULL SESSION COURSE.pdf\u003c\/p\u003e\n\u003ch3\u003eHematology Sessions:\u003c\/h3\u003e\n\u003cp\u003eSession 0 (Hematology): Anemias, Porpyrias, Red Cell Enzymes, Clotting, Cellular Morphology and Liquid Biopsies (4.00 hours)\u003c\/p\u003e\n\u003cp\u003eSession 1: Iron Deficiency, Hemoglobinopathies, Hemolytic Anemia, Hemophilias, Transfusion Medicine, Hematologic Complications of Pregnancy and Platelet Alloimmunization (9.00 hours)\u003c\/p\u003e\n\u003ch3\u003eHematologic Malignancies Sessions:\u003c\/h3\u003e\n\u003cp\u003eSession 3: Lymphomas, Multiple Myeloma, MGUS, ALL, CML, Plasma Cell Disorders, Myelodysplasia, Waldenstrom’s Macroglobulinemia and Palliative Care (9.25 hours)\u003c\/p\u003e\n\u003cp\u003eSession 4: AML, Bone Marrow Transplantation, Myeloproliferative Neoplasms, CLL, Pharmacology and T Cell Therapies (9.25 hours)\u003c\/p\u003e\n\u003ch3\u003eMedical Oncology Sessions:\u003c\/h3\u003e\n\u003cp\u003eSession 6: Renal Cell, Prostate, Bladder, Testicular, Ovarian, Endometrial Tumors, Melanoma, Carcinoid Tumors and Mesothelioma (10.00 hours)\u003c\/p\u003e\n\u003cp\u003eSession 7: GI Oncology, Pancreatic Cancer and Sarcomas (6.75 hours)\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405779390660,"sku":null,"price":182.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/George-Washington-University-Hematology-and-Medical-Oncology-Best-Practices-On-Demand-2025.jpg?v=1784216033"},{"product_id":"memorial-sloan-kettering-cancer-center-navigating-clinical-trials-key-insights-for-providers-in-oncology-2025","title":"Memorial Sloan Kettering Cancer Center Navigating Clinical Trials Key Insights for Providers in Oncology 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: physician assistants, nurse practitioners, physicians, students, registered nurses, clinical pharmacy specialists, and other allied health professionals\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecialties – All Specialties\u003c\/p\u003e\n\u003cp\u003eOverview\u003c\/p\u003e\n\u003cp\u003e— scientific communication;\u003c\/p\u003e\n\u003cp\u003e— ethical considerations and subject protection;\u003c\/p\u003e\n\u003cp\u003e— the lifecycle of translational and clinical research;\u003c\/p\u003e\n\u003cp\u003e— recent advancements and FDA approvals;\u003c\/p\u003e\n\u003cp\u003e— diversity in clinical trials with a focus on vulnerable populations;\u003c\/p\u003e\n\u003cp\u003e— fostering community partnerships and referrals; and\u003c\/p\u003e\n\u003cp\u003e— the importance of collaborative, team-based care.\u003c\/p\u003e\n\u003cp\u003eThis course is designed for physician assistants, nurse practitioners, physicians, students, registered nurses, clinical pharmacy specialists, and other allied health professionals.\u003c\/p\u003e\n\u003cp\u003eObjectives\u003c\/p\u003e\n\u003ch3\u003eThe goal of this educational activity is to:\u003c\/h3\u003e\n\u003cp\u003eEngage participants in a comprehensive learning experience using interdisciplinary didactic sessions highlighting team-based clinical research operations.\u003c\/p\u003e\n\u003cp\u003eExplore the advances in novel therapies and FDA-approved agents developed at our NCI-designated cancer center.\u003c\/p\u003e\n\u003cp\u003eDiscuss the importance of diversity within clinical trials and opportunities to address representation in clinical research.\u003c\/p\u003e\n\u003cp\u003eHighlight common challenges faced by clinical trial participants and strategies to improve the patient experience while mitigating barriers to enrollment and successful clinical trial operations.\u003c\/p\u003e\n\u003cp\u003eEmploy skills to advance practice as a clinical trial investigator and protocol expert.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eA History of Clinical Research- How We Got to Where We’re Today.mp4\u003c\/p\u003e\n\u003cp\u003eAn Introduction to Clinical Research- Historical Perspective and Contemporary Standards QA.mp4\u003c\/p\u003e\n\u003cp\u003eBeyond the Protocol- Navigating Patient-Centered Challenges QA.mp4\u003c\/p\u003e\n\u003cp\u003eClinicalTrials2025_Brochure.pdf\u003c\/p\u003e\n\u003cp\u003eCommunity-Based Clinical Trials for Addressing Immigrant Health and Cancer Disparities.mp4\u003c\/p\u003e\n\u003cp\u003eData, Design, and Decisions- The Biostatistics Behind Clinical Trials.mp4\u003c\/p\u003e\n\u003cp\u003eDiversity in Clinical Trials- Addressing Gaps and Shaping Future Recruitment Strategies.mp4\u003c\/p\u003e\n\u003cp\u003eEasing the Burden- Tackling Financial Toxicity for Clinical Trial Patients.mp4\u003c\/p\u003e\n\u003cp\u003eEnsuring Safety and Efficacy- Key Considerations in Pediatric Clinical Trials.mp4\u003c\/p\u003e\n\u003cp\u003eEthical and Safety Considerations for Vulnerable Populations.mp4\u003c\/p\u003e\n\u003cp\u003eExpanding Access- Overcoming Recruitment Barriers and Ensuring Ethical Inclusion in Clinical Trials QA.mp4\u003c\/p\u003e\n\u003cp\u003eFrom Bench to Trial- Creating Concepts for Early Stage Research.mp4\u003c\/p\u003e\n\u003cp\u003eFrom Laboratory to Clinic- Transforming Science into Therapeutic Solutions- QA.mp4\u003c\/p\u003e\n\u003cp\u003eMaking an IMPACT- Translating Data into Actionable Targets for Oncology Research.mp4\u003c\/p\u003e\n\u003cp\u003ePatient Referral and Trial Navigation- How to Use Protocols and ClinicalTrials.gov Effectively.mp4\u003c\/p\u003e\n\u003cp\u003ePioneering Cellular Therapies at MSK.mp4\u003c\/p\u003e\n\u003cp\u003eRegional Care Network Strategies for Effective Clinical Trial Implementation.mp4\u003c\/p\u003e\n\u003cp\u003eThe Human Side of Clinical Trials- Ensuring a Positive Patient Experience.mp4\u003c\/p\u003e\n\u003cp\u003eThe Power of Clear Science Communication- Connecting Patients and Providers.mp4\u003c\/p\u003e\n\u003cp\u003eWe’re All in This Together- A Panel Discussion with the Multidisciplinary Care Team.mp4\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405779554500,"sku":null,"price":26.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-Navigating-Clinical-Trials-Key-Insights-for-Providers-in-Oncology-2025.jpg?v=1784216034"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/collections\/Gemini_Generated_Image_18b2tl18b2tl18b2_5.png?v=1784221716","url":"https:\/\/medicalcoursespro.com\/collections\/medical-oncology.oembed?page=3","provider":"Medicalcoursespro","version":"1.0","type":"link"}